8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
63_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
1_CD
Accounting_GER
policies_NN
of_PIN
milestone_NN
payments_NOMZ
and_PHC
payments_NOMZ
received_VBD
on_PIN
Year_NN
to_PIN
Year_NN
to_PIN
the_DT
signing_GER
of_PIN
new_JJ
contracts_NN
._.
The_DT
Companys_NN
future_NN
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW
General_NN
information_NOMZ
cash_NN
flows_NN
will_PRMD [SPAU]
also_RB
be_VB [BYPA]
impacted_VBN
by_PIN
the_DT
Companys_NN
SkyePharma_NN
PLC_NN
the_DT
Company_NN
and_CC
its_PIT
change_NN
in_PIN
strategy_NN
as_IN
outlined_VBN
in_PIN
the_DT
EGM_NN
notice_NN
98.3_CD
32.0_CD
subsidiaries_NN
together_RB
the_DT
Group_NN
is_VPRT [BEMA]
a_DT
speciality_NOMZ
dated_VBN
16_CD
February_NN
2006_CD
,_,
principally_RB
its_PIT
stated_VBN [PUBV]
aim_NN
pharmaceutical_JJ
Group_NN
which_WDT [WHSUB]
uses_VPRT
its_PIT
multiple_JJ
drug_NN
of_PIN
moving_VBG [SUAV]
to_PIN
sustainable_JJ
profitability_NOMZ
in_PIN
the_DT
shortest_JJ
19.1_CD
29.1_CD
delivery_NN
technologies_NN
to_TO
create_VB
a_DT
product_NN
pipeline_NN
possible_JJ
time_NN
and_CC
its_PIT
refocus_VB
to_TO
concentrate_VB
on_PIN
oral_JJ
80.0_CD
for_PIN
out-licensing_JJ
to_TO
marketing_VBG
partners_NN
._.
Consequently_CONJ
the_DT
Groups_NN
0.3_CD
near_PLACE
term_NN
working_VBG [WZPRES]
capital_NN
requirements_NOMZ
are_VPRT [BEMA]
uncertain_PRED
5.8_CD
5.9_CD
The_DT
Company_NN
is_VPRT [PASS]
incorporated_VBN
and_PHC
domiciled_VBN
in_PIN
United_NN
and_CC
sensitive_JJ
to_PIN
the_DT
timing_NN
of_PIN
a_DT
number_NN
of_PIN
initiatives_NN
14.2_CD
12.0_CD
Kingdom_NN
,_,
with_PIN
its_PIT
registered_JJ
office_NN
at_PIN
105_CD
Piccadilly_NN
,_,
required_VBN [SUAV]
to_TO
provide_VB
the_DT
financial_JJ
flexibility_NOMZ
to_TO
implement_VB
0.3_CD
London_NN
W1J_NN
7NJ_NN
._.
These_DEMO
initiatives_NN
include_VPRT
the_DT
licensing_GER
0.9_CD
3.7_CD
of_PIN
Flutiform_NN
in_PIN
Europe_NN
,_,
the_DT
divestment_NOMZ
of_PIN
its_PIT
injectable_JJ
7.3_CD
5.3_CD
The_DT
principal_JJ
accounting_GER
policies_NN
adopted_VBN [WZPAST]
in_PIN
business_NOMZ
interests_NN
,_,
which_WDT [SERE]
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
require_VB [SUAV]
the_DT
preparation_NOMZ
of_PIN
these_DEMO
consolidated_JJ
financial_JJ
shareholder_NN
approval_NN
,_,
and_ANDC
the_DT
delay_NN
of_PIN
certain_JJ
statements_NOMZ
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
licensing_GER
discussions_NN
,_,
such_JJ
as_IN
US_FPP1
licensing_GER
for_PIN
1.0_CD
0.4_CD
DepoBupivacaine_NN
pending_VBG [WZPRES]
the_DT
divestment_NOMZ
of_PIN
its_PIT
7.0_CD
11.0_CD
a_DT
Basis_NN
of_PIN
preparation_NOMZ
injectables_NN
business_NOMZ
._.
13.3_CD
15.9_CD
In_PIN
accordance_NN
with_PIN
EU_NN
regulations_NOMZ
,_,
SkyePharma_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
prepare_VB
statutory_JJ
financial_JJ
statements_NOMZ
The_DT
Directors_NN
have_VPRT [PEAS]
reviewed_VBN
the_DT
working_VBG
capital_NN
which_WDT [WHSUB]
comply_VPRT
with_PIN
the_DT
International_NN
Financial_NN
requirements_NOMZ
of_PIN
the_DT
Group_NN
for_PIN
the_DT
next_JJ
twelve_CD
months_NN
Reporting_GER
Standards_NN
adopted_VBD
for_PIN
use_NN
in_PIN
the_DT
European_JJ
and_CC
have_VB
a_DT
reasonable_JJ
expectation_NOMZ
that_TOBJ
sufficient_JJ
Union_NN
IFRS_NN
starting_VBG [WZPRES]
from_PIN
the_DT
financial_JJ
year_NN
ended_VBD
funds_NN
will_PRMD
be_VB [PASS]
raised_VBN
from_PIN
these_DEMO
initiatives_NN
and_CC
have_VPRT
31_CD
December_NN
2005_CD
,_,
being_VBG [PRESP] [BEMA]
the_DT
first_JJ
financial_JJ
year_NN
,_,
therefore_CONJ
prepared_VBD
the_DT
financial_JJ
information_NOMZ
contained_VBD
commencing_VBG
after_IN
1_CD
January_NN
2005_CD
._.
herein_NN
on_PIN
a_DT
going_VBG
concern_NN
basis_NN
which_WDT [WHSUB]
assumes_VPRT [PRIV]
that_THVC
the_DT
Company_NN
will_PRMD
continue_VB
in_PIN
operational_JJ
existence_NN
The_DT
International_NN
Financial_NN
Reporting_GER
Standards_NN
for_PIN
the_DT
foreseeable_JJ
future_NN
._.
The_DT
financial_JJ
statements_NOMZ
adopted_VBN [WZPAST]
for_PIN
use_NN
in_PIN
the_DT
European_NN
Union_NN
are_VPRT [BEMA]
similar_PRED
do_VPRT
not_XX0
reflect_VB [PRIV]
any_QUAN
adjustments_NOMZ
that_TSUB
would_PRMD
be_VB [PASS]
required_VBN [SUAV]
with_PIN
the_DT
International_NN
Financial_NN
Reporting_GER
Standards_NN
to_TO
be_VB [PASS]
made_VBN
if_COND
they_TPP3
were_VBD
to_TO
be_VB [PASS]
prepared_VBN
on_PIN
a_DT
basis_NN
as_IN
issued_VBN
by_PIN
the_DT
IASB_NN
,_,
except_PIN
for_PIN
certain_JJ
provisions_NN
other_JJ
than_PIN
the_DT
going_VBG
concern_NN
basis_NN
._.
concerning_VBG
fair_JJ
value_NN
accounting_GER
for_PIN
financial_JJ
liabilities_NOMZ
and_CC
hedge_JJ
accounting_GER
,_,
which_WDT [SERE]
have_VPRT
no_SYNE
Use_NN
of_PIN
estimates_NN
impact_NN
on_PIN
the_DT
financial_JJ
statements_NOMZ
of_PIN
the_DT
Group_NN
._.
The_DT
preparation_NOMZ
of_PIN
the_DT
financial_JJ
statements_NOMZ
,_,
Consequently_CONJ
,_,
the_DT
consolidated_JJ
IFRS_NN
financial_JJ
in_PIN
conformity_NOMZ
with_PIN
IFRS_NN
,_,
requires_VPRT [SUAV]
the_DT
use_NN
of_PIN
statements_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
estimates_NN
and_PHC
assumptions_NOMZ
that_TSUB
affect_VPRT
the_DT
reported_VBN [PUBV]
are_VPRT [BEMA]
compliant_PRED
with_PIN
both_DT
the_DT
International_NN
Financial_NN
amounts_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
at_PIN
the_DT
date_NN
of_PIN
Reporting_GER
Standards_NN
as_IN
issued_VBN
by_PIN
IASB_NN
and_CC
the_DT
the_DT
financial_JJ
statements_NOMZ
and_CC
the_DT
reported_VBN [PUBV]
amounts_NN
version_NN
adopted_VBN [WZPAST]
for_PIN
use_NN
in_PIN
the_DT
European_NN
Union_NN
._.
of_PIN
revenues_NN
and_PHC
expenses_NN
during_PIN
the_DT
reporting_GER
period_NN
._.
Although_CONC
these_DEMO
estimates_NN
are_VPRT [PASS]
based_VBN
on_PIN
These_DEMO
consolidated_JJ
financial_JJ
statements_NOMZ
have_VPRT
managements_NOMZ
best_JJ
knowledge_NN
of_PIN
the_DT
amount_NN
,_,
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
IFRS_NN
and_CC
,_,
event_NN
or_CC
actions_NOMZ
,_,
actual_JJ
results_NN
may_POMD
ultimately_RB
the_DT
interpretations_NOMZ
issued_VBN [WZPAST]
by_PIN
the_DT
International_NN
differ_VPRT
from_PIN
those_DEMO
estimates_NN
._.
The_DT
areas_NN
involving_VBG [WZPRES]
Financial_JJ
Reporting_GER
Interpretations_NOMZ
Committee_NN
higher_JJ
degree_NN
of_PIN
judgement_NOMZ
or_CC
complexity_NOMZ
,_,
or_CC
IFRIC_NN
and_CC
with_PIN
those_DEMO
parts_NN
of_PIN
the_DT
Companies_NN
Act_NN
areas_NN
where_RB
assumptions_NOMZ
and_PHC
estimates_NN
are_VPRT [BEMA]
1985_CD
applicable_JJ
to_PIN
companies_NN
reporting_VBG [PUBV] [WZPRES]
under_IN
IFRS_NN
._.
significant_JJ
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
The_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
under_IN
are_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
Note_NN
3_CD
:_:
Critical_JJ
accounting_GER
the_DT
historical_JJ
cost_NN
convention_NOMZ
,_,
as_IN
modified_VBN
by_PIN
the_DT
estimates_NN
and_PHC
judgements_NOMZ
._.
revaluation_NOMZ
of_PIN
financial_JJ
assets_NN
and_CC
financial_JJ
liabilities_NOMZ
._.
Company_NN
income_NN
statement_NOMZ
The_DT
Companys_NN
working_VBG [WZPRES]
capital_NN
requirements_NOMZ
In_PIN
accordance_NN
with_PIN
the_DT
provisions_NN
of_PIN
section_NOMZ
230_CD
continue_VPRT
to_TO
be_VB [BYPA]
affected_VBN
by_PIN
the_DT
timing_NN
and_PHC
receipt_NN
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
no_SYNE
separate_JJ
income_NN
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
63_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
64_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
statement_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
presented_VBN
for_PIN
the_DT
Company_NN
._.
Share-Based_NN
Payments_NOMZ
to_PIN
equity_NOMZ
instruments_NOMZ
that_TOBJ
The_DT
results_NN
for_PIN
the_DT
Company_NN
are_VPRT [SPAU] [PASS]
also_RB
presented_VBN
were_VBD [PASS]
granted_VBN [SUAV]
on_PIN
or_CC
before_IN
7_CD
November_NN
2002_CD
and_CC
under_IN
IFRS_NN
._.
The_DT
Company_NN
elected_VBN
to_TO
adopt_VB
full_JJ
retrospective_NN
application_NOMZ
of_PIN
IFRS_NN
2_CD
,_,
b_NN
IFRS_NN
1_CD
exemptions_NOMZ
not_XX0
taking_VBG
advantage_NN
of_PIN
the_DT
IFRS_NN
1_CD
exemption_NOMZ
._.
IFRS_NN
1_CD
:_:
First-time_JJ
Adoption_NOMZ
of_PIN
International_NN
Financial_NN
Reporting_GER
Standards_NN
has_VPRT [PEAS]
been_VBN [PASS]
applied_VBN
in_PIN
preparing_VBG
Cumulative_JJ
translation_NOMZ
differences_NN
:_:
A_DT
first-time_JJ
these_DEMO
financial_JJ
statements_NOMZ
._.
IFRS_NN
1_CD
sets_VPRT
out_PIN
the_DT
adopter_NN
need_MD
not_XX0
comply_VB
retrospectively_RB
with_PIN
the_DT
procedures_NN
that_TOBJ
the_DT
Group_NN
must_NEMD
follow_VB
when_RB
it_PIT
requirements_NOMZ
in_PIN
IAS_NN
21_CD
:_:
The_DT
Effects_NN
of_PIN
Changes_NN
adopts_VPRT
IFRS_NN
for_PIN
the_DT
first_JJ
time_NN
._.
in_PIN
Foreign_NN
Exchange_NN
Rates_NN
to_TO
classify_VB
translation_NOMZ
differences_NN
as_IN
a_DT
separate_JJ
component_NN
of_PIN
equity_NOMZ
The_DT
Group_NN
has_VPRT [PEAS]
established_VBN [PRIV]
its_PIT
IFRS_NN
accounting_GER
related_VBN [WZPAST]
to_PIN
foreign_JJ
operations_NOMZ
and_CC
recycle_VB
them_TPP3
policies_NN
for_PIN
the_DT
year_NN
ending_VBG [WZPRES]
31_CD
December_NN
2005_CD
and_CC
through_PIN
the_DT
income_NN
statement_NOMZ
on_PIN
disposal_NN
of_PIN
the_DT
applied_VBN
these_DEMO
standards_NN
retrospectively_RB
to_TO
determine_VB [SUAV] [PRIV]
foreign_JJ
operations_NOMZ
._.
The_DT
Group_NN
elected_VBD
not_XX0
to_TO
take_VB
the_DT
IFRS_NN
opening_GER
balance_NN
sheet_NN
at_PIN
its_PIT
date_NN
of_PIN
transition_NOMZ
,_,
advantage_NN
of_PIN
this_DEMO
exemption_NOMZ
._.
1_CD
January_NN
2004_CD
,_,
except_PIN
where_RB
permitted_VBN
or_CC
required_VBN [SUAV]
by_PIN
IFRS_NN
1_CD
or_CC
other_JJ
applicable_JJ
standards_NN
._.
Financial_NN
instruments_NOMZ
:_:
In_PIN
its_PIT
first_JJ
IFRS_NN
financial_JJ
statements_NOMZ
a_DT
first_JJ
time_NN
adopter_NN
need_MD
not_XX0
restate_VB
Except_PIN
as_IN
noted_VBN [PRIV]
below_PLACE
,_,
at_PIN
the_DT
date_NN
of_PIN
transition_NOMZ
to_PIN
the_DT
comparative_JJ
information_NOMZ
in_PIN
compliance_NN
with_PIN
IFRS_NN
,_,
the_DT
Group_NN
recognized_VBD [PRIV]
all_QUAN
assets_NN
and_PHC
liabilities_NOMZ
IAS_NN
32_CD
:_:
Financial_NN
Instruments_NOMZ
:_:
Disclosure_NN
and_CC
as_IN
required_VBN [SUAV]
by_PIN
IFRS_NN
and_CC
derecognised_VBD
all_QUAN
assets_NN
and_PHC
presentation_NOMZ
and_PHC
IAS_NN
39_CD
:_:
Financial_NN
Instruments_NOMZ
:_:
liabilities_NOMZ
not_XX0
permitted_VBN
by_PIN
IFRS_NN
._.
Assets_NN
and_PHC
liabilities_NOMZ
Recognition_NOMZ
and_PHC
Measurement_NOMZ
._.
The_DT
Company_NN
were_VBD [BEMA]
all_QUAN
measured_VBN
in_PIN
accordance_NN
with_PIN
IFRS_NN
._.
elected_VBN
not_XX0
to_TO
take_VB
advantage_NN
of_PIN
this_DEMO
exemption_NOMZ
._.
The_DT
impact_NN
of_PIN
transition_NOMZ
from_PIN
UK_NN
GAAP_NN
to_PIN
IFRS_NN
on_PIN
c_NN
Consolidation_NOMZ
the_DT
Groups_NN
shareholders_NN
funds_NN
as_IN
at_PIN
1_CD
January_NN
2004_CD
The_DT
underlying_VBG
financial_JJ
statements_NOMZ
comprise_VPRT
a_DT
and_CC
31_CD
December_NN
2004_CD
,_,
and_ANDC
on_PIN
the_DT
Groups_NN
income_NN
consolidation_NOMZ
of_PIN
the_DT
accounts_NN
of_PIN
the_DT
Company_NN
and_CC
all_QUAN
statement_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
its_PIT
subsidiaries_NN
and_CC
includes_VPRT
the_DT
Groups_NN
share_NN
of_PIN
the_DT
is_VPRT [PASS]
discussed_VBN
in_PIN
Note_NN
37_CD
:_:
Transition_NOMZ
from_PIN
accounting_GER
results_NN
and_CC
net_JJ
assets_NN
of_PIN
its_PIT
associates_NN
._.
The_DT
accounts_NN
practices_NN
generally_RB
accepted_VBN [PRIV]
in_PIN
the_DT
UK_NN
to_PIN
of_PIN
the_DT
Groups_NN
subsidiaries_NN
and_PHC
associates_NN
are_VPRT [PASS]
made_VBN
International_NN
Financial_NN
Reporting_GER
Standards_NN
._.
The_DT
adoption_NOMZ
of_PIN
the_DT
provisions_NN
set_VBN [WZPAST]
out_PIN
in_PIN
IFRS_NN
1_CD
Subsidiaries_NN
are_VPRT [PASS]
outlined_VBN
below_PLACE
._.
Subsidiaries_NN
are_VPRT [BEMA]
all_QUAN
entities_NOMZ
over_IN
which_WDT
the_DT
Group_NN
has_VPRT
control_NN
._.
Control_NN
is_VPRT [PASS]
achieved_VBN
where_RB
the_DT
Company_NN
Business_NOMZ
combinations_NOMZ
:_:
A_DT
first-time_JJ
adopter_NN
may_POMD
has_VPRT
the_DT
power_NN
to_TO
govern_VB
the_DT
financial_JJ
and_CC
operating_VBG
elect_VB
not_XX0
to_TO
apply_VB
IFRS_NN
3_CD
:_:
Business_NOMZ
Combinations_NOMZ
policies_NN
of_PIN
an_DT
entity_NOMZ
so_RB
as_IN
to_TO
obtain_VB
benefits_NN
from_PIN
its_PIT
retrospectively_RB
to_PIN
business_NOMZ
combinations_NOMZ
that_TOBJ
activities_NOMZ
._.
Subsidiaries_NN
are_VPRT [SPAU] [PASS]
fully_AMP
consolidated_VBN
from_PIN
occurred_VBN
before_IN
the_DT
date_NN
of_PIN
transition_NOMZ
to_PIN
IFRS_NN
._.
the_DT
date_NN
on_PIN
which_WDT [PIRE]
control_NN
is_VPRT [PASS]
transferred_VBN
to_PIN
the_DT
Group_NN
._.
The_DT
Company_NN
elected_VBN
to_TO
take_VB
advantage_NN
of_PIN
this_DEMO
They_TPP3
are_VPRT [PASS]
fide-consolidated_VBN
from_PIN
the_DT
date_NN
on_PIN
which_WDT [PIRE]
exemption_NOMZ
,_,
not_XX0
applying_VBG
IFRS_NN
3_CD
to_PIN
the_DT
business_NOMZ
control_NN
ceases_VPRT
._.
The_DT
results_NN
of_PIN
subsidiaries_NN
acquired_VBN
combinations_NOMZ
that_TSUB
occurred_VBD
before_IN
the_DT
date_NN
of_PIN
or_CC
disposed_VBN
during_PIN
the_DT
year_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
transition_NOMZ
._.
Any_QUAN
unamortised_JJ
goodwill_NN
at_PIN
1_CD
January_NN
consolidated_JJ
income_NN
statement_NOMZ
from_PIN
the_DT
effective_JJ
2004_CD
,_,
calculated_VBN [PRIV] [PASTP]
in_PIN
accordance_NN
with_PIN
UK_NN
GAAP_NN
,_,
date_NN
of_PIN
acquisition_NOMZ
or_CC
up_RB
to_PIN
the_DT
effective_JJ
date_NN
of_PIN
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
IFRS_NN
accounts_NN
at_PIN
disposal_NN
,_,
as_IN
appropriate_JJ
._.
depreciated_VBN
cost_NN
after_IN
taking_VBG
into_PIN
account_NN
potential_JJ
adjustments_NOMZ
required_VBN [SUAV]
to_TO
comply_VB
with_PIN
IFRS_NN
The_NN
Group_NN
uses_VPRT
the_DT
purchase_NN
method_NN
to_TO
account_VB
measurement_NOMZ
principles_NN
._.
for_PIN
the_DT
acquisition_NOMZ
of_PIN
subsidiaries_NN
._.
The_DT
cost_NN
of_PIN
an_DT
acquisition_NOMZ
is_VPRT [PASS]
measured_VBN
as_IN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
Share-based_JJ
payments_NOMZ
:_:
A_DT
first-time_JJ
adopter_NN
is_VPRT [PASS]
assets_NN
given_VBN
,_,
equity_NOMZ
instruments_NOMZ
issued_VBN
and_CC
liabilities_NOMZ
encouraged_VBD
,_,
but_CC
not_XX0
required_VBN [SUAV]
,_,
to_TO
apply_VB
IFRS_NN
2_CD
:_:
incurred_VBN
or_CC
assumed_VBN [PRIV]
at_PIN
the_DT
date_NN
of_PIN
exchange_NN
,_,
plus_PIN
64_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
65_CD
Payments_NOMZ
to_PIN
equity_NOMZ
instruments_NOMZ
that_TSUB
costs_VPRT
directly_RB
attributable_JJ
to_PIN
the_DT
acquisition_NOMZ
._.
Identifiable_JJ
Associates_NN
accounting_GER
policies_NN
have_VPRT [PEAS]
been_VBN [PASS]
changed_VBN
on_PIN
or_CC
before_IN
7_CD
November_NN
2002_CD
and_CC
assets_NN
acquired_VBN
and_CC
liabilities_NOMZ
and_PHC
contingent_NN
where_RB
necessary_JJ
to_TO
ensure_VB [SUAV] [PRIV]
consistency_NN
with_PIN
the_DT
January_NN
2005_CD
._.
The_DT
Company_NN
elected_VBN
liabilities_NOMZ
assumed_VBD [PRIV]
in_PIN
a_DT
business_NOMZ
combination_NOMZ
policies_NN
adopted_VBN [WZPAST]
by_PIN
the_DT
Group_NN
._.
etrospective_JJ
application_NOMZ
of_PIN
IFRS_NN
2_CD
,_,
are_VPRT [PASS]
measured_VBN
initially_TIME
at_PIN
their_TPP3
fair_JJ
values_NN
at_PIN
the_DT
antage_NN
of_PIN
the_DT
IFRS_NN
1_CD
exemption_NOMZ
._.
acquisition_NOMZ
date_NN
,_,
irrespective_RB
of_PIN
the_DT
extent_NN
of_PIN
any_QUAN
d_SYM
Foreign_JJ
currency_NN
translation_NOMZ
minority_NOMZ
interest_NN
._.
The_DT
excess_NN
of_PIN
the_DT
cost_NN
of_PIN
acquisition_NOMZ
Functional_NN
and_PHC
presentation_NOMZ
currency_NN
anslation_NOMZ
differences_NN
:_:
A_DT
first-time_JJ
over_IN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
Groups_NN
share_NN
of_PIN
the_DT
Items_NN
included_VBD
in_PIN
the_DT
financial_JJ
statements_NOMZ
of_PIN
each_QUAN
of_PIN
not_XX0
comply_VB
retrospectively_RB
with_PIN
the_DT
identifiable_JJ
net_JJ
assets_NN
acquired_VBN [WZPAST]
is_VPRT [PASS]
recorded_VBN
as_IN
the_DT
Groups_NN
entities_NOMZ
are_VPRT [PASS]
measured_VBN
using_VBG
the_DT
currency_NN
in_PIN
IAS_NN
21_CD
:_:
The_DT
Effects_NN
of_PIN
Changes_NN
goodwill_NN
._.
If_COND
the_DT
cost_NN
of_PIN
acquisition_NOMZ
is_VPRT [BEMA]
less_PRED
than_PIN
the_DT
of_PIN
the_DT
primary_JJ
economic_JJ
environment_NOMZ
in_PIN
which_WDT [PIRE]
hange_NN
Rates_NN
to_TO
classify_VB
translation_NOMZ
fair_JJ
value_NN
of_PIN
the_DT
groups_NN
share_NN
of_PIN
the_DT
net_JJ
assets_NN
of_PIN
the_DT
entity_NOMZ
operates_VPRT
the_DT
functional_JJ
currency_NN
._.
a_DT
separate_JJ
component_NN
of_PIN
equity_NOMZ
the_DT
subsidiary_NN
acquired_VBN
,_,
the_DT
difference_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
The_DT
consolidated_JJ
financial_JJ
statements_NOMZ
are_VPRT [PASS]
presented_VBN
ign_NN
operations_NOMZ
and_CC
recycle_VB
them_TPP3
directly_RB
in_PIN
the_DT
income_NN
statement_NOMZ
._.
in_PIN
pound_NN
sterling_GER
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
Companys_NN
functional_JJ
come_VBN
statement_NOMZ
on_PIN
disposal_NN
of_PIN
the_DT
and_CC
presentation_NOMZ
currency_NN
._.
The_DT
Group_NN
elected_VBD
not_XX0
to_TO
take_VB
Inter-company_JJ
transactions_NOMZ
,_,
balances_NN
and_CC
unrealised_JJ
his_TPP3
exemption_NOMZ
._.
gains_NN
on_PIN
transactions_NOMZ
between_PIN
Group_NN
companies_NN
are_VPRT
Transactions_NOMZ
and_PHC
balances_NN
eliminated_VBN
._.
Unrealised_JJ
losses_NN
are_VPRT [SPAU] [PASS]
also_RB
eliminated_VBN
Foreign_JJ
currency_NN
transactions_NOMZ
by_PIN
Group_NN
companies_NN
ruments_NOMZ
:_:
In_PIN
its_PIT
first_JJ
IFRS_NN
financial_JJ
unless_COND
the_DT
transaction_NOMZ
provides_VPRT
evidence_NN
of_PIN
an_DT
are_VPRT [PASS]
translated_VBN
in_PIN
the_DT
functional_JJ
currency_NN
at_PIN
the_DT
irst_NN
time_NN
adopter_NN
need_MD
not_XX0
restate_VB
impairment_NOMZ
of_PIN
the_DT
asset_NN
transferred_VBN
._.
Subsidiaries_NN
exchange_NN
rate_NN
prevailing_VBG [WZPRES]
at_PIN
the_DT
date_NN
of_PIN
the_DT
transaction_NOMZ
._.
five_CD
information_NOMZ
in_PIN
compliance_NN
with_PIN
accounting_GER
policies_NN
have_VPRT [PEAS]
been_VBN [PASS]
changed_VBN
where_RB
Foreign_JJ
exchange_NN
gains_NN
and_PHC
losses_NN
resulting_VBG [WZPRES]
from_PIN
ial_JJ
Instruments_NOMZ
:_:
Disclosure_NN
and_CC
necessary_JJ
to_TO
ensure_VB [SUAV] [PRIV]
consistency_NN
with_PIN
the_DT
policies_NN
the_DT
settlement_NOMZ
of_PIN
such_JJ
transactions_NOMZ
and_CC
from_PIN
the_DT
nd_NN
IAS_NN
39_CD
:_:
Financial_NN
Instruments_NOMZ
:_:
adopted_VBN [PASTP]
by_PIN
the_DT
Group_NN
._.
translation_NOMZ
at_PIN
year-end_JJ
exchange_NN
rates_NN
of_PIN
monetary_JJ
nd_NN
Measurement_NOMZ
._.
The_DT
Company_NN
assets_NN
and_PHC
liabilities_NOMZ
denominated_VBN [WZPAST]
in_PIN
foreign_JJ
currencies_NN
take_VPRT
advantage_NN
of_PIN
this_DEMO
exemption_NOMZ
._.
Associates_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
,_,
except_PIN
when_RB
Associates_NN
are_VPRT [BEMA]
all_QUAN
entities_NOMZ
over_IN
which_WDT
the_DT
Group_NN
it_PIT
relates_VPRT
to_PIN
items_NN
recognized_VBN [PRIV] [WZPAST]
directly_RB
in_PIN
equity_NOMZ
n_NN
has_VPRT
the_DT
power_NN
to_TO
exercise_VB
significant_JJ
influence_NN
but_CC
e._FW
g._FW
equities_NOMZ
classified_VBN
as_IN
available_JJ
for_PIN
sale_NN
,_,
the_DT
financial_JJ
statements_NOMZ
comprise_VPRT
a_DT
not_XX0
control_VB
generally_RB
accompanying_VBG
a_DT
shareholding_GER
exchange_NN
component_NN
of_PIN
that_DEMO
gain_NN
or_CC
loss_NN
will_PRMD
be_VB [BEMA]
the_DT
accounts_NN
of_PIN
the_DT
Company_NN
and_CC
all_QUAN
of_PIN
between_PIN
20_CD
%_NN
and_CC
50_CD
%_NN
of_PIN
the_DT
voting_NN
rights_NN
._.
and_ANDC
includes_VPRT
the_DT
Groups_NN
share_NN
of_PIN
the_DT
Investments_NOMZ
in_PIN
associates_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
by_PIN
assets_NN
of_PIN
its_PIT
associates_NN
._.
The_DT
accounts_NN
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
and_CC
are_VPRT
initially_TIME
Group_NN
companies_NN
ubsidiaries_NN
and_PHC
associates_NN
are_VPRT [PASS]
made_VBN
recognized_VBN [PRIV]
at_PIN
cost_NN
._.
The_DT
Groups_NN
investment_NOMZ
in_PIN
The_DT
results_NN
and_CC
financial_JJ
position_NOMZ
of_PIN
all_QUAN
the_DT
Group_NN
ber_NN
._.
associates_NN
includes_VPRT
goodwill_NN
identified_VBN [WZPAST]
on_PIN
acquisition_NOMZ
._.
entities_NOMZ
that_TSUB
have_VPRT
a_DT
functional_JJ
currency_NN
different_JJ
from_PIN
the_DT
presentation_NOMZ
currency_NN
are_VPRT [PASS]
translated_VBN
into_PIN
the_DT
The_DT
Groups_NN
share_NN
of_PIN
its_PIT
associates_NN
post-acquisition_JJ
presentation_NOMZ
currency_NN
as_IN
follows_VPRT
:_:
all_QUAN
entities_NOMZ
over_IN
which_WDT
the_DT
Group_NN
profits_NN
or_CC
losses_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
trol_NN
is_VPRT [PASS]
achieved_VBN
where_RB
the_DT
Company_NN
statement_NOMZ
,_,
and_ANDC
its_PIT
share_NN
of_PIN
post-acquisition_JJ
i_FPP1
assets_NN
and_PHC
liabilities_NOMZ
for_PIN
each_QUAN
balance_NN
sheet_NN
o_NN
govern_VPRT
the_DT
financial_JJ
and_CC
operating_VBG
movements_NOMZ
in_PIN
reserves_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
reserves_NN
._.
presented_VBN
are_VPRT [PASS]
translated_VBN
at_PIN
the_DT
closing_GER
rate_NN
tity_NOMZ
so_RB
as_IN
to_TO
obtain_VB
benefits_NN
from_PIN
its_PIT
The_DT
cumulative_JJ
post-acquisition_NOMZ
movements_NOMZ
are_VPRT [BEMA]
at_PIN
the_DT
date_NN
of_PIN
the_DT
balance_NN
sheet_NN
:_:
iaries_NN
are_VPRT [SPAU] [PASS]
fully_AMP
consolidated_VBN
from_PIN
adjusted_VBN
against_PIN
the_DT
carrying_VBG
amount_NN
of_PIN
the_DT
h_NN
control_NN
is_VPRT [PASS]
transferred_VBN
to_PIN
the_DT
Group_NN
._.
When_RB
the_DT
Groups_NN
share_NN
of_PIN
losses_NN
in_PIN
ii_JJ
income_NN
and_PHC
expenses_NN
for_PIN
each_QUAN
income_NN
statement_NOMZ
solidated_VBN [WZPAST]
from_PIN
the_DT
date_NN
on_PIN
which_WDT [PIRE]
an_DT
associate_NN
or_CC
joint_JJ
venture_NN
equals_VPRT
or_CC
exceeds_VPRT
its_PIT
are_VPRT [PASS]
translated_VBN
at_PIN
average_JJ
exchange_NN
rates_NN
:_:
and_ANDC
The_DT
results_NN
of_PIN
subsidiaries_NN
acquired_VBN
interest_NN
or_CC
participation_NOMZ
,_,
including_VBG [PRESP]
any_QUAN
other_JJ
ng_NN
the_DT
year_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
unsecured_JJ
long-term_JJ
receivables_NN
,_,
the_DT
Group_NN
does_EMPH
iii_VB
all_QUAN
resulting_VBG
exchange_NN
differences_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
ome_NN
statement_NOMZ
from_PIN
the_DT
effective_JJ
not_XX0
recognize_VB [PRIV]
further_JJ
losses_NN
,_,
unless_COND
it_PIT
has_VPRT [PEAS]
incurred_VBN
as_IN
a_DT
separate_JJ
component_NN
of_PIN
equity_NOMZ
._.
on_PIN
or_CC
up_IN
to_PIN
the_DT
effective_JJ
date_NN
of_PIN
obligations_NOMZ
or_CC
made_VBN
payments_NOMZ
on_PIN
behalf_NN
ropriate_NN
._.
of_PIN
the_DT
associate_NN
or_CC
joint_JJ
venture_NN
._.
On_PIN
consolidation_NOMZ
,_,
exchange_NN
differences_NN
arising_VBG [WZPRES]
from_PIN
the_DT
translation_NOMZ
of_PIN
the_DT
net_JJ
investment_NOMZ
in_PIN
foreign_JJ
the_DT
purchase_NN
method_NN
to_TO
account_VB
Unrealised_JJ
gains_NN
on_PIN
transactions_NOMZ
between_PIN
the_DT
Group_NN
entities_NOMZ
,_,
are_VPRT [PASS]
taken_VBN
to_PIN
shareholders_NN
equity_NOMZ
._.
The_DT
cost_NN
of_PIN
an_DT
and_CC
its_PIT
associates_NN
are_VPRT [PASS]
eliminated_VBN
to_PIN
the_DT
extent_NN
of_PIN
the_DT
easured_VBN
as_IN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
Groups_NN
interest_NN
in_PIN
the_DT
associates_NN
._.
Unrealised_JJ
losses_NN
Goodwill_NN
and_CC
fair_JJ
value_NN
adjustments_NOMZ
arising_VBG [WZPRES]
on_PIN
the_DT
uity_NOMZ
instruments_NOMZ
issued_VBN
and_CC
liabilities_NOMZ
are_VPRT [SPAU] [PASS]
also_RB
eliminated_VBN
unless_COND
the_DT
transaction_NOMZ
provides_VPRT
acquisition_NOMZ
of_PIN
a_DT
foreign_JJ
entity_NOMZ
are_VPRT [PASS]
treated_VBN
as_IN
assets_NN
med_VBN [WZPAST]
at_PIN
the_DT
date_NN
of_PIN
exchange_NN
,_,
plus_PIN
evidence_NN
of_PIN
an_DT
impairment_NOMZ
of_PIN
the_DT
asset_NN
transferred_VBN
._.
and_ANDC
liabilities_NOMZ
of_PIN
the_DT
foreign_JJ
entity_NOMZ
and_CC
translated_VBN
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
65_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
66_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
at_PIN
the_DT
closing_GER
rate_NN
._.
On_PIN
disposal_NN
of_PIN
a_DT
foreign_JJ
entity_NOMZ
,_,
Royalty_NN
income_NN
accumulated_VBN
exchange_NN
differences_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
Royalty_NN
income_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
an_DT
accruals_NN
basis_NN
in_PIN
the_DT
income_NN
statement_NOMZ
in_PIN
the_DT
same_JJ
period_NN
in_PIN
which_WDT [PIRE]
and_CC
represents_VPRT
income_NN
earned_VBD
as_IN
a_DT
percentage_NN
of_PIN
the_DT
gain_NN
or_CC
loss_NN
on_PIN
disposal_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
._.
product_NN
sales_NN
in_PIN
accordance_NN
with_PIN
the_DT
substance_NN
of_PIN
the_DT
relevant_JJ
agreement_NOMZ
._.
e_LS
Segment_NOMZ
reporting_VBG [PUBV] [WZPRES]
The_DT
Groups_NN
primary_JJ
segment_NOMZ
for_PIN
IFRS_NN
segment_NOMZ
Manufacturing_GER
and_PHC
distribution_NOMZ
reporting_GER
is_VPRT [BEMA]
the_DT
business_NOMZ
segment_NOMZ
._.
A_DT
business_NOMZ
Manufacturing_GER
and_PHC
distribution_NOMZ
revenues_NN
principally_RB
segment_NOMZ
is_VPRT [BEMA]
a_DT
group_NN
of_PIN
assets_NN
and_PHC
operations_NOMZ
engaged_VBD
comprise_VB
contract_NN
manufacturing_GER
fees_NN
invoiced_VBD
to_PIN
in_PIN
providing_VBG
products_NN
or_CC
services_NN
that_TSUB
are_VPRT [BEMA]
subject_PRED
to_PIN
third_JJ
parties_NN
and_PHC
income_NN
from_PIN
product_NN
sales_NN
._.
Revenues_NN
risks_NN
and_PHC
returns_NN
that_TSUB
are_VPRT [BEMA]
different_PRED
from_PIN
those_DEMO
of_PIN
are_VPRT [PASS]
recognized_VBN [PRIV]
upon_PIN
transfer_NN
to_PIN
the_DT
customer_NN
of_PIN
other_JJ
business_NOMZ
segments_NOMZ
._.
significant_JJ
risks_NN
and_PHC
rewards_NN
,_,
usually_RB
upon_PIN
despatch_NN
of_PIN
goods_NN
shipped_VBN
where_RB
the_DT
sales_NN
price_NN
is_VPRT [PASS]
agreed_VBN [SUAV] [PUBV]
Geographical_NN
regions_NN
are_VPRT [BEMA]
the_DT
secondary_JJ
reporting_GER
and_PHC
collectability_NOMZ
is_VPRT [SPAU] [PASS]
reasonably_RB
assured_VBN
._.
A_DT
geographic_JJ
segment_NOMZ
is_VPRT [PASS]
engaged_VBN
in_PIN
providing_VBG
products_NN
or_CC
services_NN
within_PIN
a_DT
particular_JJ
g_NN
Intangible_JJ
assets_NN
economic_JJ
environment_NOMZ
that_TSUB
are_VPRT [BEMA]
subject_PRED
to_PIN
risks_NN
and_PHC
Goodwill_NN
return_NN
that_TSUB
are_VPRT [BEMA]
different_PRED
from_PIN
those_DEMO
of_PIN
components_NN
Goodwill_NN
represents_VPRT
the_DT
excess_NN
of_PIN
the_DT
cost_NN
of_PIN
an_DT
operating_GER
in_PIN
other_JJ
economic_JJ
environments_NOMZ
._.
acquisition_NOMZ
over_IN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
Groups_NN
share_NN
of_PIN
the_DT
net_JJ
identifiable_JJ
assets_NN
of_PIN
the_DT
acquired_VBN
subsidiary_NN
Segment_NOMZ
reporting_GER
reflects_VPRT [PRIV]
the_DT
internal_JJ
management_NOMZ
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
._.
Goodwill_NN
is_VPRT [PASS]
tested_VBN
annually_RB
reporting_VBG [PUBV]
structure_NN
and_CC
the_DT
way_NN
the_DT
business_NOMZ
for_PIN
impairment_NOMZ
and_CC
carried_VBD
at_PIN
cost_NN
less_JJ
accumulated_VBN
is_VPRT [PASS]
managed_VBN
._.
Goodwill_NN
is_VPRT [PASS]
allocated_VBN
to_TO
cash_VB
generating_VBG
units_NN
for_PIN
the_DT
purpose_NN
of_PIN
impairment_NOMZ
testing_GER
._.
f_LS
Revenue_NN
recognition_NOMZ
Each_QUAN
of_PIN
those_DEMO
cash_NN
generating_VBG [WZPRES]
units_NN
represents_VPRT
the_DT
Revenue_NN
comprises_VPRT
the_DT
fair_JJ
value_NN
for_PIN
the_DT
sale_NN
of_PIN
Groups_NN
investment_NOMZ
in_PIN
each_QUAN
country_NN
of_PIN
operation_NOMZ
._.
goods_NN
and_PHC
services_NN
,_,
net_NN
of_PIN
sales_NN
taxes_NN
,_,
rebates_NN
and_PHC
discounts_NN
and_CC
after_IN
eliminating_VBG
sales_NN
within_PIN
Intellectual_NN
property_NN
the_DT
Group_NN
._.
Revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
follows_VPRT
:_:
Intellectual_NN
property_NN
comprises_VPRT
acquired_VBN
patents_NN
,_,
trade_NN
marks_NN
,_,
know-how_NN
and_CC
other_JJ
similarly_CONJ
identified_VBN
Contract_NN
development_NOMZ
and_PHC
licensing_GER
rights_NN
._.
These_DEMP
are_VPRT [PASS]
recorded_VBN
at_PIN
their_TPP3
fair_JJ
value_NN
at_PIN
Contract_NN
development_NOMZ
and_PHC
licensing_GER
income_NN
acquisition_NOMZ
date_NN
and_CC
are_VPRT [PASS]
amortised_VBN
on_PIN
a_DT
straight_JJ
line_NN
represents_VPRT
amounts_NN
earned_VBN [WZPAST]
for_PIN
services_NN
rendered_VBN
basis_NN
over_IN
their_TPP3
estimated_VBN [PRIV]
useful_JJ
economic_JJ
lives_NN
from_PIN
under_IN
development_NOMZ
and_PHC
licensing_GER
agreements_NOMZ
,_,
the_DT
time_NN
they_TPP3
are_VPRT [BEMA]
available_PRED
for_PIN
use_NN
._.
The_DT
period_NN
over_IN
including_VBG
up-front_JJ
payments_NOMZ
,_,
milestone_NN
payments_NOMZ
,_,
which_WDT [SERE]
the_DT
Group_NN
expects_VPRT [PRIV]
to_TO
derive_VB
economic_JJ
benefits_NN
technology_NN
access_NN
fees_NN
and_PHC
research_NN
and_CC
does_VPRT
not_XX0
exceed_VB
20_CD
years_NN
._.
Revenues_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
where_RB [WHCL]
they_TPP3
are_VPRT [BEMA]
non-refundable_PRED
,_,
the_DT
Research_NN
and_PHC
development_NOMZ
Groups_NN
obligations_NOMZ
related_VBN [WZPAST]
to_PIN
the_DT
revenues_NN
have_VPRT [PEAS]
been_VBN
Research_NN
expenditure_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
discharged_VBN
and_CC
their_TPP3
collection_NOMZ
is_VPRT [SPAU] [PASS]
reasonably_RB
assured_VBN
._.
statement_NOMZ
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
it_PIT
is_VPRT [PASS]
incurred_VBN
._.
Refundable_JJ
contract_NN
revenue_NN
is_VPRT [PASS]
treated_VBN
as_IN
deferred_VBN
Development_NOMZ
expenditure_NN
is_VPRT [PASS]
capitalized_VBN
when_RB
the_DT
until_IN
such_JJ
time_NN
that_TOBJ
it_PIT
is_VPRT
no_RB
longer_RB
refundable_JJ
._.
criteria_NN
for_PIN
recognizing_VBG [PRIV]
as_IN
an_DT
asset_NN
are_VPRT [PASS]
met_VBN
In_PIN
general_JJ
up-front_JJ
payments_NOMZ
are_VPRT [PASS]
deferred_VBN
and_ANDC
when_RB
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
the_DT
project_NN
will_PRMD
be_VB [BEMA]
a_DT
success_NN
,_,
amortised_VBN [PASTP]
on_PIN
a_DT
systematic_JJ
basis_NN
over_IN
the_DT
period_NN
of_PIN
considering_VBG [PRIV]
its_PIT
commercial_JJ
and_PHC
technological_JJ
development_NOMZ
to_PIN
filing_NN
._.
Milestone_NN
payments_NOMZ
related_VBN [WZPAST]
to_PIN
feasibility_NOMZ
and_PHC
costs_NN
can_POMD
be_VB [PASS]
measured_VBN
reliably_RB
._.
scientific_JJ
or_CC
technical_JJ
achievements_NOMZ
are_VPRT [PASS]
recognized_VBN [PRIV]
Regulatory_NN
and_CC
other_JJ
uncertainties_NN
generally_RB
mean_VPRT [PRIV]
as_IN
income_NN
when_RB
the_DT
milestone_NN
is_VPRT [PASS]
accomplished_VBN
._.
that_DEMO
such_JJ
criteria_NN
are_VPRT [PASS]
not_XX0
met_VBN
._.
Where_RB
development_NOMZ
costs_NN
are_VPRT [PASS]
capitalized_VBN
they_TPP3
are_VPRT [PASS]
amortised_VBN
over_IN
their_TPP3
useful_JJ
economic_JJ
lives_NN
from_PIN
product_NN
launch_NN
._.
Prior_RB
to_PIN
product_NN
launch_NN
the_DT
asset_NN
is_VPRT [PASS]
tested_VBN
annually_RB
for_PIN
impairment_NOMZ
._.
66_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
67_CD
Computer_NN
software_NN
is_VPRT [PASS]
written_VBN [PUBV]
down_RP
immediately_TIME
to_PIN
its_PIT
recoverable_JJ
s_PRP
recognized_VBD [PRIV]
on_PIN
an_DT
accruals_NN
basis_NN
Costs_NN
that_TSUB
are_VPRT [SPAU] [PASS]
directly_RB
associated_VBN
with_PIN
the_DT
purchase_NN
amount_NN
if_COND
the_DT
assets_NN
carrying_VBG [WZPRES]
amount_NN
is_VPRT [BEMA]
greater_PRED
than_PIN
ncome_NN
earned_VBN
as_IN
a_DT
percentage_NN
of_PIN
and_CC
implementation_NOMZ
of_PIN
identifiable_JJ
and_PHC
unique_JJ
its_PIT
estimated_VBN [PRIV]
recoverable_JJ
amount_NN
._.
accordance_NN
with_PIN
the_DT
substance_NN
of_PIN
software_NN
products_NN
by_PIN
the_DT
Group_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
eement_NOMZ
._.
Expenditures_NN
that_TSUB
enhance_VPRT
and_CC
Gains_NN
and_PHC
losses_NN
on_PIN
disposals_NN
are_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
extend_VPRT
the_DT
benefits_NN
of_PIN
computer_NN
software_NN
programs_NN
comparing_VBG [WZPRES]
the_DT
disposal_NN
proceeds_NN
with_PIN
the_DT
carrying_VBG
nd_NN
distribution_NOMZ
beyond_IN
their_TPP3
original_JJ
specifications_NOMZ
and_PHC
lives_NN
are_VPRT
amount_NN
and_CC
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
._.
nd_JJ
distribution_NOMZ
revenues_NN
principally_RB
recognized_VBN [PRIV]
as_IN
a_DT
capital_NN
improvement_NOMZ
and_CC
added_VBD [PUBV]
to_TO
ct_VB
manufacturing_GER
fees_NN
invoiced_VBD
to_PIN
the_DT
original_JJ
cost_NN
of_PIN
the_DT
software_NN
._.
Direct_JJ
costs_NN
include_VPRT
i_FPP1
Impairment_NOMZ
of_PIN
assets_NN
income_NN
from_PIN
product_NN
sales_NN
._.
Revenues_NN
the_DT
software_NN
development_NOMZ
employee_NN
costs_NN
and_CC
an_DT
Assets_NN
that_TSUB
have_VPRT
an_DT
indefinite_JJ
useful_JJ
life_NN
are_VPRT
not_XX0
pon_VB
transfer_NN
to_PIN
the_DT
customer_NN
of_PIN
appropriate_JJ
portion_NOMZ
of_PIN
relevant_JJ
overheads_NN
._.
Software_NN
subject_NN
to_PIN
amortisation_NOMZ
and_CC
are_VPRT [PASS]
tested_VBN
annually_RB
for_PIN
and_CC
rewards_NN
,_,
usually_RB
upon_PIN
despatch_NN
costs_NN
are_VPRT [PASS]
amortised_VBN
over_IN
their_TPP3
useful_JJ
economic_JJ
lives_NN
,_,
impairment_NOMZ
._.
Assets_NN
that_TSUB
are_VPRT [BEMA]
subject_PRED
to_PIN
amortisation_NOMZ
d_SYM
where_RB
the_DT
sales_NN
price_NN
is_VPRT [PASS]
agreed_VBN [SUAV] [PUBV]
generally_RB
a_DT
period_NN
of_PIN
3_CD
to_PIN
5_CD
years_NN
._.
or_CC
depreciation_NOMZ
are_VPRT [PASS]
reviewed_VBN
for_PIN
impairment_NOMZ
y_NN
is_VPRT [SPAU] [PASS]
reasonably_RB
assured_VBN
._.
whenever_RB
events_NN
or_CC
changes_NN
in_PIN
circumstances_NN
h_VPRT
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
indicate_VPRT [PRIV]
that_THVC
the_DT
carrying_VBG
amount_NN
may_POMD
not_XX0
be_VB
sets_NN
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
recoverable_JJ
._.
An_DT
impairment_NOMZ
loss_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
for_PIN
cost_NN
of_PIN
purchase_NN
or_CC
construction_NOMZ
less_RB
provision_NN
for_PIN
the_DT
amount_NN
by_PIN
which_WDT [PIRE]
the_DT
assets_NN
carrying_VBG [WZPRES]
amount_NN
ents_VPRT
the_DT
excess_NN
of_PIN
the_DT
cost_NN
of_PIN
an_DT
depreciation_NOMZ
and_PHC
impairment_NOMZ
._.
The_DT
cost_NN
of_PIN
property_NN
,_,
exceeds_VPRT
its_PIT
recoverable_JJ
amount_NN
._.
The_DT
recoverable_JJ
the_DT
fair_JJ
value_NN
of_PIN
the_DT
Groups_NN
share_NN
of_PIN
plant_NN
and_PHC
equipment_NOMZ
includes_VPRT
acquisition_NOMZ
costs_NN
and_PHC
amount_NN
is_VPRT [BEMA]
the_DT
higher_JJ
of_PIN
an_DT
assets_NN
fair_JJ
value_NN
less_RB
ble_JJ
assets_NN
of_PIN
the_DT
acquired_VBN
subsidiary_NN
labor_NN
and_PHC
overhead_NN
costs_NN
arising_VBG [WZPRES]
directly_RB
from_PIN
the_DT
costs_NN
to_TO
sell_VB
and_CC
value_NN
in_PIN
use_NN
._.
Goodwill_NN
is_VPRT [PASS]
tested_VBN
annually_RB
construction_NOMZ
or_CC
acquisition_NOMZ
of_PIN
an_DT
item_NN
of_PIN
property_NN
,_,
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
in_PIN
the_DT
year_NN
and_CC
carried_VBD
at_PIN
cost_NN
less_JJ
accumulated_VBN
plant_NN
and_PHC
equipment_NOMZ
._.
For_PIN
the_DT
purposes_NN
of_PIN
assessing_VBG
impairment_NOMZ
,_,
es_VPRT
._.
Goodwill_NN
is_VPRT [PASS]
allocated_VBN
to_TO
cash_VB
assets_NN
are_VPRT [PASS]
grouped_VBN
at_PIN
the_DT
lowest_JJ
levels_NN
for_PIN
which_WDT [PIRE]
for_PIN
the_DT
purpose_NN
of_PIN
impairment_NOMZ
testing_GER
._.
Subsequent_JJ
costs_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
assets_NN
carrying_VBG [WZPRES]
there_EX
are_VPRT
separately_RB
identifiable_JJ
cash_NN
in_PIN
flows_NN
cashsh_VPRT
generating_VBG
units_NN
represents_VPRT
the_DT
amount_NN
or_CC
recognized_VBN [PRIV]
as_IN
a_DT
separate_JJ
asset_NN
,_,
as_IN
generating_VBG
units_NN
._.
ent_NN
in_PIN
each_QUAN
country_NN
of_PIN
operation_NOMZ
._.
appropriate_JJ
,_,
only_DWNT
when_RB
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
future_JJ
economic_JJ
benefits_NN
associated_VBN [WZPAST]
with_PIN
the_DT
item_NN
will_PRMD
flow_VB
The_DT
expected_JJ
cash_NN
flows_VPRT
generated_VBN
by_PIN
the_DT
assets_NN
are_VPRT [BEMA]
erty_PRED
to_PIN
the_DT
Group_NN
and_CC
the_DT
cost_NN
of_PIN
the_DT
item_NN
can_POMD
be_VB [PASS]
discounted_VBN
using_VBG
asset_NN
specific_JJ
discount_NN
rates_NN
which_WDT [WHSUB]
erty_VPRT
comprises_VPRT
acquired_VBN
patents_NN
,_,
measured_VBN [PASTP]
reliably_RB
._.
All_QUAN
other_JJ
repairs_NN
and_PHC
maintenance_NN
reflect_VPRT [PRIV] [THATD]
the_DT
risks_NN
associated_VBN [WZPAST]
with_PIN
the_DT
groups_NN
of_PIN
assets_NN
._.
ow-how_NN
and_CC
other_JJ
similarly_CONJ
identified_VBN
expenditures_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
These_DEMO
risks_NN
vary_VPRT
with_PIN
the_DT
nature_NN
and_CC
the_DT
location_NOMZ
of_PIN
e_SYM
recorded_VBN
at_PIN
their_TPP3
fair_JJ
value_NN
at_PIN
during_PIN
the_DT
financial_JJ
period_NN
in_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [PASS]
incurred_VBN
._.
and_ANDC
are_VPRT [PASS]
amortised_VBN
on_PIN
a_DT
straight_JJ
line_NN
estimated_VBN [PRIV]
useful_JJ
economic_JJ
lives_NN
from_PIN
Depreciation_NOMZ
is_VPRT [PASS]
not_XX0
provided_VBN
on_PIN
freehold_JJ
land_NN
or_CC
j_NN
Investments_NOMZ
e_SYM
available_JJ
for_PIN
use_NN
._.
The_DT
period_NN
over_IN
projects_NN
under_IN
construction_NOMZ
._.
On_PIN
other_JJ
property_NN
,_,
plant_NN
The_DT
Group_NN
classifies_VPRT
its_PIT
investments_NOMZ
according_VBG [WZPRES]
to_TO
expects_VPRT [PRIV]
to_TO
derive_VB
economic_JJ
benefits_NN
and_PHC
equipment_NOMZ
,_,
depreciation_NOMZ
is_VPRT [PASS]
provided_VBN
on_PIN
the_DT
the_DT
purpose_NN
for_PIN
which_WDT [PIRE]
the_DT
investments_NOMZ
were_VBD [BEMA]
20_CD
years_NN
._.
difference_NN
between_PIN
the_DT
cost_NN
of_PIN
an_DT
item_NN
and_CC
its_PIT
acquired_VBN
._.
Management_NOMZ
determines_VPRT [SUAV] [PRIV] [THATD]
the_DT
classification_NOMZ
estimated_VBN [PRIV]
residual_JJ
value_NN
,_,
in_PIN
equal_JJ
annual_JJ
instalments_NOMZ
of_PIN
investments_NOMZ
at_PIN
initial_JJ
recognition_NOMZ
and_CC
re-evaluates_VPRT
evelopment_NOMZ
over_IN
the_DT
estimated_VBN [PRIV]
useful_JJ
lives_NN
of_PIN
the_DT
assets_NN
as_IN
follows_VPRT
:_:
the_DT
designation_NOMZ
at_PIN
every_QUAN
reporting_GER
date_NN
._.
The_DT
Group_NN
diture_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
has_VPRT
the_DT
following_VBG
categories_NN
of_PIN
investments_NOMZ
:_:
Freehold_NN
buildings_GER
2_CD
%_NN
5_CD
%_NN
period_NN
in_PIN
which_WDT [PIRE]
it_PIT
is_VPRT [PASS]
incurred_VBN
._.
Laboratory_NN
equipment_NOMZ
and_PHC
machines_NN
10_CD
%_NN
33_CD
%_NN
penditure_NN
is_VPRT [PASS]
capitalized_VBN
when_RB
the_DT
Available-for-sale_JJ
financial_JJ
assets_NN
Office_NN
and_CC
other_JJ
equipment_NOMZ
10_CD
%_NN
33_CD
%_NN
nising_NN
as_IN
an_DT
asset_NN
are_VPRT [PASS]
met_VBN
Available-for-sale_JJ
financial_JJ
assets_NN
are_VPRT [BEMA]
non-derivatives_JJ
Motor_NN
vehicles_NN
20_CD
%_NN
ble_NN
that_TOBJ
the_DT
project_NN
will_PRMD
be_VB [BEMA]
a_DT
success_NN
,_,
that_DEMP
are_VPRT [PASS]
not_XX0
acquired_VBN
to_TO
generate_VB
profit_NN
from_PIN
shortShort_NN
leasehold_VBD
property_NN
period_NN
of_PIN
the_DT
lease_NN
ommercial_JJ
and_PHC
technological_JJ
term_NN
fluctuations_NOMZ
in_PIN
price_NN
._.
They_TPP3
are_VPRT [PASS]
included_VBN
in_PIN
nonsts_NN
can_POMD
be_VB [PASS]
measured_VBN
reliably_RB
._.
current_JJ
assets_NN
unless_COND
management_NOMZ
intends_VPRT [SUAV]
to_PIN
other_JJ
uncertainties_NN
generally_RB
mean_VPRT [PRIV]
Assets_NN
in_PIN
the_DT
course_NN
of_PIN
construction_NOMZ
are_VPRT [PASS]
depreciated_VBN
dispose_VB
of_PIN
the_DT
asset_NN
within_PIN
12_CD
months_NN
of_PIN
the_DT
balance_NN
a_DT
are_VPRT [PASS]
not_XX0
met_VBN
._.
Where_RB
development_NOMZ
when_RB
they_TPP3
have_VPRT [PEAS]
been_VBN [PASS]
brought_VBN
into_PIN
operational_JJ
use_NN
._.
ised_VBN
they_TPP3
are_VPRT [PASS]
amortised_VBN
over_IN
their_TPP3
lives_NN
from_PIN
product_NN
launch_NN
._.
The_DT
assets_NN
residual_JJ
values_NN
and_CC
useful_JJ
lives_NN
are_VPRT [BEMA]
Available-for-sale_JJ
investments_NOMZ
are_VPRT [SPAU] [PASS]
initially_TIME
recorded_VBN
launch_NN
the_DT
asset_NN
is_VPRT [PASS]
tested_VBN
annually_RB
reviewed_VBN
,_,
and_ANDC
adjusted_VBN
if_COND
appropriate_JJ
,_,
at_PIN
each_QUAN
at_PIN
cost_NN
,_,
being_VBG [PRESP] [BEMA]
the_DT
fair_JJ
value_NN
of_PIN
consideration_NOMZ
given_VBN
,_,
balance_NN
sheet_NN
date_NN
._.
An_DT
assets_NN
carrying_VBG [WZPRES]
amount_NN
plus_PIN
transaction_NOMZ
costs_NN
._.
Subsequently_TIME
,_,
available-for-sale_JJ
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
67_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
68_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
investments_NOMZ
comprising_VBG [WZPRES]
marketable_JJ
equity_NOMZ
securities_NOMZ
is_VPRT [PASS]
made_VBN
for_PIN
obsolete_JJ
,_,
slow-moving_JJ
or_CC
defective_JJ
items_NN
that_TSUB
are_VPRT [PASS]
traded_VBN
in_PIN
active_JJ
markets_NN
are_VPRT [PASS]
carried_VBN
at_PIN
their_TPP3
where_RB
appropriate_JJ
._.
fair_JJ
value_NN
as_IN
of_PIN
each_QUAN
balance_NN
sheet_NN
date_NN
._.
l_NN
Trade_NN
receivables_NN
Unrealised_JJ
gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
from_PIN
changes_NN
Trade_NN
receivables_NN
are_VPRT [BEMA]
non-derivative_JJ
financial_JJ
assets_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
non-monetary_JJ
securities_NOMZ
classified_VBN [WZPAST]
with_PIN
fixed_VBN
or_CC
determinable_JJ
payments_NOMZ
that_TSUB
are_VPRT
not_XX0
as_IN
available-for-sale_JJ
investments_NOMZ
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
quoted_VBN
in_PIN
an_DT
active_JJ
market_NN
._.
They_TPP3
arise_VPRT
when_RB
the_DT
equity_NOMZ
._.
When_RB
available-for-sale_JJ
investments_NOMZ
are_VPRT [PASS]
sold_VBN
Group_NN
provides_VPRT
money_NN
,_,
goods_NN
or_CC
services_NN
directly_RB
to_TO
or_CC
impaired_VBN
,_,
the_DT
accumulated_VBN
fair_JJ
value_NN
adjustments_NOMZ
a_DT
debtor_NN
with_PIN
no_SYNE
intention_NOMZ
of_PIN
trading_VBG
the_DT
receivable_NN
._.
in_PIN
equity_NOMZ
are_VPRT [PASS]
recycled_VBN
into_PIN
the_DT
income_NN
statement_NOMZ
as_IN
They_TPP3
are_VPRT [PASS]
included_VBN
in_PIN
current_JJ
assets_NN
,_,
except_PIN
for_PIN
gains_NN
and_PHC
losses_NN
from_PIN
investment_NOMZ
securities_NOMZ
._.
maturities_NOMZ
greater_JJ
than_PIN
12_CD
months_NN
after_IN
the_DT
balance_NN
sheet_NN
date_NN
._.
These_DEMP
are_VPRT [PASS]
classified_VBN
as_IN
non-current_JJ
The_NN
Group_NN
assesses_VPRT
at_PIN
each_QUAN
balance_NN
sheet_NN
date_NN
assets_NN
._.
Trade_NN
receivables_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
initially_TIME
at_PIN
whether_IN
there_EX
is_VPRT
objective_JJ
evidence_NN
that_TOBJ
a_DT
financial_JJ
fair_JJ
value_NN
less_RB
provision_NN
for_PIN
impairment_NOMZ
._.
A_DT
provision_NN
asset_NN
or_CC
a_DT
group_NN
of_PIN
financial_JJ
assets_NN
is_VPRT [PASS]
impaired_VBN
._.
for_PIN
impairment_NOMZ
of_PIN
trade_NN
receivables_NN
is_VPRT [PASS]
established_VBN [PRIV]
If_COND
any_QUAN
such_JJ
evidence_NN
exists_VPRT
for_PIN
available-for-sale_NN
when_RB
there_EX
is_VPRT
objective_JJ
evidence_NN
that_TOBJ
the_DT
Group_NN
will_PRMD
financial_JJ
assets_NN
,_,
the_DT
cumulative_JJ
loss_NN
measured_VBN
as_IN
not_XX0
be_VB [BEMA]
able_PRED
to_TO
collect_VB
all_QUAN
amounts_NN
due_JJ
according_VBG
to_PIN
the_DT
difference_NN
between_PIN
the_DT
acquisition_NOMZ
cost_NN
and_CC
the_DT
the_DT
original_JJ
terms_NN
of_PIN
the_DT
receivables_NN
._.
current_JJ
fair_JJ
value_NN
,_,
less_JJ
any_QUAN
impairment_NOMZ
loss_NN
on_PIN
that_DEMO
financial_JJ
asset_NN
previously_TIME
recognized_VBN [PRIV]
is_VPRT [PASS]
removed_VBN
m_NN
Cash_NN
and_PHC
cash_NN
equivalents_NN
from_PIN
equity_NOMZ
and_CC
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Cash_NN
and_PHC
cash_NN
equivalents_NN
are_VPRT [BEMA]
highly_AMP
liquid_JJ
Impairment_NOMZ
losses_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
income_NN
investments_NOMZ
that_TSUB
are_VPRT [BEMA]
readily_RB
convertible_PRED
to_TO
known_VBN [PRIV]
statement_NOMZ
on_PIN
equity_NOMZ
instruments_NOMZ
are_VPRT [BEMA]
not_XX0
reversed_JJ
amounts_NN
of_PIN
cash_NN
and_ANDC
which_WDT
are_VPRT [BEMA]
subject_PRED
to_PIN
an_DT
through_PIN
the_DT
income_NN
statement_NOMZ
._.
insignificant_JJ
risk_NN
of_PIN
changes_NN
in_PIN
value_NN
._.
Cash_NN
and_PHC
cash_NN
equivalents_NN
are_VPRT [PASS]
carried_VBN
in_PIN
the_DT
balance_NN
sheet_NN
at_PIN
cost_NN
._.
Financial_JJ
assets_NN
at_PIN
fair_JJ
value_NN
through_PIN
profit_NN
or_CC
loss_NN
For_PIN
the_DT
purposes_NN
of_PIN
the_DT
cash_NN
flow_NN
statement_NOMZ
,_,
cash_NN
The_DT
Group_NN
classifies_VPRT
investments_NOMZ
in_PIN
this_DEMO
category_NN
and_PHC
cash_NN
equivalents_NN
comprise_VPRT
cash_NN
at_PIN
bank_NN
and_ANDC
if_COND
acquired_VBN
principally_RB
for_PIN
the_DT
purpose_NN
of_PIN
selling_GER
in_PIN
in_PIN
hand_NN
,_,
short_JJ
term_NN
deposits_NN
,_,
marketable_JJ
securities_NOMZ
the_DT
short_JJ
term_NN
or_CC
if_COND
so_RB
designated_VBN
by_PIN
management_NOMZ
._.
Bank_NN
overdrafts_NN
are_VPRT [PASS]
included_VBN
within_PIN
Financial_JJ
assets_NN
at_PIN
fair_JJ
value_NN
through_PIN
profit_NN
or_CC
loss_NN
borrowings_GER
in_PIN
current_JJ
liabilities_NOMZ
on_PIN
the_DT
balance_NN
sheet_NN
._.
are_VPRT [SPAU] [PASS]
initially_TIME
recorded_VBN
,_,
and_ANDC
subsequently_TIME
carried_VBD
,_,
at_PIN
fair_JJ
value_NN
._.
Realised_VBN [PRIV]
and_CC
unrealised_JJ
gains_NN
and_PHC
losses_NN
n_VPRT
Borrowings_GER
arising_VBG [WZPRES]
from_PIN
changes_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
assets_NN
held_VBN [PRIV] [WZPAST]
in_PIN
Borrowings_GER
are_VPRT [PASS]
recognized_VBN [PRIV]
initially_TIME
at_PIN
fair_JJ
value_NN
,_,
this_DEMO
category_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
net_NN
of_PIN
transaction_NOMZ
costs_NN
incurred_VBN
._.
Borrowings_GER
are_VPRT [BEMA]
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
they_TPP3
arise_VPRT
._.
Financial_JJ
assets_NN
at_PIN
subsequently_TIME
stated_VBN [PUBV]
at_PIN
amortised_JJ
cost_NN
,_,
any_QUAN
difference_NN
fair_JJ
value_NN
through_PIN
profit_NN
or_CC
loss_NN
are_VPRT [PASS]
classified_VBN
as_IN
between_PIN
proceeds_NN
net_NN
of_PIN
transaction_NOMZ
costs_NN
and_CC
current_JJ
assets_NN
if_COND
they_TPP3
are_VPRT [SPAU] [PASS]
either_RB
held_VBN [PRIV]
for_PIN
trading_VBG
the_DT
redemption_NOMZ
value_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
or_CC
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
realized_VBN [PRIV]
within_PIN
12_CD
months_NN
statement_NOMZ
over_IN
the_DT
period_NN
of_PIN
the_DT
borrowings_GER
using_VBG [WZPRES]
of_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Borrowings_GER
are_VPRT [PASS]
classified_VBN
as_IN
current_JJ
liabilities_NOMZ
unless_COND
the_DT
Group_NN
has_VPRT
an_DT
k_NN
Inventories_NN
unconditional_JJ
right_NN
to_TO
defer_VB
settlement_NOMZ
of_PIN
the_DT
liability_NOMZ
Inventories_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_PHC
net_NN
for_PIN
at_PIN
least_JJ
12_CD
months_NN
after_IN
the_DT
balance_NN
sheet_NN
date_NN
._.
Cost_NN
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
using_VBG
the_DT
firstin-first-out_PIN
FIFO_NN
method_NN
._.
The_DT
cost_NN
of_PIN
finished_JJ
o_NN
Convertible_JJ
bonds_NN
goods_NN
and_PHC
work_NN
in_PIN
progress_NN
comprises_VPRT
raw_JJ
On_PIN
issue_NN
the_DT
debt_NN
and_PHC
equity_NOMZ
components_NN
of_PIN
a_DT
materials_NN
,_,
direct_JJ
labor_NN
,_,
other_JJ
direct_JJ
costs_NN
and_CC
convertible_JJ
bond_NN
are_VPRT [PASS]
separated_VBN
and_PHC
recorded_VBN
at_PIN
fair_JJ
an_DT
appropriate_JJ
proportion_NOMZ
of_PIN
related_JJ
production_NOMZ
value_NN
net_NN
of_PIN
issue_NN
costs_NN
._.
The_DT
fair_JJ
value_NN
of_PIN
the_DT
liability_NOMZ
overheads_NN
,_,
based_VBN [PASTP]
on_PIN
the_DT
normal_JJ
level_NN
of_PIN
production_NOMZ
portion_NOMZ
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
applying_VBG
a_DT
market_NN
interest_NN
capacity_NOMZ
._.
Net_JJ
realisable_JJ
value_NN
is_VPRT [BEMA]
the_DT
estimated_VBN [PRIV]
selling_GER
rate_NN
for_PIN
an_DT
equivalent_JJ
non-convertible_JJ
bond_NN
to_PIN
the_DT
price_NN
in_PIN
the_DT
ordinary_JJ
course_NN
of_PIN
business_NOMZ
,_,
less_JJ
forecast_NN
cash_NN
flows_VPRT
under_IN
the_DT
convertible_JJ
bond_NN
applicable_JJ
variable_JJ
selling_GER
expenses_NN
._.
This_DEMO
amount_NN
is_VPRT [PASS]
recorded_VBN
as_IN
a_DT
liability_NOMZ
68_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
69_CD
olete_NN
,_,
slow-moving_JJ
or_CC
defective_JJ
items_NN
on_PIN
an_DT
amortised_JJ
cost_NN
basis_NN
until_IN
extinguished_VBN
on_PIN
recorded_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
,_,
together_RB
with_PIN
te_NN
._.
conversion_NN
or_CC
maturity_NOMZ
of_PIN
the_DT
bonds_NN
._.
The_DT
remainder_NN
any_QUAN
changes_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
hedged_JJ
asset_NN
of_PIN
the_DT
proceeds_NN
of_PIN
the_DT
bond_NN
is_VPRT [PASS]
allocated_VBN
to_PIN
the_DT
or_CC
liability_NOMZ
that_TSUB
are_VPRT [BEMA]
attributable_PRED
to_PIN
the_DT
hedged_VBN
risk_NN
._.
bles_NN
conversion_NN
option_NOMZ
which_WDT [WHSUB]
is_VPRT [PASS]
recognized_VBN [PRIV]
and_PHC
included_VBN
s_PRP
are_VPRT [BEMA]
non-derivative_JJ
financial_JJ
assets_NN
in_PIN
shareholders_NN
equity_NOMZ
,_,
net_NN
of_PIN
income_NN
tax_NN
effects_NN
._.
Cash_NN
flow_NN
hedge_NN
erminable_JJ
payments_NOMZ
that_TSUB
are_VPRT [BEMA]
not_XX0
The_DT
value_NN
of_PIN
the_DT
conversion_NN
option_NOMZ
is_VPRT [PASS]
not_XX0
changed_VBN
The_DT
effective_JJ
portion_NOMZ
of_PIN
changes_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
five_CD
market_NN
._.
They_TPP3
arise_VPRT
when_RB
the_DT
in_PIN
subsequent_JJ
periods_NN
._.
derivatives_NN
that_TSUB
are_VPRT [PASS]
designated_VBN
and_PHC
qualify_VB
as_IN
cash_NN
money_NN
,_,
goods_NN
or_CC
services_NN
directly_RB
to_TO
flow_VB
hedges_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
equity_NOMZ
._.
The_DT
gain_NN
or_CC
intention_NOMZ
of_PIN
trading_VBG
the_DT
receivable_NN
._.
p_NN
Paul_NN
Capital_NN
funding_VBG [WZPRES]
liabilities_NOMZ
loss_NN
relating_VBG [WZPRES]
to_PIN
the_DT
ineffective_JJ
portion_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
d_SYM
in_PIN
current_JJ
assets_NN
,_,
except_PIN
for_PIN
The_DT
Group_NN
entered_VBD
into_PIN
two_CD
transactions_NOMZ
with_PIN
Paul_NN
immediately_TIME
in_PIN
the_DT
income_NN
statement_NOMZ
._.
er_JJ
than_PIN
12_CD
months_NN
after_IN
the_DT
balance_NN
Capital_NN
Royalty_NN
Acquisition_NOMZ
Fund_NN
Paul_NN
Capital_NN
in_PIN
Amounts_NN
deferred_VBN [WZPAST]
in_PIN
equity_NOMZ
are_VPRT [PASS]
recycled_VBN
in_PIN
the_DT
e_SYM
are_VPRT [PASS]
classified_VBN
as_IN
non-current_JJ
2000_CD
and_CC
2002_CD
._.
Under_IN
these_DEMO
transactions_NOMZ
Paul_NN
Capital_NN
income_NN
statement_NOMZ
in_PIN
the_DT
periods_NN
when_RB
the_DT
hedged_VBN
ceivables_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
initially_TIME
at_PIN
provided_VBN
a_DT
total_NN
of_PIN
$_$
60m_CD
in_PIN
return_NN
for_PIN
the_DT
sale_NN
of_PIN
a_DT
item_NN
will_PRMD
affect_VB
profit_NN
or_CC
loss_NN
._.
A_DT
provision_NN
portion_NOMZ
of_PIN
the_DT
potential_JJ
future_NN
royalty_NN
and_PHC
revenue_NN
of_PIN
trade_NN
receivables_NN
is_VPRT [PASS]
established_VBN [PRIV]
streams_NN
on_PIN
a_DT
selection_NOMZ
of_PIN
the_DT
Groups_NN
products_NN
._.
Derivatives_NN
that_TSUB
do_VPRT
not_XX0
qualify_VB
for_PIN
hedge_JJ
accounting_GER
jective_NN
evidence_NN
that_TOBJ
the_DT
Group_NN
will_PRMD
The_DT
proceeds_NN
received_VBD
from_PIN
Paul_NN
Capital_NN
meet_VPRT
the_DT
Changes_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
any_QUAN
derivative_JJ
instruments_NOMZ
llect_VPRT
all_QUAN
amounts_NN
due_JJ
according_VBG
to_PIN
definition_NOMZ
of_PIN
a_DT
financial_JJ
liability_NOMZ
under_IN
IAS_NN
39_CD
,_,
and_ANDC
are_VPRT
that_DEMP
do_VPRT
not_XX0
qualify_VB
for_PIN
hedge_JJ
accounting_GER
are_VPRT
ms_NN
of_PIN
the_DT
receivables_NN
._.
treated_VBN
as_IN
such_JJ
and_CC
recorded_VBN
in_PIN
borrowings_GER
at_PIN
the_DT
recognized_VBN [PRIV]
immediately_TIME
in_PIN
the_DT
income_NN
statement_NOMZ
._.
net_JJ
present_JJ
value_NN
of_PIN
royalties_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
to_TO
sh_VB
equivalents_NN
Paul_NN
Capital_NN
over_IN
the_DT
term_NN
of_PIN
the_DT
agreements_NOMZ
at_PIN
the_DT
r_NN
Leases_VPRT
quivalents_NN
are_VPRT [BEMA]
highly_AMP
liquid_JJ
effective_JJ
interest_NN
rates_NN
at_PIN
inception_NOMZ
of_PIN
the_DT
arrangements_NOMZ
._.
Lease_NN
agreements_NOMZ
which_WDT [WHSUB]
transfer_VPRT
to_PIN
the_DT
Group_NN
t_NN
are_VPRT [BEMA]
readily_RB
convertible_PRED
to_TO
known_VBN [PRIV] [THATD]
Interest_NN
is_VPRT [PASS]
charged_VBN
on_PIN
the_DT
liability_NOMZ
and_PHC
royalties_NN
paid_VBD
substantially_RB
all_QUAN
the_DT
risks_NN
and_PHC
rewards_NN
of_PIN
ownership_NN
and_ANDC
which_WDT
are_VPRT [BEMA]
subject_PRED
to_PIN
an_DT
to_PIN
Paul_NN
Capital_NN
are_VPRT [PASS]
treated_VBN
as_IN
repayment_NOMZ
of_PIN
the_DT
liability_NOMZ
._.
of_PIN
an_DT
asset_NN
are_VPRT [PASS]
classified_VBN
as_IN
finance_NN
leases_NN
._.
Finance_NN
of_PIN
changes_NN
in_PIN
value_NN
._.
Cash_NN
and_PHC
cash_NN
leases_NN
are_VPRT [PASS]
capitalized_VBN
at_PIN
the_DT
inception_NOMZ
of_PIN
the_DT
lease_NN
carried_VBD
in_PIN
the_DT
balance_NN
sheet_NN
at_PIN
cost_NN
._.
q_NN
Derivative_JJ
financial_JJ
instruments_NOMZ
at_PIN
the_DT
lower_JJ
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
leased_VBN
property_NN
,_,
s_VPRT [BEMA]
of_PIN
the_DT
cash_NN
flow_NN
statement_NOMZ
,_,
cash_NN
The_DT
Group_NN
uses_VPRT
derivative_JJ
financial_JJ
instruments_NOMZ
to_PIN
plant_NN
and_PHC
equipment_NOMZ
or_CC
the_DT
present_JJ
value_NN
of_PIN
minimum_JJ
lents_NN
comprise_VPRT
cash_NN
at_PIN
bank_NN
and_CC
manage_VB
its_PIT
exposure_NN
to_PIN
fluctuations_NOMZ
in_PIN
interest_NN
and_PHC
lease_NN
payments_NOMZ
._.
Each_QUAN
lease_NN
payment_NOMZ
is_VPRT [PASS]
allocated_VBN
rm_NN
deposits_NN
,_,
marketable_JJ
securities_NOMZ
foreign_JJ
exchange_NN
rates_NN
._.
Specifically_RB
,_,
the_DT
Group_NN
uses_VPRT
between_PIN
the_DT
liability_NOMZ
and_PHC
finance_NN
charges_NN
so_RB
as_IN
to_PIN
Bank_NN
overdrafts_NN
are_VPRT [PASS]
included_VBN
within_PIN
interest_NN
rate_NN
swaps_NN
,_,
forward_RB
currency_NN
contracts_NN
and_CC
achieve_VB
a_DT
constant_JJ
rate_NN
on_PIN
the_DT
finance_NN
balance_NN
rrent_JJ
liabilities_NOMZ
on_PIN
the_DT
balance_NN
sheet_NN
._.
The_DT
corresponding_JJ
rental_JJ
obligations_NOMZ
,_,
net_NN
of_PIN
finance_NN
charges_NN
,_,
are_VPRT [PASS]
included_VBN
in_PIN
other_JJ
longDerivatives_NN
are_VPRT [SPAU] [PASS]
initially_TIME
recognized_VBN [PRIV]
at_PIN
fair_JJ
value_NN
on_PIN
term_NN
payables_NN
._.
These_DEMO
payments_NOMZ
are_VPRT [PASS]
split_VBN
between_PIN
recognized_VBN [PRIV]
initially_TIME
at_PIN
fair_JJ
value_NN
,_,
the_DT
date_NN
a_DT
derivative_JJ
contract_NN
is_VPRT [PASS]
entered_VBN
into_PIN
and_CC
capital_NN
and_PHC
interest_NN
elements_NOMZ
using_VBG [WZPRES]
the_DT
annuity_NOMZ
n_NN
costs_NN
incurred_VBN
._.
Borrowings_GER
are_VPRT
are_VPRT [BEMA]
subsequently_TIME
re-measured_PRED
at_PIN
their_TPP3
fair_JJ
value_NN
._.
The_DT
interest_NN
element_NOMZ
of_PIN
the_DT
lease_NN
rental_NN
is_VPRT [PASS]
ated_VBN
at_PIN
amortised_JJ
cost_NN
,_,
any_QUAN
difference_NN
The_DT
Group_NN
designates_VPRT
certain_JJ
derivatives_NN
as_IN
either_DT
:_:
included_VBN [PASTP]
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Assets_NN
held_VBN [PRIV]
under_IN
ds_NN
net_NN
of_PIN
transaction_NOMZ
costs_NN
and_PHC
hedges_NN
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
recognized_VBN [PRIV]
assets_NN
or_CC
finance_NN
leases_NN
are_VPRT [PASS]
depreciated_VBN
on_PIN
a_DT
basis_NN
consistent_JJ
value_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
liabilities_NOMZ
fair_JJ
value_NN
hedge_NN
:_:
or_CC
with_PIN
similar_JJ
owned_VBN
assets_NN
or_CC
the_DT
lease_NN
term_NN
if_COND
shorter_JJ
._.
he_TPP3
period_NN
of_PIN
the_DT
borrowings_GER
using_VBG [WZPRES]
hedges_NN
of_PIN
highly_AMP
probable_JJ
forecast_NN
transactions_NOMZ
rest_VPRT
method_NN
._.
Borrowings_GER
are_VPRT [BEMA]
classified_JJ
cash_NN
flow_NN
hedges_NN
._.
All_QUAN
other_JJ
leases_NN
are_VPRT [PASS]
classified_VBN
as_IN
operating_VBG
leases_NN
._.
ties_NN
unless_COND
the_DT
Group_NN
has_VPRT
an_DT
Payments_NOMZ
made_VBN
under_IN
operating_VBG
leases_NN
,_,
net_NN
of_PIN
lease_NN
ght_NN
to_TO
defer_VB
settlement_NOMZ
of_PIN
the_DT
liability_NOMZ
For_PIN
relationships_NN
where_RB
hedge_JJ
accounting_GER
is_VPRT [PASS]
applied_VBN
incentives_NN
or_CC
premiums_NN
received_VBD
,_,
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
onths_NN
after_IN
the_DT
balance_NN
sheet_NN
date_NN
._.
the_DT
Group_NN
documents_NOMZ
at_PIN
the_DT
inception_NOMZ
of_PIN
the_DT
income_NN
statement_NOMZ
on_PIN
a_DT
straight_JJ
line_NN
basis_NN
over_IN
the_DT
transaction_NOMZ
the_DT
relationship_NN
between_PIN
hedging_VBG
period_NN
of_PIN
the_DT
lease_NN
._.
bonds_NN
instruments_NOMZ
and_CC
hedged_VBN
items_NN
,_,
as_RB
well_RB
as_IN
its_PIT
risk_NN
bt_NN
and_PHC
equity_NOMZ
components_NN
of_PIN
a_DT
management_NOMZ
objective_NN
and_PHC
strategy_NN
for_PIN
undertaking_VBG
s_PRP
Employee_NN
benefits_NN
are_VPRT [PASS]
separated_VBN
and_PHC
recorded_VBN
at_PIN
fair_JJ
various_JJ
hedge_NN
transactions_NOMZ
and_PHC
reviews_NN
this_DEMO
Pension_NN
obligations_NOMZ
e_LS
costs_NN
._.
The_DT
fair_JJ
value_NN
of_PIN
the_DT
liability_NOMZ
documentation_NOMZ
on_PIN
an_DT
ongoing_JJ
basis_NN
._.
The_DT
Group_NN
operates_VPRT
various_JJ
defined_VBN
contribution_NOMZ
mined_VBN [WZPAST]
by_PIN
applying_VBG
a_DT
market_NN
interest_NN
plans_NN
for_PIN
its_PIT
employees_NN
in_PIN
the_DT
UK_NN
and_PHC
US_FPP1
._.
alent_JJ
non-convertible_JJ
bond_NN
to_PIN
the_DT
Fair_NN
value_NN
hedge_NN
The_DT
Groups_NN
contributions_NOMZ
to_PIN
these_DEMO
plans_NN
are_VPRT [PASS]
charged_VBN
ws_NN
under_IN
the_DT
convertible_JJ
bond_NN
Changes_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
derivatives_NN
that_TSUB
are_VPRT [BEMA]
to_PIN
the_DT
income_NN
statement_NOMZ
in_PIN
the_DT
period_NN
to_PIN
which_WDT [PIRE]
they_TPP3
amount_NN
is_VPRT [PASS]
recorded_VBN
as_IN
a_DT
liability_NOMZ
designated_VBN
and_PHC
qualify_VB
as_IN
fair_JJ
value_NN
hedges_NN
are_VPRT
relate_VB
,_,
and_ANDC
the_DT
assets_NN
are_VPRT [PASS]
held_VBN [PRIV]
in_PIN
separate_JJ
trustee_NN
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
69_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
70_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
administered_VBN
funds_NN
._.
The_DT
Group_NN
has_VPRT
no_SYNE
further_JJ
payment_NOMZ
Non-market_NN
vesting_VBG [WZPRES]
conditions_NOMZ
are_VPRT [PASS]
included_VBN
in_PIN
obligations_NOMZ
once_TIME
the_DT
contributions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
paid_VBN
._.
estimates_NN
about_IN
the_DT
number_NN
of_PIN
options_NOMZ
that_TSUB
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
become_VB
exercisable_JJ
._.
The_DT
Group_NN
operates_VPRT
a_DT
funded_JJ
defined_VBN
benefit_NN
scheme_NN
in_PIN
respect_NN
of_PIN
its_PIT
employees_NN
in_PIN
Switzerland_NN
and_CC
an_DT
The_NN
Group_NN
provides_VPRT
finance_NN
to_PIN
an_DT
employee_NN
share_NN
unfunded_JJ
defined_VBN
benefit_NN
scheme_NN
in_PIN
respect_NN
of_PIN
its_PIT
ownership_NN
trust_NN
to_TO
purchase_VB
company_NN
shares_NN
on_PIN
employees_NN
in_PIN
France_NN
._.
the_DT
open_JJ
market_NN
to_TO
meet_VB
the_DT
Groups_NN
obligation_NOMZ
to_TO
provide_VB
shares_NN
when_RB
employees_NN
exercise_VPRT
their_TPP3
The_DT
liability_NOMZ
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
balance_NN
sheet_NN
in_PIN
options_NOMZ
or_CC
awards_NN
._.
The_DT
costs_NN
of_PIN
running_VBG
the_DT
employee_NN
respect_NN
of_PIN
the_DT
defined_VBN
benefit_NN
pension_NN
plans_NN
is_VPRT [BEMA]
the_DT
share_NN
ownership_NN
trust_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
present_JJ
value_NN
of_PIN
the_DT
defined_VBN
benefit_NN
obligations_NOMZ
at_PIN
the_DT
statement_NOMZ
as_IN
they_TPP3
accrue_VPRT
._.
Shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
balance_NN
sheet_NN
date_NN
less_RB
the_DT
fair_JJ
value_NN
of_PIN
plan_NN
assets_NN
,_,
employee_NN
share_NN
ownership_NN
trust_NN
are_VPRT [PASS]
deducted_VBN
from_PIN
together_RB
with_PIN
adjustments_NOMZ
for_PIN
unrecognised_JJ
past_JJ
shareholders_NN
equity_NOMZ
._.
Defined_VBN
benefit_NN
obligations_NOMZ
for_PIN
the_DT
schemes_NN
are_VPRT [PASS]
calculated_VBN [PRIV]
annually_RB
by_PIN
independent_JJ
At_PIN
each_QUAN
balance_NN
sheet_NN
date_NN
,_,
the_DT
entity_NOMZ
revises_VPRT
its_PIT
actuaries_NN
using_VBG [WZPRES]
the_DT
projected_VBN
unit_NN
credit_NN
method_NN
._.
estimates_NN
of_PIN
the_DT
number_NN
of_PIN
options_NOMZ
that_TSUB
are_VPRT [PASS]
expected_VBN [PRIV]
The_DT
present_JJ
value_NN
of_PIN
the_DT
defined_VBN
benefit_NN
obligations_NOMZ
to_TO
become_VB
exercisable_JJ
._.
It_PIT
recognizes_VPRT [PRIV] [THATD]
the_DT
impact_NN
are_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
discounting_VBG
the_DT
estimated_JJ
future_NN
of_PIN
the_DT
revision_NN
of_PIN
original_JJ
estimates_NN
,_,
if_COND
any_QUAN
,_,
in_PIN
the_DT
cash_NN
outflows_NN
using_VBG [WZPRES]
interest_NN
rates_NN
of_PIN
high_JJ
quality_NOMZ
income_NN
statement_NOMZ
,_,
and_ANDC
a_DT
corresponding_JJ
adjustment_NOMZ
corporate_JJ
bonds_NN
that_TSUB
are_VPRT [PASS]
denominated_VBN
in_PIN
the_DT
currency_NN
to_PIN
equity_NOMZ
over_IN
the_DT
remaining_VBG
vesting_JJ
period_NN
._.
in_PIN
which_WDT [PIRE]
the_DT
benefits_NN
will_PRMD
be_VB [PASS]
paid_VBN
,_,
and_ANDC
that_DEMP
have_VPRT
terms_NN
to_PIN
maturity_NOMZ
approximating_GER
to_PIN
the_DT
terms_NN
of_PIN
the_DT
t_NN
Provisions_NN
related_VBN
pension_NN
liability_NOMZ
._.
Service_NN
costs_NN
are_VPRT [PASS]
included_VBN
in_PIN
Provisions_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
the_DT
Group_NN
has_VPRT
a_DT
staff_NN
costs_NN
and_CC
charged_VBN
to_PIN
income_NN
statement_NOMZ
over_IN
the_DT
present_JJ
legal_JJ
or_CC
constructive_JJ
obligation_NOMZ
as_CONJ
a_NULL
result_NULL
remaining_VBG [WZPRES]
average_JJ
expected_JJ
service_NN
lives_NN
of_PIN
employees_NN
._.
of_PIN
past_JJ
events_NN
,_,
if_COND
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
an_DT
outflow_NN
of_PIN
resources_NN
will_PRMD
be_VB [PASS]
required_VBN [SUAV]
to_TO
settle_VB
the_DT
obligation_NOMZ
Actuarial_JJ
gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
from_PIN
experience_NN
and_CC
the_DT
amount_NN
can_POMD
be_VB [SPAU] [PASS]
reliably_RB
estimated_VBN [PRIV]
._.
adjustments_NOMZ
and_PHC
changes_NN
actuarial_JJ
assumptions_NOMZ
Restructuring_GER
charges_NN
are_VPRT [PASS]
provided_VBN
in_PIN
the_DT
period_NN
are_VPRT [PASS]
charged_VBN
or_CC
credited_VBN
to_PIN
equity_NOMZ
in_PIN
the_DT
Consolidated_NN
in_PIN
which_WDT [PIRE]
management_NOMZ
has_VPRT [PEAS]
committed_VBN
to_PIN
a_DT
plan_NN
and_PHC
Statement_NOMZ
of_PIN
Recognised_NN
Income_NN
and_PHC
Expense_NN
in_PIN
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
an_DT
obligation_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
incurred_VBN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
they_TPP3
arise_VPRT
._.
that_DEMP
can_POMD
be_VB [SPAU] [PASS]
reliably_RB
estimated_VBN [PRIV]
._.
Provisions_NN
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
for_PIN
future_JJ
operating_GER
losses_NN
._.
The_DT
Group_NN
recognizes_VPRT [PRIV]
actuarial_JJ
gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
from_PIN
experience_NN
adjustments_NOMZ
and_PHC
changes_NN
in_PIN
u_JJ
Taxation_NOMZ
actuarial_JJ
assumptions_NOMZ
directly_RB
in_PIN
equity_NOMZ
,_,
in_PIN
the_DT
period_NN
Current_JJ
tax_NN
is_VPRT [BEMA]
the_DT
expected_JJ
tax_NN
payable_JJ
on_PIN
the_DT
taxable_JJ
they_TPP3
have_VPRT [PEAS]
occurred_VBN
,_,
in_PIN
accordance_NN
to_PIN
the_DT
alternative_JJ
income_NN
for_PIN
the_DT
year_NN
using_VBG [WZPRES]
the_DT
tax_NN
rates_NN
and_PHC
laws_NN
that_DEMO
treatment_NOMZ
allowed_VBN [SUAV] [WZPAST]
by_PIN
the_DT
amendment_NOMZ
to_PIN
IAS_NN
19_CD
:_:
have_VB [PEAS]
been_VBN [PASS]
enacted_VBN
or_CC
substantially_RB
enacted_VBN
at_PIN
the_DT
Employee_NN
benefits_NN
Actuarial_JJ
gains_NN
and_PHC
losses_NN
,_,
balance_NN
sheet_NN
date_NN
,_,
and_ANDC
any_QUAN
adjustment_NOMZ
to_PIN
tax_NN
group_NN
plans_NN
and_PHC
disclosures_NN
._.
payable_JJ
in_PIN
respect_NN
of_PIN
previous_JJ
years_NN
._.
Share-based_JJ
compensation_NOMZ
Deferred_JJ
income_NN
tax_NN
is_VPRT [PASS]
provided_VBN
in_PIN
full_JJ
,_,
using_VBG [PRESP]
the_DT
Incentives_NN
in_PIN
the_DT
form_NN
of_PIN
shares_NN
are_VPRT [PASS]
provided_VBN
to_PIN
liability_NOMZ
method_NN
,_,
on_PIN
temporary_JJ
differences_NN
arising_VBG [WZPRES]
employees_NN
under_IN
share_NN
option_NOMZ
,_,
share_NN
purchase_NN
between_PIN
the_DT
tax_NN
bases_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
and_CC
and_CC
long_JJ
term_NN
incentive_NN
plans_NN
._.
The_DT
fair_JJ
value_NN
of_PIN
the_DT
their_TPP3
carrying_VBG
amounts_NN
in_PIN
the_DT
consolidated_JJ
financial_JJ
employee_NN
services_NN
received_VBN [WZPAST]
in_PIN
exchange_NN
for_PIN
the_DT
grant_NN
statements_NOMZ
._.
Deferred_JJ
tax_NN
assets_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
to_PIN
of_PIN
the_DT
options_NOMZ
and_PHC
rewards_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
an_DT
the_DT
extent_NN
that_TOBJ
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
future_JJ
taxable_JJ
expense_NN
._.
The_DT
total_JJ
amount_NN
to_TO
be_VB [PASS]
expensed_VBN
over_IN
the_DT
profits_NN
will_PRMD
be_VB [BEMA]
available_PRED
against_PIN
which_WDT [PIRE]
the_DT
temporary_JJ
vesting_JJ
period_NN
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
reference_NN
to_PIN
the_DT
fair_JJ
differences_NN
can_POMD
be_VB [PASS]
utilised_VBN
._.
Deferred_JJ
income_NN
tax_NN
is_VPRT
value_NN
of_PIN
the_DT
options_NOMZ
granted_VBN [SUAV]
,_,
which_WDT [SERE]
excludes_VPRT
the_DT
determined_VBN [SUAV] [PRIV]
using_VBG
tax_NN
rates_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
enacted_VBN
impact_NN
of_PIN
any_QUAN
non-market_JJ
vesting_GER
conditions_NOMZ
for_PIN
or_CC
substantially_RB
enacted_VBN
by_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
example_NN
,_,
profitability_NOMZ
and_PHC
sales_NN
growth_NN
targets_NN
._.
Deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
not_XX0
discounted_VBN
._.
70_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
71_CD
ting_NN
conditions_NOMZ
are_VPRT [PASS]
included_VBN
in_PIN
v_NN
Deferred_JJ
consideration_NOMZ
Interest_NN
rate_NN
risk_VB
the_DT
number_NN
of_PIN
options_NOMZ
that_TSUB
are_VPRT
Provisions_NN
for_PIN
deferred_JJ
consideration_NOMZ
comprise_VPRT
the_DT
The_NN
Group_NN
borrows_VPRT
at_PIN
fixed_VBN
and_PHC
floating_VBG
rates_NN
of_PIN
ome_NN
exercisable_JJ
._.
fair_JJ
value_NN
of_PIN
contingent_JJ
consideration_NOMZ
arising_VBG [WZPRES]
from_PIN
interest_NN
as_IN
deemed_VBN [PRIV]
appropriate_JJ
for_PIN
its_PIT
circumstances_NN
._.
The_DT
eventual_JJ
outcome_NN
is_VPRT [BEMA]
subject_PRED
to_PIN
the_DT
Where_RB
necessary_JJ
the_DT
Group_NN
uses_VPRT
interest_NN
rate_NN
swaps_NN
des_FW
finance_NN
to_PIN
an_DT
employee_NN
share_NN
Groups_NN
future_JJ
performance_NN
and_CC
certain_JJ
contractual_JJ
to_TO
achieve_VB
the_DT
desired_VBN [SUAV]
interest_NN
rate_NN
profile_NN
._.
to_TO
purchase_VB
company_NN
shares_NN
on_PIN
terms_NN
._.
Provisions_NN
are_VPRT [PASS]
reviewed_VBN
annually_RB
by_PIN
the_DT
to_TO
meet_VB
the_DT
Groups_NN
obligation_NOMZ
Directors_NN
,_,
and_ANDC
changes_NN
to_PIN
the_DT
estimated_VBN [PRIV]
fair_JJ
value_NN
Credit_NN
risk_NN
s_VPRT
when_RB
employees_NN
exercise_VPRT
their_TPP3
of_PIN
the_DT
contingent_JJ
consideration_NOMZ
are_VPRT [PASS]
recorded_VBN
as_IN
an_DT
The_NN
Group_NN
is_VPRT [PASS]
exposed_VBN
to_PIN
credit_NN
related_VBN
losses_NN
in_PIN
the_DT
s._NN
The_DT
costs_NN
of_PIN
running_VBG
the_DT
employee_NN
adjustment_NOMZ
to_PIN
goodwill_NN
or_CC
the_DT
underlying_JJ
asset_NN
value_NN
._.
event_NN
of_PIN
non-performance_JJ
by_PIN
third_JJ
parties_NN
to_PIN
financial_JJ
trust_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
instruments_NOMZ
._.
The_DT
Group_NN
does_VPRT
not_XX0
expect_VB [PRIV] [THATD]
any_QUAN
third_JJ
ey_NN
accrue_VPRT
._.
Shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
2_CD
Financial_NN
risk_NN
management_NOMZ
parties_NN
to_TO
fail_VB
to_TO
meet_VB
their_TPP3
obligations_NOMZ
given_VBN
the_DT
policy_NN
ownership_NN
trust_NN
are_VPRT [PASS]
deducted_VBN
from_PIN
of_PIN
selecting_VBG
only_DWNT
parties_NN
with_PIN
high_JJ
credit_NN
ratings_GER
and_PHC
uity_NOMZ
._.
Financial_NN
risk_NN
factors_NN
minimizing_VBG [WZPRES]
its_PIT
exposure_NN
to_PIN
any_QUAN
one_CD
institution_NOMZ
._.
The_DT
Group_NN
holds_VPRT [PRIV]
financial_JJ
instruments_NOMZ
to_TO
finance_VB
sheet_NN
date_NN
,_,
the_DT
entity_NOMZ
revises_VPRT
its_PIT
its_PIT
operations_NOMZ
and_CC
to_TO
manage_VB
the_DT
currency_NN
risk_NN
that_TOBJ
Price_NN
risk_NN
number_NN
of_PIN
options_NOMZ
that_TSUB
are_VPRT [PASS]
expected_VBN [PRIV]
arises_VPRT
from_PIN
these_DEMO
operations_NOMZ
._.
It_PIT
is_VPRT [BEMA]
the_DT
Groups_NN
policy_NN
The_DT
Group_NN
is_VPRT [PASS]
exposed_VBN
to_PIN
equity_NOMZ
securities_NOMZ
price_NN
risk_NN
isable_JJ
._.
It_PIT
recognizes_VPRT [PRIV]
the_DT
impact_NN
that_TOBJ
no_SYNE
speculative_JJ
trading_GER
in_PIN
financial_JJ
instruments_NOMZ
because_CAUS
of_PIN
investments_NOMZ
which_WDT [WHSUB]
have_VPRT [PEAS]
been_VBN [PASS]
classified_VBN
original_JJ
estimates_NN
,_,
if_COND
any_QUAN
,_,
in_PIN
the_DT
shall_PRMD
be_VB [PASS]
undertaken_VBN
._.
The_DT
Group_NN
finances_VPRT
its_PIT
operations_NOMZ
on_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
as_IN
at_PIN
fair_JJ
value_NN
nt_NN
,_,
and_ANDC
a_DT
corresponding_JJ
adjustment_NOMZ
through_PIN
a_DT
combination_NOMZ
of_PIN
equity_NOMZ
,_,
convertible_JJ
bonds_NN
,_,
through_PIN
profit_NN
or_CC
loss_NN
._.
bank_NN
loans_NN
and_CC
other_JJ
borrowings_GER
._.
The_DT
main_JJ
risks_NN
arising_VBG [WZPRES]
from_PIN
the_DT
Groups_NN
financial_JJ
instruments_NOMZ
are_VPRT
Fair_NN
value_NN
estimation_NOMZ
liquidity_NOMZ
risk_NN
,_,
foreign_JJ
currency_NN
risk_NN
,_,
interest_NN
rate_NN
risk_NN
,_,
The_DT
fair_JJ
value_NN
of_PIN
financial_JJ
instruments_NOMZ
traded_VBN [WZPAST]
in_PIN
ecognised_VBN
when_RB
the_DT
Group_NN
has_VPRT
a_DT
credit_NN
risk_NN
and_PHC
price_NN
risk_NN
._.
active_JJ
markets_NN
such_JJ
as_IN
trading_GER
and_PHC
obligation_NOMZ
as_CONJ
a_NULL
result_NULL
sale_NN
securities_NOMZ
is_VPRT [PASS]
based_VBN
on_PIN
quoted_VBN
market_NN
prices_NN
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
an_DT
outflow_NN
of_PIN
Liquidity_NOMZ
risk_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
The_DT
quoted_VBN
market_NN
price_NN
e_SYM
required_VBN [SUAV]
to_TO
settle_VB
the_DT
obligation_NOMZ
The_DT
Groups_NN
policy_NN
is_VPRT
to_TO
maintain_VB [PUBV]
continuity_NOMZ
of_PIN
funding_GER
used_VBN [WZPAST]
for_PIN
financial_JJ
assets_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Group_NN
is_VPRT [BEMA]
the_DT
can_POMD
be_VB [SPAU] [PASS]
reliably_RB
estimated_VBN [PRIV]
._.
through_PIN
a_DT
mixture_NN
of_PIN
long-term_JJ
debt_NN
and_PHC
bank_NN
loans_NN
,_,
current_JJ
bid_NN
price_NN
._.
Quoted_VBN
market_NN
prices_NN
or_CC
dealer_NN
harges_NN
are_VPRT [PASS]
provided_VBN
in_PIN
the_DT
period_NN
raised_VBD
to_TO
cover_VB
specific_JJ
projects_NN
,_,
and_ANDC
through_PIN
the_DT
quotes_NN
for_PIN
similar_JJ
instruments_NOMZ
are_VPRT [PASS]
used_VBN
for_PIN
other_JJ
ement_NOMZ
has_VPRT [PEAS]
committed_VBN
to_PIN
a_DT
plan_NN
and_PHC
issue_NN
of_PIN
shares_NN
to_PIN
collaborative_JJ
partners_NN
,_,
where_RB
financial_JJ
instruments_NOMZ
._.
The_DT
fair_JJ
value_NN
of_PIN
forward_RB
t_VB
an_DT
obligation_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
incurred_VBN
necessary_JJ
,_,
to_TO
finance_VB
development_NOMZ
contracts_NN
._.
Shortforeign_NN
exchange_NN
contracts_NN
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
using_VBG
bly_RB
estimated_VBN [PRIV]
._.
Provisions_NN
are_VPRT
not_XX0
term_NN
flexibility_NOMZ
is_VPRT [PASS]
provided_VBN
through_PIN
the_DT
use_NN
of_PIN
overdrafts_NN
._.
forward_RB
exchange_NN
market_NN
rates_NN
at_PIN
the_DT
balance_NN
sheet_NN
uture_NN
operating_GER
losses_NN
._.
The_DT
nominal_JJ
value_NN
less_RB
estimated_JJ
credit_NN
Foreign_JJ
currency_NN
risk_NN
adjustments_NOMZ
of_PIN
trade_NN
receivables_NN
and_PHC
payables_NN
are_VPRT [BEMA]
All_QUAN
of_PIN
the_DT
Groups_NN
operations_NOMZ
are_VPRT [PASS]
based_VBN
overseas_PLACE
in_PIN
assumed_VBN [PRIV]
to_PIN
approximate_JJ
their_TPP3
fair_JJ
values_NN
._.
The_DT
fair_JJ
e_SYM
expected_VBN [PRIV]
tax_NN
payable_JJ
on_PIN
the_DT
taxable_JJ
Continental_NN
Europe_NN
and_PHC
North_NN
America_NN
giving_VBG [WZPRES]
rise_NN
value_NN
of_PIN
the_DT
liabilities_NOMZ
for_PIN
the_DT
disclosure_NN
purposes_NN
ear_NN
using_VBG [WZPRES]
the_DT
tax_NN
rates_NN
and_PHC
laws_NN
that_DEMO
to_PIN
exposures_NN
to_PIN
changes_NN
in_PIN
foreign_JJ
exchange_NN
rates_NN
is_VPRT [BYPA]
estimated_VBN [PRIV]
by_PIN
discounting_VBG
the_DT
future_JJ
cash_NN
flows_VPRT
ed_VBN
or_CC
substantially_RB
enacted_VBN
at_PIN
the_DT
notably_RB
the_DT
Swiss_JJ
Franc_NN
,_,
Euro_NN
and_PHC
US_FPP1
Dollar_NN
._.
at_PIN
the_DT
current_JJ
market_NN
interest_NN
rates_NN
that_DEMP
is_VPRT [BEMA]
available_PRED
ate_VBD
,_,
and_ANDC
any_QUAN
adjustment_NOMZ
to_PIN
tax_NN
To_TO
minimize_VB
the_DT
impact_NN
of_PIN
any_QUAN
fluctuations_NOMZ
,_,
the_DT
to_PIN
the_DT
Group_NN
for_PIN
similar_JJ
financial_JJ
instruments_NOMZ
._.
Groups_NN
policy_NN
has_VPRT [SPAU] [PEAS]
historically_RB
been_VBN
to_TO
maintain_VB [PUBV]
natural_JJ
hedges_NN
by_PIN
relating_VBG
the_DT
structure_NN
of_PIN
3_CD
Critical_JJ
accounting_GER
estimates_NN
and_PHC
judgements_NOMZ
e_LS
tax_NN
is_VPRT [PASS]
provided_VBN
in_PIN
full_JJ
,_,
using_VBG [PRESP]
the_DT
borrowings_GER
to_PIN
the_DT
trading_GER
cash_NN
flows_VPRT
that_DEMP
generate_VB
on_PIN
temporary_JJ
differences_NN
arising_VBG [WZPRES]
them_TPP3
._.
Where_RB
subsidiaries_NN
are_VPRT [PASS]
funded_VBN
centrally_RB
,_,
this_DEMP
is_VPRT [BEMA]
The_DT
preparation_NOMZ
of_PIN
the_DT
Consolidated_NN
Financial_NN
bases_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
and_CC
achieved_VBN
by_PIN
the_DT
use_NN
of_PIN
long-term_JJ
loans_NN
,_,
the_DT
exchange_NN
Statements_NOMZ
requires_VPRT [SUAV]
the_DT
Group_NN
to_TO
make_VB
estimates_NN
mounts_NN
in_PIN
the_DT
consolidated_JJ
financial_JJ
differences_NN
on_PIN
which_WDT [PIRE]
are_VPRT [PASS]
taken_VBN
to_PIN
reserves_NN
._.
and_ANDC
judgements_NOMZ
that_TSUB
affect_VPRT
the_DT
reported_VBN [PUBV]
amounts_NN
of_PIN
erred_VBN
tax_NN
assets_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
to_PIN
Where_RB
it_PIT
has_VPRT [PEAS]
not_XX0
been_VBN [BEMA]
possible_PRED
to_TO
use_VB
natural_JJ
assets_NN
,_,
liabilities_NOMZ
,_,
revenues_NN
and_PHC
expenses_NN
,_,
and_ANDC
related_VBN
is_VPRT [BEMA]
probable_PRED
that_THAC
future_JJ
taxable_JJ
hedges_NN
,_,
currency_NN
options_NOMZ
,_,
accrual_NN
forward_RB
options_NOMZ
disclosure_NN
of_PIN
contingent_JJ
assets_NN
and_PHC
liabilities_NOMZ
._.
ailable_JJ
against_PIN
which_WDT [PIRE]
the_DT
temporary_JJ
and_PHC
forward_JJ
currency_NN
contracts_NN
are_VPRT [PASS]
used_VBN
._.
The_DT
Group_NN
The_NN
Group_NN
bases_VPRT
its_PIT
estimates_NN
and_PHC
judgements_NOMZ
on_PIN
be_VB [PASS]
utilised_VBN
._.
Deferred_JJ
income_NN
tax_NN
is_VPRT
has_VPRT [PEAS]
used_VBN
these_DEMO
financial_JJ
instruments_NOMZ
during_PIN
the_DT
historical_JJ
experience_NN
and_CC
on_PIN
various_JJ
other_JJ
assumptions_NOMZ
g_VPRT
tax_NN
rates_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
enacted_VBN
year_NN
to_TO
minimize_VB
the_DT
currency_NN
exposure_NN
on_PIN
that_DEMO
it_PIT
considers_VPRT [PRIV]
to_TO
be_VB [BEMA]
reasonable_PRED
._.
Actual_JJ
results_NN
may_POMD
enacted_VBN
by_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
differ_VPRT
from_PIN
these_DEMO
estimates_NN
under_IN
different_JJ
assumptions_NOMZ
ets_VPRT
and_CC
liabilities_NOMZ
are_VPRT [PASS]
not_XX0
discounted_VBN
._.
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
71_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
72_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
Revenue_NN
recognition_NOMZ
reviewed_VBN [WZPAST]
annually_RB
by_PIN
the_DT
Directors_NN
,_,
who_WP
make_VPRT
The_DT
Groups_NN
revenue_NN
comprises_VPRT
revenues_NN
from_PIN
significant_JJ
judgments_NOMZ
as_IN
to_PIN
the_DT
estimated_VBN [PRIV]
fair_JJ
value_NN
contract_NN
development_NOMZ
and_PHC
licensing_GER
,_,
royalties_NN
and_CC
of_PIN
the_DT
contingent_JJ
consideration_NOMZ
._.
Based_VBN [PASTP]
on_PIN
these_DEMO
manufacturing_GER
and_PHC
distribution_NOMZ
._.
The_DT
Group_NN
enters_VPRT
judgments_NOMZ
,_,
changes_NN
to_PIN
the_DT
estimated_VBN [PRIV]
fair_JJ
value_NN
of_PIN
a_DT
wide_JJ
variety_NN
of_PIN
collaborative_JJ
arrangements_NOMZ
with_PIN
the_DT
consideration_NOMZ
are_VPRT [PASS]
recorded_VBN
._.
its_PIT
partners_NN
from_PIN
which_WDT [PIRE]
it_PIT
may_POMD
earn_VB
all_QUAN
,_,
or_CC
some_QUAN
of_PIN [STPR]
,_,
these_DEMO
revenue_NN
streams_NN
._.
The_DT
application_NOMZ
of_PIN
the_DT
Contingent_NN
Liabilities_NOMZ
Groups_NN
revenue_NN
recognition_NOMZ
policy_NN
set_VBN [WZPAST]
out_PIN
earlier_TIME
Provisions_NN
for_PIN
contingent_JJ
liabilities_NOMZ
are_VPRT [BEMA]
dependent_PRED
in_PIN
this_DEMO
note_NN
to_PIN
its_PIT
complex_JJ
collaboration_NOMZ
agreements_NOMZ
upon_PIN
estimates_NN
and_PHC
assessments_NOMZ
of_PIN
whether_IN
the_DT
requires_VPRT [SUAV]
significant_JJ
estimates_NN
and_PHC
judgement_NOMZ
._.
criteria_NN
for_PIN
recognition_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
met_VBN
,_,
including_VBG [PRESP]
In_CONJ
particular_NULL
,_,
in_PIN
arrangements_NOMZ
with_PIN
multiple_JJ
estimates_NN
by_PIN
the_DT
Directors_NN
as_IN
to_PIN
the_DT
probable_JJ
outcome_NN
deliverables_NN
,_,
there_EX
may_POMD
be_VB
significant_JJ
judgement_NOMZ
in_PIN
and_CC
the_DT
amount_NN
of_PIN
the_DT
potential_JJ
cost_NN
of_PIN
resolution_NOMZ
._.
separating_VBG [PRESP]
the_DT
different_JJ
revenue_NN
generating_VBG [WZPRES]
activities_NOMZ
._.
Any_QUAN
estimate_NN
for_PIN
such_JJ
an_DT
accrual_NN
would_PRMD
be_VB [PASS]
developed_VBN
in_PIN
consultation_NOMZ
with_PIN
external_JJ
legal_JJ
advisors_NN
handling_VBG [WZPRES]
Paul_NN
Capital_NN
funding_VBG [WZPRES]
liabilities_NOMZ
the_DT
Groups_NN
defense_NN
in_PIN
these_DEMO
matters_NN
and_CC
would_PRMD
be_VB [BEMA]
The_DT
proceeds_NN
received_VBD
from_PIN
Paul_NN
Capital_NN
are_VPRT [PASS]
treated_VBN
based_VBN
upon_PIN
an_DT
analysis_NN
of_PIN
potential_JJ
outcomes_NN
._.
as_IN
a_DT
liability_NOMZ
under_IN
IAS_NN
39_CD
and_CC
are_VPRT [PASS]
recorded_VBN
within_PIN
borrowings_GER
at_PIN
the_DT
net_JJ
present_JJ
value_NN
of_PIN
royalties_NN
Pensions_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
to_PIN
Paul_NN
Capital_NN
at_PIN
the_DT
effective_JJ
The_DT
Group_NN
recognizes_VPRT [PRIV]
actuarial_JJ
gains_NN
and_PHC
losses_NN
interest_NN
rate_NN
at_PIN
inception_NOMZ
of_PIN
the_DT
agreement_NOMZ
._.
arising_VBG [PRESP]
from_PIN
experience_NN
adjustments_NOMZ
and_PHC
changes_NN
in_PIN
Therefore_CONJ
in_PIN
order_NN
to_TO
be_VB [BEMA]
able_PRED
to_TO
record_VB
the_DT
funding_GER
actuarial_JJ
assumptions_NOMZ
directly_RB
in_PIN
equity_NOMZ
,_,
in_PIN
the_DT
period_NN
liability_NOMZ
significant_JJ
estimation_NOMZ
of_PIN
certain_JJ
of_PIN
the_DT
they_TPP3
have_VPRT [PEAS]
occurred_VBN
,_,
in_PIN
accordance_NN
to_PIN
the_DT
alternative_NN
Groups_NN
future_JJ
cash_NN
flows_VPRT
is_VPRT [PASS]
required_VBN [SUAV]
._.
Royalty_NN
cash_NN
treatment_NOMZ
allowed_VBN [SUAV] [WZPAST]
by_PIN
the_DT
amendment_NOMZ
to_PIN
IAS_NN
19_CD
:_:
flows_NN
are_VPRT [SPAU] [PASS]
periodically_RB
reassessed_VBN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
Employee_NN
benefits_NN
Actuarial_JJ
gains_NN
and_PHC
losses_NN
,_,
estimated_VBN [PRIV]
funding_GER
liability_NOMZ
._.
In_CONJ
addition_NULL
such_JJ
flows_NN
group_NN
plans_NN
and_PHC
disclosures_NN
._.
The_DT
costs_NN
are_VPRT [PASS]
assessed_VBN
are_VPRT [BEMA]
subject_PRED
to_PIN
foreign_JJ
exchange_NN
movements_NOMZ
._.
in_PIN
accordance_NN
with_PIN
advice_NN
received_VBN [WZPAST]
from_PIN
independent_JJ
actuaries_NN
._.
These_DEMO
assumptions_NOMZ
include_VPRT
inflation_NOMZ
rate_NN
,_,
Impairment_NOMZ
of_PIN
goodwill_NN
rate_NN
of_PIN
increase_NN
in_PIN
salaries_NN
,_,
discount_NN
rate_NN
and_CC
The_DT
Group_NN
tests_NN
annually_RB
whether_IN
goodwill_NN
has_VPRT [PEAS]
suffered_VBN
expected_VBN [PRIV]
return_NN
on_PIN
plan_NN
assets_NN
and_CC
are_VPRT [PASS]
disclosed_VBN [PUBV]
any_QUAN
impairment_NOMZ
,_,
in_PIN
accordance_NN
with_PIN
the_DT
accounting_GER
in_PIN
Note_NN
27_CD
:_:
Retirement_NOMZ
benefit_NN
obligations_NOMZ
._.
policy_NN
stated_VBD [PUBV]
earlier_TIME
in_PIN
this_DEMO
note_NN
._.
The_DT
recoverable_JJ
The_DT
selection_NOMZ
of_PIN
different_JJ
assumptions_NOMZ
could_POMD
affect_VB
amounts_NN
of_PIN
cash-generating_JJ
units_NN
have_VPRT [PEAS]
been_VBN [BEMA]
the_DT
future_JJ
results_NN
of_PIN
the_DT
Group_NN
._.
determined_VBN [SUAV] [PRIV]
based_VBN
on_PIN
value-in-use_JJ
calculations_NOMZ
._.
These_DEMO
calculations_NOMZ
require_VPRT [SUAV]
the_DT
use_NN
of_PIN
estimates_NN
._.
The_DT
estimates_NN
Share_NN
based_VBN
compensation_NOMZ
used_VBN [WZPAST]
in_PIN
goodwill_NN
impairment_NOMZ
testing_GER
as_IN
at_PIN
31_CD
December_NN
Incentives_NN
in_PIN
the_DT
form_NN
of_PIN
shares_NN
are_VPRT [PASS]
provided_VBN
to_PIN
2005_CD
and_CC
2004_CD
are_VPRT [PASS]
presented_VBN
in_PIN
Note_NN
12_CD
:_:
Goodwill_NN
._.
employees_NN
under_IN
share_NN
option_NOMZ
,_,
share_NN
purchase_NN
and_CC
long_JJ
term_NN
incentive_NN
plans_NN
._.
The_DT
fair_JJ
value_NN
of_PIN
the_DT
Impairment_NOMZ
of_PIN
other_JJ
intangible_JJ
assets_NN
and_PHC
property_NN
,_,
employee_NN
services_NN
received_VBN [WZPAST]
in_PIN
exchange_NN
for_PIN
the_DT
grant_NN
plant_NN
ant_NN
equipment_NOMZ
of_PIN
the_DT
options_NOMZ
and_PHC
rewards_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
an_DT
The_NN
Group_NN
tests_VPRT
annually_RB
whether_IN
other_JJ
intangible_JJ
expense_NN
._.
The_DT
expense_NN
is_VPRT [PASS]
based_VBN
upon_PIN
a_DT
number_NN
of_PIN
assets_NN
and_PHC
property_NN
,_,
plant_NN
ant_NN
equipment_NOMZ
have_VPRT [PEAS]
assumptions_NOMZ
disclosed_VBN [PUBV] [WZPAST]
in_PIN
Note_NN
28_CD
:_:
Share_NN
capital_NN
._.
suffered_VBN
any_QUAN
impairment_NOMZ
,_,
in_PIN
accordance_NN
with_PIN
The_DT
selection_NOMZ
of_PIN
different_JJ
assumptions_NOMZ
could_POMD
affect_VB
the_DT
accounting_GER
policy_NN
stated_VBN [PUBV] [WZPAST]
earlier_TIME
in_PIN
this_DEMO
note_NN
._.
the_DT
future_JJ
results_NN
of_PIN
the_DT
Group_NN
._.
Amortisation_NOMZ
lives_VPRT
Deferred_NN
Consideration_NOMZ
Other_JJ
intangible_JJ
assets_NN
are_VPRT [PASS]
recorded_VBN
at_PIN
their_TPP3
fair_JJ
Provisions_NN
for_PIN
deferred_JJ
consideration_NOMZ
payable_JJ
by_PIN
value_NN
at_PIN
acquisition_NOMZ
date_NN
and_CC
are_VPRT [PASS]
amortised_VBN
on_PIN
the_DT
Group_NN
comprise_VPRT
the_DT
fair_JJ
value_NN
of_PIN
contingent_NN
a_DT
straight_JJ
line_NN
basis_NN
over_IN
their_TPP3
estimated_VBN [PRIV] [THATD]
useful_JJ
consideration_NOMZ
arising_VBG [WZPRES]
from_PIN
acquisitions_NOMZ
._.
The_DT
eventual_JJ
economic_JJ
lives_NN
from_PIN
the_DT
time_NN
they_TPP3
are_VPRT [BEMA]
available_PRED
for_PIN
outcome_NN
is_VPRT [BEMA]
subject_PRED
to_PIN
the_DT
Groups_NN
future_JJ
performance_NN
use_NN
._.
Any_QUAN
change_NN
in_PIN
the_DT
estimated_VBN [PRIV]
useful_JJ
economic_JJ
and_PHC
certain_JJ
contractual_JJ
terms_NN
._.
Provisions_NN
are_VPRT
lives_NN
could_POMD
affect_VB
the_DT
future_JJ
results_NN
of_PIN
the_DT
Group_NN
._.
72_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
73_CD
ly_RB
by_PIN
the_DT
Directors_NN
,_,
who_WP
make_VPRT
Taxation_NOMZ
ments_NOMZ
as_IN
to_PIN
the_DT
estimated_VBN [PRIV]
fair_JJ
value_NN
Current_JJ
tax_NN
is_VPRT [BEMA]
the_DT
expected_JJ
tax_NN
payable_JJ
on_PIN
the_DT
taxable_JJ
t_NN
consideration_NOMZ
._.
Based_VBN [PASTP]
on_PIN
these_DEMO
income_NN
for_PIN
the_DT
year_NN
using_VBG [WZPRES]
the_DT
tax_NN
rates_NN
and_PHC
laws_NN
that_TSUB
ges_VPRT
to_PIN
the_DT
estimated_VBN [PRIV]
fair_JJ
value_NN
of_PIN
have_VPRT [PEAS]
been_VBN [PASS]
enacted_VBN
or_CC
substantially_RB
enacted_VBN
at_PIN
the_DT
n_NN
are_VPRT [PASS]
recorded_VBN
._.
balance_NN
sheet_NN
date_NN
,_,
and_ANDC
any_QUAN
adjustment_NOMZ
to_PIN
tax_NN
payable_JJ
in_PIN
respect_NN
of_PIN
previous_JJ
years_NN
._.
The_DT
Group_NN
has_VPRT
lities_NOMZ
open_JJ
tax_NN
issues_NN
with_PIN
a_DT
number_NN
of_PIN
revenue_NN
authorities_NOMZ
ntingent_JJ
liabilities_NOMZ
are_VPRT [BEMA]
dependent_PRED
and_CC
,_,
on_PIN
the_DT
basis_NN
of_PIN
external_JJ
professional_JJ
advice_NN
,_,
and_ANDC
assessments_NOMZ
of_PIN
whether_IN
the_DT
continues_VPRT
to_TO
believe_VB [PRIV]
that_THVC
it_PIT
has_VPRT [PEAS]
made_VBN
adequate_JJ
nition_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
met_VBN
,_,
including_VBG
provision_NN
for_PIN
any_QUAN
liabilities_NOMZ
that_TSUB
may_POMD
arise_VB
from_PIN
these_DEMO
Directors_NN
as_IN
to_PIN
the_DT
probable_JJ
outcome_NN
open_JJ
assessments_NOMZ
._.
The_DT
ultimate_JJ
liability_NOMZ
for_PIN
such_JJ
of_PIN
the_DT
potential_JJ
cost_NN
of_PIN
resolution_NOMZ
._.
matters_NN
may_POMD
vary_VB
from_PIN
the_DT
amounts_NN
provided_VBN
,_,
and_ANDC
such_PDT
an_DT
accrual_NN
would_PRMD
be_VB [PASS]
developed_VBN
is_VPRT [BEMA]
dependent_PRED
upon_PIN
negotiations_NOMZ
with_PIN
the_DT
relevant_JJ
with_PIN
external_JJ
legal_JJ
advisors_NN
handling_VBG [WZPRES]
tax_NN
authorities_NOMZ
._.
nce_NN
in_PIN
these_DEMO
matters_NN
and_CC
would_PRMD
be_VB
nalysis_NN
of_PIN
potential_JJ
outcomes_NN
._.
4_CD
Segment_NOMZ
information_NOMZ
Primary_JJ
reporting_GER
format_NN
business_NOMZ
segments_NOMZ
nises_VPRT
actuarial_JJ
gains_NN
and_PHC
losses_NN
Based_VBN [WZPAST]
on_PIN
the_DT
risks_NN
and_PHC
returns_NN
of_PIN
the_DT
various_JJ
segments_NOMZ
,_,
the_DT
Directors_NN
consider_VPRT [PRIV]
that_THVC
the_DT
Groups_NN
primary_JJ
erience_NN
adjustments_NOMZ
and_PHC
changes_NN
in_PIN
reporting_VBG [PUBV] [THATD]
format_NN
is_VPRT [BEMA]
by_PIN
business_NOMZ
segment_NOMZ
with_PIN
geographical_JJ
reporting_GER
being_VBG [WZPRES] [BEMA]
the_DT
secondary_JJ
format_NN
._.
The_DT
Group_NN
ptions_NOMZ
directly_RB
in_PIN
equity_NOMZ
,_,
in_PIN
the_DT
period_NN
is_VPRT [BEMA]
a_DT
speciality_NOMZ
pharmaceutical_JJ
company_NN
,_,
using_VBG [PRESP]
its_PIT
multiple_JJ
drug_NN
delivery_NN
technologies_NN
to_TO
create_VB
a_DT
product_NN
ed_VBD
,_,
in_PIN
accordance_NN
to_PIN
the_DT
alternative_JJ
pipeline_NN
for_PIN
out-licensing_JJ
to_TO
marketing_VBG
partners_NN
._.
The_DT
business_NOMZ
segments_NOMZ
consist_VPRT
of_PIN
the_DT
Injectable_JJ
business_NOMZ
ed_VBN [WZPAST]
by_PIN
the_DT
amendment_NOMZ
to_PIN
IAS_NN
19_CD
:_:
and_ANDC
the_DT
Oral_NN
and_PHC
Inhalation_NOMZ
business_NOMZ
._.
Business_NOMZ
segment_NOMZ
data_NN
includes_VPRT
an_DT
allocation_NOMZ
of_PIN
corporate_JJ
costs_NN
to_PIN
ts_NN
Actuarial_JJ
gains_NN
and_PHC
losses_NN
,_,
each_QUAN
segment_NOMZ
on_PIN
an_DT
appropriate_JJ
basis_NN
._.
There_EX
are_VPRT
no_SYNE
material_NN
inter-segment_NOMZ
transfers_NN
._.
The_DT
costs_NN
are_VPRT [PASS]
assessed_VBN
segments_NOMZ
of_PIN
UK_NN
,_,
Europe_NN
,_,
North_NN
America_NN
and_CC
Rest_VB
of_PIN
the_DT
World_NN
reflect_VPRT [PRIV]
the_DT
Groups_NN
most_EMPH
significant_JJ
regional_JJ
th_NN
advice_NN
received_VBD
from_PIN
independent_JJ
markets_NN
._.
Revenue_NN
is_VPRT [BYPA]
shown_VBN [PRIV]
by_PIN
business_NOMZ
segment_NOMZ
,_,
revenue_NN
stream_NN
and_PHC
location_NOMZ
of_PIN
customer_NN
._.
Other_JJ
geographic_JJ
assumptions_NOMZ
include_VPRT
inflation_NOMZ
rate_NN
,_,
information_NOMZ
is_VPRT [BYPA]
provided_VBN
by_PIN
location_NOMZ
of_PIN
operation_NOMZ
._.
All_QUAN
Group_NN
activities_NOMZ
are_VPRT
continuing_VBG
operations_NOMZ
._.
in_PIN
salaries_NN
,_,
discount_NN
rate_NN
and_CC
on_PIN
plan_NN
assets_NN
and_CC
are_VPRT [PASS]
disclosed_VBN [PUBV]
Revenue_NN
by_PIN
business_NOMZ
segment_NOMZ
:_:
Year_NN
ended_VBD
Year_NN
ended_VBD
ement_NOMZ
benefit_NN
obligations_NOMZ
._.
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
different_JJ
assumptions_NOMZ
could_POMD
affect_VB
m_FW
m_FW [BEMA]
s_PRP
of_PIN
the_DT
Group_NN
._.
Injectable_JJ
10.5_CD
25.6_CD
Oral_NN
and_PHC
Inhalation_NOMZ
50.8_CD
49.6_CD
mpensation_NOMZ
61.3_CD
75.2_CD
form_NN
of_PIN
shares_NN
are_VPRT [PASS]
provided_VBN
to_PIN
r_NN
share_NN
option_NOMZ
,_,
share_NN
purchase_NN
Revenue_NN
earned_VBD
can_POMD
be_VB [PASS]
analyzed_VBN
as_IN
:_:
centive_JJ
plans_NN
._.
The_DT
fair_JJ
value_NN
of_PIN
the_DT
Contract_NN
development_NOMZ
and_PHC
licensing_GER
es_VPRT
received_VBN
in_PIN
exchange_NN
for_PIN
the_DT
grant_NN
Milestone_NN
payments_NOMZ
22.1_CD
33.4_CD
d_SYM
rewards_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
an_DT
Research_NN
and_PHC
development_NOMZ
costs_NN
recharged_VBD
5.5_CD
6.0_CD
pense_NN
is_VPRT [PASS]
based_VBN
upon_PIN
a_DT
number_NN
of_PIN
27.6_CD
39.4_CD
closed_VBN
in_PIN
Note_NN
28_CD
:_:
Share_NN
capital_NN
._.
Royalties_NN
21.7_CD
25.9_CD
different_JJ
assumptions_NOMZ
could_POMD
affect_VB
Manufacturing_GER
and_PHC
distribution_NOMZ
12.0_CD
9.9_CD
s_PRP
of_PIN
the_DT
Group_NN
._.
Total_JJ
revenue_NN
61.3_CD
75.2_CD
es_NN
assets_NN
are_VPRT [PASS]
recorded_VBN
at_PIN
their_TPP3
fair_JJ
on_PIN
date_NN
and_CC
are_VPRT [PASS]
amortised_VBN
on_PIN
asis_NN
over_IN
their_TPP3
estimated_VBN [PRIV]
useful_JJ
rom_NN
the_DT
time_NN
they_TPP3
are_VPRT [BEMA]
available_PRED
for_PIN
in_PIN
the_DT
estimated_VBN [PRIV]
useful_JJ
economic_JJ
the_DT
future_JJ
results_NN
of_PIN
the_DT
Group_NN
._.
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
73_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
74_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
Operating_VBG
loss_NN
by_PIN
business_NOMZ
segment_NOMZ
:_:
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW
Injectable_FW
18.6_CD
1.4_CD
Oral_NN
and_PHC
Inhalation_NOMZ
2.5_CD
1.0_CD
Operating_GER
loss_NN
pre_NN
exceptional_JJ
items_NN
16.1_CD
0.4_CD
Exceptional_JJ
items_NN
21.4_CD
2.7_CD
Operating_GER
loss_NN
37.5_CD
3.1_CD
Share_NN
of_PIN
loss_NN
in_PIN
associate_JJ
0.8_CD
Net_JJ
interest_NN
12.3_CD
15.3_CD
Tax_NN
0.3_CD
0.2_CD
Loss_NN
after_IN
tax_NN
50.9_CD
18.6_CD
Total_JJ
assets_NN
by_PIN
business_NOMZ
segment_NOMZ
:_:
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_NN
m_NN
Injectable_NN
57.1_CD
60.4_CD
Oral_NN
and_PHC
Inhalation_NOMZ
93.3_CD
95.6_CD
Total_JJ
operating_VBG
assets_NN
150.4_CD
156.0_CD
Investments_NOMZ
in_PIN
associates_NN
0.2_CD
14.3_CD
Available-for-sale_JJ
financial_JJ
assets_NN
1.6_CD
5.2_CD
Financial_NN
assets_NN
at_PIN
fair_JJ
value_NN
through_PIN
profit_NN
and_PHC
loss_NN
0.4_CD
1.1_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
34.3_CD
15.3_CD
Total_JJ
assets_NN
186.9_CD
191.9_CD
Total_JJ
liabilities_NOMZ
by_PIN
business_NOMZ
segment_NOMZ
:_:
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_NN
m_NN
Injectable_NN
40.1_CD
30.5_CD
Oral_NN
and_PHC
Inhalation_NOMZ
41.4_CD
54.0_CD
Total_JJ
operating_VBG
liabilities_NOMZ
81.5_CD
84.5_CD
Short-term_JJ
borrowings_GER
:_:
convertible_JJ
bonds_NN
9.4_CD
Short-term_JJ
borrowings_GER
:_:
other_JJ
2.7_CD
3.9_CD
Long-term_JJ
borrowings_GER
:_:
convertible_JJ
bonds_NN
63.6_CD
50.4_CD
Long-term_JJ
borrowings_GER
:_:
other_JJ
7.2_CD
7.2_CD
Total_JJ
liabilities_NOMZ
155.0_CD
155.4_CD
74_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
75_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
and_CC
intangible_JJ
assets_NN
by_PIN
business_NOMZ
segment_NOMZ
:_:
Year_NN
ended_VBD
Year_NN
ended_VBD
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW
m_FW
m_FW [BEMA]
18.6_CD
1.4_CD
Additions_NOMZ
2.5_CD
1.0_CD
Injectable_NN
1.8_CD
2.3_CD
16.1_CD
0.4_CD
Oral_NN
and_PHC
Inhalation_NOMZ
3.3_CD
4.9_CD
21.4_CD
2.7_CD
5.1_CD
7.2_CD
37.5_CD
3.1_CD
0.8_CD
Depreciation_NOMZ
and_PHC
Amortisation_NOMZ
12.3_CD
15.3_CD
Injectable_NN
1.9_CD
1.9_CD
0.3_CD
0.2_CD
Oral_NN
and_PHC
Inhalation_NOMZ
6.4_CD
6.3_CD
50.9_CD
18.6_CD
8.3_CD
8.2_CD
Investments_NOMZ
in_PIN
associates_NN
by_PIN
business_NOMZ
segment_NOMZ
:_:
Year_NN
ended_VBD
Year_NN
ended_VBD
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW
m_FW
m_FW [BEMA]
57.1_CD
60.4_CD
Injectable_JJ
0.2_CD
14.3_CD
93.3_CD
95.6_CD
Oral_NN
and_PHC
Inhalation_NOMZ
150.4_CD
156.0_CD
0.2_CD
14.3_CD
0.2_CD
14.3_CD
Secondary_JJ
reporting_GER
format_NN
geographic_JJ
1.6_CD
5.2_CD
0.4_CD
1.1_CD
Revenue_NN
by_PIN
location_NOMZ
of_PIN
customer_NN
:_:
Year_NN
ended_VBD
Year_NN
ended_VBD
34.3_CD
15.3_CD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
186.9_CD
191.9_CD
m_NN
m_NN
UK_NN
23.9_CD
15.2_CD
Europe_NN
23.8_CD
26.0_CD
Year_NN
ended_VBD
Year_NN
ended_VBD
North_NN
America_NN
8.7_CD
29.2_CD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW
Rest_VB
of_PIN
World_NN
4.9_CD
4.8_CD
40.1_CD
30.5_CD
61.3_CD
75.2_CD
41.4_CD
54.0_CD
81.5_CD
84.5_CD
Total_JJ
assets_NN
by_PIN
location_NOMZ
of_PIN
operation_NOMZ
:_:
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
9.4_CD
m_NN
m_NN [BEMA]
2.7_CD
3.9_CD
UK_NN
37.7_CD
30.0_CD
63.6_CD
50.4_CD
Europe_NN
56.9_CD
89.7_CD
7.2_CD
7.2_CD
North_NN
America_NN
92.3_CD
72.2_CD
155.0_CD
155.4_CD
186.9_CD
191.9_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
and_CC
intangible_JJ
asset_NN
additions_NOMZ
by_PIN
location_NOMZ
of_PIN
operation_NOMZ
:_:
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW
Europe_NN
3.3_CD
4.9_CD
North_NN
America_NN
1.8_CD
2.3_CD
5.1_CD
7.2_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
75_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
76_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
5_CD
Exceptional_JJ
items_NN
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_NN
m_NN
Impairments_NOMZ
19.4_CD
3.5_CD
Abortive_JJ
transaction_NOMZ
costs_NN
2.0_CD
Restructuring_GER
costs_NN
1.2_CD
Profit_NN
on_PIN
disposal_NN
of_PIN
available-for-sale_JJ
investment_NOMZ
2.0_CD
Convertible_JJ
bonds_NN
exchange_NN
6.2_CD
21.4_CD
8.9_CD
Following_VBG
the_DT
Strategic_NN
Review_NN
and_CC
the_DT
Groups_NN
decision_NN
to_TO
focus_VB
on_PIN
its_PIT
core_NN
oral_JJ
and_PHC
pulmonary_JJ
products_NN
and_CC
to_TO
divest_VB
its_PIT
injectable_JJ
business_NOMZ
,_,
the_DT
Group_NN
no_RB
longer_RB
views_VPRT
its_PIT
collaborations_NOMZ
with_PIN
Astralis_NN
,_,
Vital_NN
Living_VBG [WZPRES]
and_CC
Micap_NN
as_IN
strategic_JJ
and_CC
these_DEMO
investments_NOMZ
have_VPRT [SPAU] [PEAS]
therefore_CONJ
been_VBN [PASS]
impaired_VBN
resulting_VBG
in_PIN
an_DT
exceptional_JJ
charge_NN
of_PIN
19.4_CD
million_CD
._.
See_VB [PRIV]
notes_NN
15_CD
:_:
Investments_NOMZ
in_PIN
associates_NN
and_CC
16_CD
:_:
Available_JJ
for_PIN
sale_NN
financial_JJ
assets_NN
._.
During_PIN
the_DT
year_NN
the_DT
Group_NN
incurred_VBD
2.0_CD
million_CD
legal_JJ
and_PHC
professional_JJ
fees_NN
relating_VBG [WZPRES]
to_PIN
an_DT
aborted_JJ
strategic_JJ
transaction_NOMZ
._.
Exceptional_JJ
items_NN
for_PIN
2004_CD
include_VPRT
a_DT
charge_NN
of_PIN
3.5_CD
million_CD
relating_VBG
to_PIN
the_DT
impairment_NOMZ
in_PIN
the_DT
investment_NOMZ
in_PIN
Vital_NN
Living_VBG [WZPRES]
and_CC
1.2_CD
million_CD
relating_VBG
to_PIN
the_DT
reorganisation_NOMZ
of_PIN
some_QUAN
research_NN
and_PHC
development_NOMZ
operations_NOMZ
and_CC
other_JJ
business_NOMZ
functions_NOMZ
._.
In_CONJ
addition_NULL
,_,
2.0_CD
million_CD
relates_VPRT
to_PIN
the_DT
profit_NN
on_PIN
disposal_NN
of_PIN
the_DT
Groups_NN
investment_NOMZ
in_PIN
Transition_NOMZ
Therapeutics_NN
and_CC
a_DT
charge_NN
of_PIN
6.2_CD
million_CD
relates_VPRT
to_PIN
the_DT
exchange_NN
of_PIN
convertible_JJ
bonds_NN
._.
6_CD
Operating_GER
expenses_NN
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW
Cost_NN
of_PIN
sales_NN
29.2_CD
28.2_CD
Selling_GER
,_,
marketing_GER
and_PHC
distribution_NOMZ
expenses_NN
5.9_CD
1.7_CD
Depreciation_NOMZ
6.2_CD
6.0_CD
Amortisation_NOMZ
2.1_CD
2.2_CD
Research_NN
and_PHC
development_NOMZ
expenses_NN
26.0_CD
28.0_CD
Loss_NN
gain_NN
on_PIN
financial_JJ
assets_NN
at_PIN
fair_JJ
value_NN
through_PIN
profit_NN
or_CC
loss_NN
0.7_CD
0.1_CD
Fair_NN
value_NN
gain_NN
loss_NN
on_PIN
derivative_JJ
financial_JJ
instruments_NOMZ
0.3_CD
0.5_CD
Profit_NN
on_PIN
disposal_NN
of_PIN
available_JJ
for_PIN
sale_NN
financial_JJ
assets_NN
0.3_CD
Other_JJ
operating_GER
expenses_NN
8.1_CD
9.1_CD
Operating_GER
expenses_NN
before_IN
exceptional_JJ
items_NN
77.6_CD
75.6_CD
Impairments_NOMZ
19.4_CD
3.5_CD
Abortive_JJ
transaction_NOMZ
costs_NN
2.0_CD
Restructuring_GER
costs_NN
1.2_CD
Profit_NN
on_PIN
disposal_NN
of_PIN
available_JJ
for_PIN
sale_NN
financial_JJ
assets_NN
2.0_CD
Total_JJ
operating_GER
expenses_NN
99.0_CD
78.3_CD
76_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
77_CD
Services_NN
provided_VBN [WZPAST]
by_PIN
the_DT
Groups_NN
auditor_NN
and_PHC
network_NN
firms_NN
Year_NN
ended_VBD
Year_NN
ended_VBD
It_PIT
is_VPRT [BEMA]
the_DT
Groups_NN
policy_NN
to_TO
employ_VB
the_DT
auditors_NN
on_PIN
assignments_NOMZ
additional_JJ
to_PIN
their_TPP3
statutory_JJ
audit_NN
duties_NN
where_RB
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW [BEMA]
their_TPP3
expertise_NN
and_PHC
experience_NN
with_PIN
the_DT
Group_NN
are_VPRT [BEMA]
important_PRED
,_,
principally_RB
tax_NN
advice_NN
and_CC
due_JJ
diligence_NN
reporting_VBG [PUBV] [WZPRES]
on_PIN
acquisitions_NOMZ
,_,
or_CC
where_RB
they_TPP3
are_VPRT [PASS]
awarded_VBN
assignments_NOMZ
on_PIN
a_DT
competitive_JJ
basis_NN
._.
During_PIN
the_DT
year_NN
the_DT
Group_NN
19.4_CD
3.5_CD
including_VBG
its_PIT
overseas_PLACE
subsidiaries_NN
obtained_VBD
the_DT
following_JJ
services_NN
from_PIN
the_DT
Groups_NN
auditor_NN
at_PIN
costs_NN
detailed_JJ
2.0_CD
below_PLACE
:_:
1.2_CD
Year_NN
ended_VBD
Year_NN
ended_VBD
2.0_CD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_NN
m_NN [BEMA]
6.2_CD
21.4_CD
8.9_CD
Audit_NN
services_NN
statutory_JJ
audit_NN
0.4_CD
0.3_CD
audit_NN
related_VBN
regulatory_JJ
reporting_GER
0.2_CD
0.2_CD
re_NN [BEMA]
oral_PRED
and_PHC
pulmonary_PRED
products_NN
Further_JJ
assurance_NN
services_NN
1.2_CD
1.0_CD
orations_NOMZ
with_PIN
Astralis_NN
,_,
Vital_NN
Living_VBG [WZPRES]
Tax_NN
services_NN
red_JJ
resulting_VBG
in_PIN
an_DT
exceptional_JJ
charge_NN
compliance_NN
services_NN
0.1_CD
e_SYM
for_PIN
sale_NN
financial_JJ
assets_NN
._.
During_PIN
the_DT
advisory_JJ
services_NN
0.2_CD
0.6_CD
o_IN
an_DT
aborted_JJ
strategic_JJ
transaction_NOMZ
._.
2.0_CD
2.2_CD
impairment_NOMZ
in_PIN
the_DT
investment_NOMZ
in_PIN
ch_NN
and_PHC
development_NOMZ
operations_NOMZ
and_CC
Included_VBN
in_PIN
the_DT
analysis_NN
above_PLACE
are_VPRT
audit_NN
fees_NN
paid_VBN [WZPAST]
to_PIN
the_DT
Groups_NN
auditor_NN
in_PIN
the_DT
UK_NN
of_PIN
227,000_CD
2004_CD
:_:
177,000_CD
disposal_NN
of_PIN
the_DT
Groups_NN
investment_NOMZ
of_PIN
which_WDT [PIRE]
15,000_CD
2004_CD
:_:
14,000_CD
was_VBD [PASS]
paid_VBN
in_PIN
respect_NN
of_PIN
the_DT
parent_NN
company_NN
._.
Also_RB
included_VBN
above_PLACE
are_VPRT [PASS]
fees_NN
paid_VBD
ange_NN
of_PIN
convertible_JJ
bonds_NN
._.
to_PIN
the_DT
Groups_NN
auditor_NN
in_PIN
respect_NN
of_PIN
non-audit_JJ
services_NN
in_PIN
the_DT
UK_NN
of_PIN
1,295,000_CD
2004_CD
:_:
1,141,000_CD
._.
7_CD
Staff_NN
costs_NN
Year_NN
ended_VBD
Year_NN
ended_VBD
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW
m_FW
m_FW [BEMA]
29.2_CD
28.2_CD
Wages_NN
and_PHC
salaries_NN
19.7_CD
19.2_CD
5.9_CD
1.7_CD
Equity_NOMZ
settled_VBD
share_NN
based_VBN
payments_NOMZ
1.9_CD
2.9_CD
6.2_CD
6.0_CD
Social_NN
security_NOMZ
costs_VPRT
2.9_CD
2.9_CD
2.1_CD
2.2_CD
Pensions_NN
26.0_CD
28.0_CD
defined_VBN
benefit_NN
plans_VPRT
0.2_CD
0.7_CD
0.7_CD
0.1_CD
defined_VBN
contribution_NOMZ
plans_VPRT
0.7_CD
1.3_CD
0.3_CD
0.5_CD
Other_JJ
benefits_NN
0.8_CD
0.3_CD
26.2_CD
27.0_CD
8.1_CD
9.1_CD
77.6_CD
75.6_CD
The_DT
average_JJ
number_NN
of_PIN
people_NN
,_,
including_VBG
executive_JJ
directors_NN
,_,
employed_VBN [PASTP]
by_PIN
the_DT
Group_NN
during_PIN
the_DT
period_NN
was_VBD [BEMA]
19.4_CD
3.5_CD
457_CD
persons_NN
2004_CD
:_:
438_CD
persons_NN
and_CC
the_DT
Company_NN
numbers_NN
18_CD
persons_NN
2004_CD
:_:
18_CD
persons_NN
._.
2.0_CD
1.2_CD
Average_JJ
number_NN
of_PIN
employees_NN
by_PIN
business_NOMZ
segment_NOMZ
:_:
2.0_CD
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
99.0_CD
78.3_CD
Injectable_JJ
129_CD
113_CD
Oral_NN
and_PHC
Inhalation_NOMZ
328325457438_CD
The_DT
Groups_NN
key_JJ
management_NOMZ
comprises_VPRT
only_DWNT
Directors_NN
and_PHC
Director_NN
remuneration_NOMZ
for_PIN
the_DT
year_NN
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
audited_JJ
part_NN
of_PIN
the_DT
Remuneration_NOMZ
Report_NN
._.
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
77_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
78_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
8_CD
Other_JJ
income_NN
and_PHC
expenses_NN
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW
Loss_NN
gain_NN
on_PIN
financial_JJ
assets_NN
at_PIN
fair_JJ
value_NN
through_PIN
profit_NN
or_CC
loss_NN
0.7_CD
0.1_CD
Profit_NN
on_PIN
disposal_NN
of_PIN
available-for-sale_JJ
investment_NOMZ
0.3_CD
2.0_CD
0.4_CD
2.1_CD
9_CD
Finance_NN
costs_NN
and_PHC
income_NN
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW
Interest_NN
and_CC
similar_JJ
expense_NN
:_:
Interest_NN
:_:
bank_NN
borrowings_GER
0.5_CD
0.7_CD
Paul_NN
Capital_NN
arrangements_NOMZ
12.7_CD
11.3_CD
interest_NN
on_PIN
convertible_JJ
bonds_NN
5.8_CD
5.7_CD
19.0_CD
17.7_CD
Foreign_JJ
exchange_NN
on_PIN
Paul_NN
Capital_NN
arrangements_NOMZ
3.3_CD
Fair_NN
value_NN
losses_NN
on_PIN
financial_JJ
instruments_NOMZ
:_:
loss_NN
on_PIN
exchange_NN
of_PIN
convertible_JJ
bonds_NN
6.2_CD
Total_JJ
interest_NN
and_CC
similar_JJ
expense_NN
22.3_CD
23.9_CD
Interest_NN
and_CC
similar_JJ
income_NN
:_:
Paul_NN
Capital_NN
change_NN
in_PIN
estimated_JJ
future_JJ
payments_NOMZ
9.0_CD
6.0_CD
Other_JJ
interest_NN
income_NN
1.0_CD
0.8_CD
Foreign_JJ
exchange_NN
on_PIN
Paul_NN
Capital_NN
arrangements_NOMZ
1.8_CD
Total_JJ
interest_NN
and_CC
similar_JJ
income_NN
10.0_CD
8.6_CD
10_CD
Income_NN
tax_NN
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW [BEMA]
Current_JJ
income_NN
tax_NN
expense_NN
:_:
Foreign_NN
tax_NN
0.3_CD
0.2_CD
There_EX
was_VBD
no_SYNE
deferred_JJ
tax_NN
component_NN
in_PIN
the_DT
tax_NN
charge_NN
._.
Foreign_JJ
tax_NN
relates_VPRT
principally_RB
to_TO
withholding_VBG
tax_NN
paid_VBN [WZPAST]
on_PIN
remittance_NN
of_PIN
royalties_NN
to_PIN
Switzerland_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
not_XX0
recoverable_PRED
._.
78_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
79_CD
The_DT
tax_NN
on_PIN
the_DT
Groups_NN
losses_NN
before_IN
tax_NN
differs_VPRT
from_PIN
the_DT
theoretical_JJ
amount_NN
that_TSUB
would_PRMD
arise_VB
using_VBG
Year_NN
ended_VBD
Year_NN
ended_VBD
the_DT
standard_JJ
rate_NN
of_PIN
corporation_NOMZ
tax_NN
in_PIN
the_DT
UK_NN
._.
The_DT
differences_NN
are_VPRT [PASS]
explained_VBN [PUBV]
below_PLACE
:_:
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
Year_NN
ended_VBD
Year_NN
ended_VBD
m_FW
m_FW [BEMA]
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
%_NN
%_NN
0.7_CD
0.1_CD
Rate_NN
of_PIN
corporation_NOMZ
tax_NN
in_PIN
the_DT
UK_NN
30.0_CD
30.0_CD
0.3_CD
2.0_CD
0.4_CD
2.1_CD
Effects_NN
of_PIN
:_:
Adjustments_NOMZ
in_PIN
respect_NN
of_PIN
foreign_JJ
tax_NN
rates_NN
4.4_CD
17.2_CD
Adjustment_NOMZ
to_PIN
tax_NN
in_PIN
respect_NN
of_PIN
prior_JJ
periods_NN
0.1_CD
Year_NN
ended_VBD
Year_NN
ended_VBD
Expenses_NN
not_XX0
deductible_JJ
for_PIN
tax_NN
purposes_NN
7.1_CD
8.2_CD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
Tax_NN
losses_NN
for_PIN
which_WDT [PIRE]
no_SYNE
deferred_JJ
tax_NN
asset_NN
was_VBD [PASS]
recognized_VBN [PRIV]
19.6_CD
40.0_CD
m_NN
m_NN
Tax_NN
losses_NN
utilised_VBD
1.0_CD
1.9_CD
Capital_NN
allowances_NN
utilised_VBD
0.2_CD
Withholding_GER
taxes_NN
0.6_CD
0.7_CD
0.5_CD
0.7_CD
Other_JJ
0.1_CD
1.3_CD
12.7_CD
11.3_CD
Effective_JJ
tax_NN
rate_NN
0.6_CD
1.0_CD
5.8_CD
5.7_CD
19.0_CD
17.7_CD
3.3_CD
The_DT
Group_NN
has_VPRT [PEAS]
estimated_VBN [PRIV]
total_JJ
tax_NN
losses_NN
available_JJ
to_TO
be_VB [PASS]
set_VBN
off_PIN
against_PIN
future_JJ
taxable_JJ
profits_NN
of_PIN
280.0_CD
million_CD
31_CD
December_NN
2004_CD
:_:
271.1_CD
million_CD
._.
These_DEMO
losses_NN
arise_VPRT
primarily_RB
in_PIN
Switzerland_NN
and_CC
the_DT
US_FPP1
._.
Of_PIN
the_DT
6.2_CD
280.0_CD
million_CD
of_PIN
losses_NN
carried_VBD
forward_RB
,_,
22.0_CD
million_CD
expire_VPRT
in_PIN
2006_CD
,_,
65.1_CD
million_CD
expire_VPRT
between_PIN
2007_CD
and_CC
22.3_CD
23.9_CD
2009_CD
,_,
191.6_CD
million_CD
expire_VPRT
from_PIN
2010_CD
onwards_NN
and_CC
1.3_CD
million_CD
of_PIN
losses_NN
may_POMD
be_VB [PASS]
carried_VBN
forward_RB
indefinitely_RB
._.
The_DT
Group_NN
also_RB
has_VPRT
other_JJ
tax_NN
allowances_NN
available_JJ
of_PIN
59.8_CD
million_CD
31_CD
December_NN
2004_CD
:_:
56.6_CD
million_CD
9.0_CD
6.0_CD
No_DT
deferred_VBN
tax_NN
asset_NN
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
,_,
given_VBN
the_DT
uncertainty_NN
of_PIN
the_DT
recoverability_NOMZ
of_PIN
the_DT
Groups_NN
tax_NN
losses_NN
1.0_CD
0.8_CD
carried_VBD
forward_RB
._.
1.8_CD
10.0_CD
8.6_CD
11_CD
Earnings_GER
per_PIN
share_NN
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW [PASS]
Year_NN
ended_VBD
Year_NN
ended_VBD
Attributable_JJ
loss_NN
before_IN
exceptional_JJ
items_NN
29.5_CD
9.7_CD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW [BEMA]
Exceptional_JJ
items_NN
21.4_CD
8.9_CD
Basic_JJ
and_PHC
diluted_JJ
attributable_JJ
loss_NN
50.9_CD
18.6_CD
0.3_CD
0.2_CD
Number_NN
Number_NN
m_FW
m_FW [BEMA]
Basic_PRED
and_PHC
diluted_PRED
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
in_PIN
issue_NN
624.9_CD
615.2_CD
yalties_NN
to_PIN
Switzerland_NN
which_WDT [WHOBJ]
Loss_NN
per_PIN
Ordinary_NN
Share_NN
before_IN
exceptional_JJ
items_NN
4.7_CD
p_NN
1.6_CD
p_NN
Exceptional_JJ
items_NN
3.4_CD
p_NN
1.4_CD
p_NN
Basic_JJ
and_PHC
diluted_JJ
loss_NN
per_PIN
Ordinary_NN
Share_NN
8.1_CD
p_NN
3.0_CD
p_NN
There_EX
is_VPRT
no_SYNE
difference_NN
between_PIN
basic_JJ
and_PHC
diluted_JJ
loss_NN
per_PIN
share_NN
since_OSUB
in_PIN
a_DT
loss_NN
making_VBG [WZPRES]
year_NN
all_QUAN
potential_JJ
shares_NN
from_PIN
convertible_JJ
bonds_NN
,_,
stock_NN
options_NOMZ
,_,
warrants_NN
and_CC
contingent_JJ
issuance_NN
of_PIN
shares_NN
are_VPRT [BEMA]
anti_JJ
dilutive_JJ
._.
Shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
SkyePharma_NN
PLC_NN
General_NN
Employee_NN
Benefit_NN
Trust_NN
have_VPRT [PEAS]
been_VBN [PASS]
excluded_VBN
from_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
._.
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
79_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
80_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
12_CD
Goodwill_NN
As_IN
at_PIN
As_IN
at_PIN
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
Group_NN
m_FW
m_FW
Cost_NN
Beginning_GER
of_PIN
the_DT
year_NN
82.7_CD
82.7_CD
Additions_NOMZ
during_PIN
the_DT
year_NN
Exchange_NN
differences_NN
End_NN
of_PIN
the_DT
year_NN
82.7_CD
82.7_CD
Accumulated_VBN
impairment_NOMZ
and_PHC
depreciation_NOMZ
Beginning_GER
of_PIN
the_DT
year_NN
14.0_CD
14.0_CD
Amortisation_NOMZ
charge_NN
Exchange_NN
differences_NN
End_NN
of_PIN
the_DT
year_NN
14.0_CD
14.0_CD
Net_JJ
book_NN
value_NN
Beginning_GER
of_PIN
the_DT
year_NN
68.7_CD
68.7_CD
End_NN
of_PIN
the_DT
year_NN
68.7_CD
68.7_CD
Goodwill_NN
arose_VBD
on_PIN
the_DT
acquisition_NOMZ
of_PIN
SkyePharma_NN
Inc_NN
35.6_CD
million_CD
,_,
SkyePharma_NN
Canada_NN
Inc_NN
29.2_CD
million_CD
and_CC
SkyePharma_NN
AB_NN
3.9_CD
million_CD
and_CC
has_VPRT [PEAS]
been_VBN [PASS]
allocated_VBN
to_PIN
the_DT
following_JJ
business_NOMZ
segments_NOMZ
cashgenerating_VBG [WZPRES]
units_NN
:_:
As_IN
at_PIN
As_IN
at_PIN
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW
Injectables_NN
38.6_CD
38.6_CD
Oral_NN
and_PHC
Inhalation_NOMZ
30.1_CD
30.1_CD
68.7_CD
68.7_CD
Goodwill_NN
is_VPRT [PASS]
not_XX0
amortised_VBN
but_CC
is_VPRT [PASS]
tested_VBN
annually_RB
for_PIN
impairment_NOMZ
or_CC
more_EMPH
frequently_RB
if_COND
there_EX
are_VPRT
indications_NOMZ
that_DEMO
goodwill_NN
might_POMD
be_VB [PASS]
impaired_VBN
._.
Value_NN
in_PIN
use_NN
calculations_NOMZ
are_VPRT [SPAU] [PASS]
generally_RB
utilised_VBN
to_TO
calculate_VB [PRIV]
recoverable_JJ
amount_NN
._.
Value_NN
in_PIN
use_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
as_IN
the_DT
net_JJ
present_JJ
value_NN
of_PIN
the_DT
projected_VBN
risk-adjusted_JJ
cash_NN
flows_NN
of_PIN
the_DT
cashgenerating_VBG
unit_NN
to_PIN
which_WDT [PIRE]
goodwill_NN
is_VPRT [PASS]
allocated_VBN
._.
The_DT
cash_NN
flow_NN
projections_NOMZ
are_VPRT [PASS]
based_VBN
on_PIN
the_DT
most_EMPH
recent_JJ
business_NOMZ
plans_NN
approved_VBN [WZPAST]
by_PIN
management_NOMZ
which_WDT [WHSUB]
cover_VPRT
a_DT
period_NN
of_PIN
10_CD
years_NN
,_,
and_ANDC
are_VPRT [PASS]
adjusted_VBN
where_RB
necessary_JJ
to_TO
take_VB
account_NN
of_PIN
longer_JJ
patent_NN
lives_NN
._.
The_DT
discount_NN
rate_NN
applied_VBD
may_POMD
vary_VB
depending_VBG
on_PIN
the_DT
risk_NN
profile_NN
of_PIN
the_DT
asset_NN
being_VBG [WZPRES] [PASS]
valued_VBN
but_CC
is_VPRT [BEMA]
typically_RB
15_CD
%_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
Groups_NN
average_VPRT
pre-tax_JJ
discount_NN
rate_NN
derived_VBN [WZPAST]
from_PIN
a_DT
capital_NN
asset_NN
pricing_GER
model_NN
._.
The_DT
key_JJ
assumptions_NOMZ
for_PIN
the_DT
value_NN
in_PIN
use_NN
calculations_NOMZ
are_VPRT [BEMA]
those_DEMP
regarding_VBG
the_DT
launch_NN
dates_NN
of_PIN
products_NN
,_,
their_TPP3
growth_NN
rates_NN
,_,
the_DT
discount_NN
rates_NN
used_VBN
and_CC
the_DT
period_NN
over_IN
which_WDT
the_DT
cash_NN
flows_NN
are_VPRT [PASS]
projected_VBN
._.
The_DT
assumptions_NOMZ
made_VBN
reflect_VPRT [PRIV]
past_JJ
experience_NN
,_,
market_NN
research_NN
and_PHC
expectations_NOMZ
of_PIN
future_JJ
market_NN
trends_NN
._.
Goodwill_NN
was_VBD [PASS]
tested_VBN
for_PIN
impairment_NOMZ
both_DT
at_PIN
31_CD
December_NN
2005_CD
and_CC
31_CD
December_NN
2004_CD
._.
All_QUAN
amortisation_NOMZ
charges_NN
in_PIN
the_DT
year_NN
have_VPRT [PEAS]
been_VBN [PASS]
charged_VBN
through_PIN
administrative_JJ
expenses_NN
._.
requently_RB
if_COND
there_EX
are_VPRT
indications_NOMZ
that_TSUB
ed_VBD
to_TO
calculate_VB [PRIV]
recoverable_JJ
amount_NN
._.
Intellectual_NN
property_NN
acquired_VBN [WZPAST]
during_PIN
2005_CD
mainly_RB
relates_VPRT
to_PIN
the_DT
purchase_NN
of_PIN
licenses_NN
to_PIN
intellectual_JJ
property_NN
in_PIN
the_DT
area_NN
of_PIN
pulmonary_JJ
delivery_NN
._.
djusted_JJ
cash_NN
flows_NN
of_PIN
the_DT
cashare_JJ
based_VBN
on_PIN
the_DT
most_EMPH
recent_JJ
Included_VBN
within_PIN
intellectual_JJ
property_NN
is_VPRT [BEMA]
2.0_CD
million_CD
of_PIN
assets_NN
which_WDT [WHSUB]
are_VPRT
not_XX0
yet_RB
in_PIN
use_NN
._.
These_DEMO
assets_NN
have_VPRT
s_PRP
,_,
and_ANDC
are_VPRT [PASS]
adjusted_VBN
where_RB
necessary_JJ
not_XX0
been_VBN [PASS]
amortised_VBN
but_CC
have_VPRT [PEAS]
been_VBN [PASS]
tested_VBN
for_PIN
impairment_NOMZ
consistent_JJ
with_PIN
the_DT
method_NN
set_VBN [WZPAST]
out_PIN
for_PIN
goodwill_NN
depending_VBG [WZPRES]
on_PIN
the_DT
risk_NN
profile_NN
in_PIN
note_NN
12_CD
._.
e_LS
pre-tax_JJ
discount_NN
rate_NN
derived_VBN
g_IN
the_DT
launch_NN
dates_NN
of_PIN
products_NN
,_,
cash_NN
flows_NN
are_VPRT [PASS]
projected_VBN
._.
ectations_NOMZ
of_PIN
future_JJ
market_NN
trends_NN
._.
Included_VBN [PASTP]
in_PIN
freehold_NN
property_NN
is_VPRT [BEMA]
an_DT
amount_NN
of_PIN
4.9_CD
million_CD
2004_CD
:_:
5.1_CD
million_CD
in_PIN
respect_NN
of_PIN
land_NN
which_WDT [WHSUB]
is_VPRT [PASS]
not_XX0
depreciated_VBN
._.
At_PIN
31_CD
December_NN
2005_CD
,_,
the_DT
carrying_VBG
amount_NN
of_PIN
the_DT
Groups_NN
laboratory_NN
equipment_NOMZ
and_PHC
machines_NN
includes_VPRT
an_DT
amount_NN
of_PIN
Nil_NN
2004_CD
:_:
1.2_CD
million_CD
and_CC
motor_NN
vehicles_NN
an_DT
amount_NN
of_PIN
0.1_CD
million_CD
2004_CD
:_:
0.1_CD
million_CD
in_PIN
respect_NN
of_PIN
assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
arrangements_NOMZ
._.
82_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
83_CD
At_PIN
31_CD
December_NN
2005_CD
,_,
the_DT
net_JJ
book_NN
value_NN
of_PIN
the_DT
tangible_JJ
assets_NN
pledged_VBN [SUAV]
as_IN
collateral_NN
in_PIN
the_DT
framework_NN
of_PIN
various_JJ
borrowing_GER
agreements_NOMZ
disclosed_VBN [PUBV] [WZPAST]
in_PIN
Note_NN
23_CD
:_:
Borrowings_GER
was_VBD [BEMA]
1.9_CD
million_CD
2004_CD
:_:
2.1_CD
million_CD
._.
Office_NN
and_PHC
Motor_NN
quipment_NOMZ
vehicles_NN
Total_JJ
The_DT
Group_NN
did_VBD
not_XX0
identify_VB
any_QUAN
tangible_JJ
assets_NN
temporarily_RB
idle_JJ
as_IN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Impairment_NOMZ
16.3_CD
End_NN
of_PIN
the_DT
year_NN
0.2_CD
14.3_CD
ion_NN
in_PIN
respect_NN
of_PIN
land_NN
which_WDT [WHOBJ]
The_DT
investment_NOMZ
in_PIN
Astralis_NN
Limited_NN
was_VBD [PASS]
recorded_VBN
at_PIN
0.2_CD
million_CD
at_PIN
31_CD
December_NN
2005_CD
2004_CD
:_:
14.3_CD
million_CD
and_CC
had_VBD
a_DT
market_NN
value_NN
of_PIN
0.4_CD
million_CD
2004_CD
:_:
9.6_CD
million_CD
._.
Following_VBG [PRESP]
the_DT
Strategic_NN
Review_NN
and_CC
the_DT
Groups_NN
pment_NOMZ
and_PHC
machines_NN
includes_VPRT
decision_NN
to_TO
focus_VB
on_PIN
its_PIT
core_NN
oral_JJ
and_PHC
pulmonary_JJ
products_NN
and_CC
to_TO
divest_VB
its_PIT
injectable_JJ
business_NOMZ
,_,
the_DT
Group_NN
0.1_CD
million_CD
2004_CD
:_:
0.1_CD
million_CD
no_SYNE
longer_JJ
views_NN
its_PIT
collaboration_NOMZ
with_PIN
Astralis_NN
as_IN
strategic_JJ
._.
This_DEMP
combined_VBN
with_PIN
the_DT
current_JJ
uncertainties_NN
ments_NOMZ
._.
concerning_VBG
Astralis_NN
financial_JJ
position_NOMZ
resulted_VBD
in_PIN
the_DT
Group_NN
impairing_VBG [WZPRES]
its_PIT
investment_NOMZ
to_PIN
its_PIT
estimated_VBN [PRIV]
fair_JJ
value_NN
._.
As_IN
at_PIN
As_IN
at_PIN
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
Company_NN
m_NN
m_NN
Beginning_GER
of_PIN
the_DT
year_NN
14.3_CD
Reclassification_NOMZ
of_PIN
investment_NOMZ
as_IN
associate_JJ
14.2_CD
Additions_NOMZ
3.0_CD
0.1_CD
Impairment_NOMZ
17.1_CD
End_NN
of_PIN
the_DT
year_NN
0.2_CD
14.3_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
83_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
84_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
16_CD
Available_JJ
for_PIN
sale_NN
financial_JJ
assets_NN
As_IN
at_PIN
As_IN
at_PIN
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
Group_NN
m_FW
m_FW
Beginning_GER
of_PIN
the_DT
year_NN
5.2_CD
22.0_CD
Exchange_NN
0.1_CD
Reclassification_NOMZ
as_IN
associate_JJ
14.2_CD
Additions_NOMZ
0.1_CD
2.0_CD
Disposal_NN
1.8_CD
0.6_CD
Impairments_NOMZ
2.6_CD
3.5_CD
Revaluation_NOMZ
surplus_NN
deficit_NN
transfer_NN
0.6_CD
0.5_CD
End_NN
of_PIN
the_DT
year_NN
1.6_CD
5.2_CD
As_IN
at_PIN
As_IN
at_PIN
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
Company_NN
m_NN
m_NN
Beginning_GER
of_PIN
the_DT
year_NN
3.6_CD
16.3_CD
Reclassification_NOMZ
as_IN
associate_JJ
14.2_CD
Additions_NOMZ
0.1_CD
2.0_CD
Disposal_NN
1.8_CD
Revaluation_NOMZ
surplus_NN
deficit_NN
transfer_NN
0.6_CD
0.5_CD
End_NN
of_PIN
the_DT
year_NN
1.3_CD
3.6_CD
Group_NN
and_PHC
Company_NN
Available_NN
for_PIN
sale_NN
financial_JJ
assets_NN
comprise_VPRT
the_DT
following_VBG
unlisted_JJ
securities_NOMZ
:_:
Vectura_NN
Group_NN
plc_NN
Vectura_NN
is_VPRT [BEMA]
a_DT
UK_NN
emerging_VBG [WZPRES]
pharmaceutical_JJ
company_NN
traded_VBN [WZPAST]
on_PIN
the_DT
Alternative_NN
Investment_NOMZ
Market_NN
._.
Vectura_NN
is_VPRT
developing_VBG
a_DT
range_NN
of_PIN
inhaled_JJ
drugs_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
lung_NN
diseases_NN
and_PHC
conditions_NOMZ
where_RB
delivery_NN
via_PIN
the_DT
lungs_NN
can_POMD
provide_VB
significant_JJ
benefits_NN
,_,
such_JJ
as_IN
rapid_JJ
onset_NN
of_PIN
action_NOMZ
,_,
improved_VBD
efficacy_NN
and_CC
improved_VBD
tolerability_NOMZ
compared_VBN [WZPAST]
with_PIN
current_JJ
therapies_NN
._.
During_PIN
2005_CD
the_DT
Group_NN
sold_VBD
2_CD
million_CD
ordinary_JJ
shares_NN
in_PIN
Vectura_NN
for_PIN
1.6_CD
million_CD
._.
As_IN
at_PIN
31_CD
December_NN
2005_CD
the_DT
remaining_VBG
holding_GER
was_VBD [BEMA]
1.2_CD
million_CD
ordinary_JJ
shares_NN
._.
The_DT
investment_NOMZ
was_VBD [PASS]
recorded_VBN
at_PIN
1.0_CD
million_CD
at_PIN
31_CD
December_NN
2005_CD
2004_CD
:_:
2.0_CD
million_CD
._.
In_PIN
January_NN
2006_CD
the_DT
Group_NN
sold_VBD
the_DT
remaining_VBG
1.2_CD
million_CD
ordinary_JJ
shares_NN
._.
Vital_JJ
Living_VBG
Inc_NN
Vital_NN
Living_VBG [WZPRES]
primarily_RB
develops_VPRT
and_PHC
markets_VPRT
evidence-based_JJ
nutriceuticals_NN
._.
These_DEMP
are_VPRT [PASS]
developed_VBN
for_PIN
incorporation_NOMZ
by_PIN
physicians_NN
into_PIN
a_DT
standard_JJ
physician_NN
patient_NN
program_NN
,_,
supported_VBN [PASTP]
by_PIN
a_DT
specially_RB
designed_VBN
compliance_NN
regimen_NN
._.
Vital_JJ
Living_VBG
is_VPRT [PASS]
based_VBN
in_PIN
the_DT
US_FPP1
._.
During_PIN
2005_CD
the_DT
Group_NN
received_VBD
2,101,422_CD
Vital_JJ
Living_VBG
common_JJ
shares_NN
with_PIN
a_DT
value_NN
of_PIN
68,000_CD
$_$
120,000_CD
in_PIN
lieu_NN
of_PIN
interest_NN
due_JJ
on_PIN
the_DT
12_CD
%_NN
senior_JJ
secured_VBN
convertible_JJ
notes_NN
._.
As_IN
at_PIN
31_CD
December_NN
2005_CD
the_DT
total_JJ
SkyePharma_NN
holding_GER
was_VBD [BEMA]
16,993,599_CD
common_JJ
shares_NN
,_,
1_CD
million_CD
series_NN
D_NN
convertible_JJ
preferred_JJ
shares_NN
,_,
$_$
1_CD
million_CD
12_CD
%_NN
senior_JJ
secured_VBN
convertible_JJ
notes_NN
due_JJ
2008_CD
and_CC
4_CD
million_CD
warrants_NN
expiring_VBG [WZPRES]
2008_CD
,_,
representing_VBG [PRESP]
approximately_RB
17.2_CD
%_NN
of_PIN
the_DT
common_JJ
shares_NN
._.
The_DT
investment_NOMZ
in_PIN
Vital_NN
Living_VBG [WZPRES]
was_VBD [PASS]
recorded_VBN
at_PIN
0.4_CD
million_CD
at_PIN
31_CD
December_NN
2005_CD
2004_CD
:_:
1.7_CD
million_CD
._.
The_DT
Company_NN
recorded_VBN
0.1_CD
million_CD
at_PIN
31_CD
December_NN
2005_CD
2004_CD
:_:
0.1_CD
million_CD
._.
Following_VBG [PRESP]
the_DT
Strategic_NN
Review_NN
and_CC
the_DT
Groups_NN
decision_NN
to_TO
focus_VB
on_PIN
its_PIT
core_NN
oral_JJ
and_PHC
pulmonary_JJ
products_NN
and_CC
to_TO
divest_VB
its_PIT
injectable_JJ
business_NOMZ
,_,
the_DT
Group_NN
no_RB
longer_RB
views_VPRT
its_PIT
collaboration_NOMZ
with_PIN
Vital_JJ
Living_VBG
as_IN
strategic_JJ
and_CC
this_DEMO
investment_NOMZ
has_VPRT [SPAU] [PEAS]
therefore_CONJ
been_VBN [PASS]
impaired_VBN
._.
84_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
85_CD
Micap_NN
plc_NN
As_IN
at_PIN
As_IN
at_PIN
Micap_NN
plc_NN
is_VPRT [BEMA]
a_DT
UK_NN
science-based_JJ
technology_NN
company_NN
traded_VBD
on_PIN
the_DT
Alternative_NN
Investment_NOMZ
Market_NN
._.
As_IN
at_PIN
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW [BEMA]
31_CD
December_NN
2005_CD
the_DT
total_JJ
SkyePharma_NN
holding_GER
was_VBD [BEMA]
5,238,334_CD
ordinary_JJ
shares_NN
and_CC
1,830,000_CD
convertible_JJ
shares_NN
,_,
representing_VBG [PRESP]
approximately_RB
9.4_CD
%_NN
of_PIN
the_DT
ordinary_JJ
share_NN
capital_NN
._.
The_DT
investment_NOMZ
in_PIN
Micap_NN
recorded_VBD
5.2_CD
22.0_CD
at_PIN
0.2_CD
million_CD
at_PIN
31_CD
December_NN
2005_CD
2004_CD
:_:
1.5_CD
million_CD
._.
Following_VBG [PRESP]
the_DT
Strategic_NN
Review_NN
and_CC
the_DT
Groups_NN
0.1_CD
decision_NN
to_TO
focus_VB
on_PIN
its_PIT
core_NN
oral_JJ
and_PHC
pulmonary_JJ
products_NN
and_CC
to_TO
divest_VB
its_PIT
injectable_JJ
business_NOMZ
,_,
the_DT
Group_NN
14.2_CD
no_SYNE
longer_JJ
views_NN
its_PIT
collaboration_NOMZ
with_PIN
Micap_NN
as_IN
strategic_JJ
and_CC
this_DEMO
investment_NOMZ
has_VPRT [SPAU] [PEAS]
therefore_CONJ
been_VBN [PASS]
impaired_VBN
._.
0.1_CD
2.0_CD
1.8_CD
0.6_CD
Cade_NN
Struktur_NN
Corp_NN
2.6_CD
3.5_CD
Cade_NN
Struktur_NN
was_VBD [BEMA]
formerly_TIME
a_DT
drug_NN
delivery_NN
company_NN
engaged_VBD
in_PIN
research_NN
and_PHC
development_NOMZ
and_CC
worldwide_JJ
0.6_CD
0.5_CD
commercialisation_NOMZ
of_PIN
pharmaceutical_JJ
formulations_NOMZ
._.
The_DT
current_JJ
business_NOMZ
is_VPRT [BEMA]
the_DT
development_NOMZ
,_,
financing_GER
and_CC
1.6_CD
5.2_CD
completion_NOMZ
of_PIN
industrial_JJ
and_CC
infrastructure_NN
projects_NN
in_PIN
Europe_NN
._.
As_IN
at_PIN
31_CD
December_NN
2005_CD
,_,
the_DT
total_JJ
SkyePharma_NN
As_IN
at_PIN
As_IN
at_PIN
holding_GER
of_PIN
Cade_NN
Struktur_NN
,_,
a_DT
Canadian_JJ
company_NN
,_,
was_VBD [BEMA]
869,086_CD
shares_NN
,_,
representing_VBG [PRESP]
approximately_RB
10.1_CD
%_NN
of_PIN
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
the_DT
ordinary_JJ
share_NN
capital_NN
._.
The_DT
shares_NN
were_VBD [SPAU] [PASS]
originally_TIME
acquired_VBN
consequent_JJ
upon_PIN
the_DT
acquisition_NOMZ
of_PIN
the_DT
assets_NN
m_VPRT
m_NN [BEMA]
of_PIN
Hyal_NN
Pharmaceutical_NN
Corp._NN
._.
SkyePharma_NN
has_VPRT [PEAS]
not_XX0
attributed_VBN
a_DT
fair_JJ
value_NN
to_PIN
these_DEMO
shares_NN
and_CC
they_TPP3
have_VPRT [PEAS]
been_VBN [BEMA]
3.6_CD
16.3_CD
recorded_VBN
at_PIN
Nil_NN
2004_CD
:_:
Nil_NN
._.
14.2_CD
0.1_CD
2.0_CD
17_CD
Shares_NN
in_PIN
and_CC
loans_NN
to_PIN
Group_NN
undertakings_GER
1.8_CD
Shares_NN
in_PIN
Group_NN
Loans_NN
to_PIN
Group_NN
undertakings_GER
undertakings_GER
Total_JJ
0.6_CD
0.5_CD
Company_NN
m_NN
m_NN
m_NN [BEMA]
1.3_CD
3.6_CD
Beginning_GER
of_PIN
the_DT
year_NN
163.5_CD
237.3_CD
400.8_CD
Additions_NOMZ
19.0_CD
19.0_CD
Provision_NN
80.0_CD
80.0_CD
es_NN
:_:
End_NN
of_PIN
the_DT
year_NN
163.5_CD
176.3_CD
339.8_CD
Following_VBG
the_DT
Strategic_NN
Review_NN
the_DT
Company_NN
has_VPRT [PEAS]
reviewed_VBN
the_DT
funding_GER
of_PIN
its_PIT
overseas_PLACE
subsidiaries_NN
and_CC
tive_JJ
Investment_NOMZ
Market_NN
._.
Vectura_NN
is_VPRT [PASS]
recorded_VBN
a_DT
provision_NN
in_PIN
respect_NN
of_PIN
recoverability_NOMZ
of_PIN
loans_NN
to_PIN
Group_NN
undertakings_GER
of_PIN
80.0_CD
million_CD
._.
nd_NN
conditions_NOMZ
where_RB
delivery_NN
via_PIN
the_DT
ved_VBN
efficacy_NN
and_CC
improved_VBD
tolerability_NOMZ
Principal_NN
subsidiaries_NN
are_VPRT [PASS]
detailed_VBN
in_PIN
note_NN
35_CD
:_:
Principal_NN
subsidiaries_NN
._.
rdinary_JJ
shares_NN
in_PIN
Vectura_NN
for_PIN
on_PIN
ordinary_JJ
shares_NN
._.
The_DT
investment_NOMZ
18_CD
Inventories_NN
January_NN
2006_CD
the_DT
Group_NN
sold_VBD
the_DT
As_RB
at_PIN
As_IN
at_PIN
31_CD
December_NN
2005_CD
31_CD
December2004_NN
Group_NN
m_FW
m_FW
Raw_FW
materials_NN
and_CC
consumables_VPRT
2.1_CD
1.2_CD
s._NN
These_DEMP
are_VPRT [PASS]
developed_VBN
for_PIN
Work_NN
in_PIN
progress_NN
1.0_CD
0.2_CD
upported_VBN
by_PIN
a_DT
specially_RB
designed_VBN
Finished_VBN
goods_NN
1.0_CD
0.1_CD
up_IN
received_VBN
2,101,422_CD
Vital_NN
Living_VBG [WZPRES]
4.1_CD
1.5_CD
n_IN
the_DT
12_CD
%_NN
senior_JJ
secured_VBN
convertible_JJ
Inventory_NN
provisions_NN
0.5_CD
,_,
599_CD
common_JJ
shares_NN
,_,
1_CD
million_CD
3.6_CD
1.5_CD
vertible_JJ
notes_NN
due_JJ
2008_CD
and_CC
4_CD
million_CD
n_JJ
shares_NN
._.
The_DT
investment_NOMZ
in_PIN
The_DT
cost_NN
of_PIN
inventories_NN
recognized_VBN [PRIV]
as_IN
an_DT
expense_NN
and_CC
included_VBD
in_PIN
cost_NN
of_PIN
sales_NN
is_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
Note_NN
6_CD
:_:
million_CD
._.
The_DT
Company_NN
recorded_VBN
Operating_GER
expenses_NN
._.
egic_JJ
Review_NN
and_CC
the_DT
Groups_NN
decision_NN
le_FW
business_NOMZ
,_,
the_DT
Group_NN
no_RB
longer_RB
as_IN
therefore_CONJ
been_VBN [PASS]
impaired_VBN
._.
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
85_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
86_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
19_CD
Trade_NN
and_CC
other_JJ
receivables_NN
Group_NN
Group_NN
Company_NN
Company_NN
As_IN
at_PIN
As_IN
at_PIN
As_IN
at_PIN
As_IN
at_PIN
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW
m_FW
m_FW
Trade_NN
receivables_NN
2.4_CD
3.5_CD
Less_RB
provision_NN
for_PIN
impairment_NOMZ
0.1_CD
Net_JJ
trade_NN
receivables_NN
2.3_CD
3.5_CD
Amounts_NN
owed_VBN [WZPAST]
by_PIN
subsidiary_NN
undertakings_GER
5.2_CD
5.2_CD
Other_JJ
receivables_NN
2.2_CD
1.9_CD
0.5_CD
1.0_CD
Interest_NN
receivable_JJ
0.6_CD
0.4_CD
Prepayments_NOMZ
and_CC
accrued_VBN
income_NN
9.1_CD
12.4_CD
0.2_CD
14.2_CD
18.2_CD
5.7_CD
6.4_CD
20_CD
Financial_NN
assets_NN
at_PIN
fair_JJ
value_NN
through_PIN
profit_NN
and_PHC
loss_NN
Group_NN
Group_NN
As_IN
at_PIN
As_IN
at_PIN
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW
Beginning_GER
of_PIN
the_DT
year_NN
1.1_CD
1.0_CD
Revaluation_NOMZ
to_PIN
fair_JJ
value_NN
0.7_CD
0.1_CD
End_NN
of_PIN
the_DT
year_NN
0.4_CD
1.1_CD
Financial_NN
assets_NN
at_PIN
fair_JJ
value_NN
through_PIN
profit_NN
or_CC
loss_NN
comprise_VPRT
5_CD
%_NN
convertible_JJ
loan_NN
notes_NN
due_JJ
at_PIN
par_NN
in_PIN
June_NN
2007_CD
._.
The_DT
notes_NN
were_VBD [PASS]
received_VBN
from_PIN
GeneMedix_NN
plc_NN
in_PIN
2002_CD
as_IN
an_DT
initial_JJ
payment_NOMZ
under_IN
an_DT
agreement_NOMZ
to_TO [SPIN]
jointly_RB
develop_VB
an_DT
extended_JJ
release_NN
formulation_NOMZ
of_PIN
Interferon_NN
alpha-2b_JJ
using_VBG
SkyePharmas_NN
DepoFoam_NN
technology_NN
._.
The_DT
notes_NN
are_VPRT [BEMA]
convertible_PRED
at_PIN
any_QUAN
time_NN
,_,
at_PIN
SkyePharmas_NN
option_NOMZ
,_,
into_PIN
between_PIN
approximately_RB
8.3_CD
million_CD
and_CC
11.2_CD
million_CD
GeneMedix_NN
ordinary_JJ
shares_NN
._.
There_EX
are_VPRT
no_SYNE
restrictions_NOMZ
or_CC
a_DT
lock-up_JJ
period_NN
on_PIN
conversion_NN
of_PIN
the_DT
notes_NN
._.
GeneMedix_NN
can_POMD
elect_VB
to_TO
redeem_VB
in_PIN
cash_NN
some_QUAN
or_CC
all_QUAN
of_PIN
the_DT
notes_NN
on_PIN
conversion_NN
._.
The_DT
notes_NN
were_VBD [PASS]
designated_VBN
as_RB
at_PIN
fair_JJ
value_NN
through_PIN
profit_NN
or_CC
loss_NN
on_PIN
initial_JJ
recognition_NOMZ
._.
21_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
Group_NN
Group_NN
Company_NN
Company_NN
As_IN
at_PIN
As_IN
at_PIN
As_IN
at_PIN
As_IN
at_PIN
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW
m_FW
m_FW
Cash_NN
at_PIN
bank_NN
and_CC
in_PIN
hand_NN
26.8_CD
15.3_CD
24.1_CD
11.3_CD
Short_JJ
term_NN
deposits_NN
7.5_CD
7.5_CD
34.3_CD
15.3_CD
31.6_CD
11.3_CD
The_DT
short_JJ
term_NN
deposit_NN
is_VPRT [BEMA]
a_DT
dual_JJ
currency_NN
deposit_NN
of_PIN
sterling_GER
versus_PIN
US_FPP1
dollars_NN
,_,
which_WDT [SERE]
earns_VPRT
an_DT
effective_JJ
interest_NN
rate_NN
of_PIN
10.5_CD
%_NN
._.
If_COND
the_DT
sterling_GER
US_FPP1
dollar_NN
spot_NN
rate_NN
is_VPRT [BEMA]
at_PIN
or_CC
above_PLACE
1.75_CD
at_PIN
expiry_NN
,_,
the_DT
7.5_CD
million_CD
deposit_NN
will_PRMD
be_VB [PASS]
returned_VBN
in_PIN
US_FPP1
dollars_NN
at_PIN
1.75_CD
$_$
13.1_CD
million_CD
,_,
otherwise_CONJ
it_PIT
will_PRMD
be_VB [PASS]
returned_VBN
in_PIN
sterling_GER
._.
22_CD
Trade_NN
and_CC
other_JJ
payables_NN
Group_NN
Group_NN
Company_NN
Company_NN
As_IN
at_PIN
As_IN
at_PIN
As_IN
at_PIN
As_IN
at_PIN
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW
m_FW
m_FW
Trade_NN
payables_NN
6.8_CD
6.7_CD
0.6_CD
0.6_CD
Amounts_NN
owed_VBN [WZPAST]
to_PIN
subsidiary_NN
undertakings_GER
89.7_CD
77.3_CD
Other_JJ
taxation_NOMZ
and_CC
social_JJ
security_NOMZ
costs_NN
2.0_CD
1.2_CD
0.1_CD
0.1_CD
Accruals_NN
12.2_CD
12.7_CD
1.1_CD
2.5_CD
21.0_CD
20.6_CD
91.5_CD
80.5_CD
86_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
87_CD
23_CD
Borrowings_GER
Company_NN
Company_NN
Group_NN
Group_NN
Company_NN
Company_NN
As_IN
at_PIN
As_IN
at_PIN
As_IN
at_PIN
As_IN
at_PIN
As_IN
at_PIN
As_IN
at_PIN
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW [BEMA]
Current_JJ
Convertible_JJ
bonds_NN
due_JJ
June_NN
2005_CD
9.4_CD
9.4_CD
5.2_CD
5.2_CD
Bank_NN
borrowings_GER
2.3_CD
3.5_CD
0.8_CD
1.9_CD
0.5_CD
1.0_CD
Property_NN
mortgage_NN
0.3_CD
0.3_CD
Paul_NN
Capital_NN
funding_VBG [WZPRES]
liabilities_NOMZ
0.7_CD
0.2_CD
Finance_NN
lease_NN
liabilities_NOMZ
0.1_CD
0.1_CD
5.7_CD
6.4_CD
Other_JJ
current_JJ
borrowings_GER
3.4_CD
3.9_CD
0.8_CD
1.9_CD
Total_JJ
current_JJ
borrowings_GER
3.4_CD
13.3_CD
0.8_CD
11.3_CD
Group_NN
Group_NN
As_IN
at_PIN
As_IN
at_PIN
Non-current_JJ
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW [BEMA]
Convertible_JJ
bonds_NN
due_JJ
May_POMD
2024_CD
50.8_CD
50.4_CD
1.1_CD
1.0_CD
Convertible_JJ
bonds_NN
due_JJ
June_NN
2025_CD
12.8_CD
0.7_CD
0.1_CD
63.6_CD
50.4_CD
0.4_CD
1.1_CD
Bank_NN
borrowings_GER
0.6_CD
0.6_CD
Property_NN
mortgage_NN
6.6_CD
7.1_CD
ble_NN
loan_NN
notes_NN
due_JJ
at_PIN
par_NN
in_PIN
June_NN
Paul_NN
Capital_NN
funding_VBG [WZPRES]
liabilities_NOMZ
43.9_CD
44.7_CD
ayment_NOMZ
under_IN
an_DT
agreement_NOMZ
to_TO
jointly_RB
Finance_NN
lease_NN
liabilities_NOMZ
0.1_CD
yePharmas_NN
DepoFoam_NN
technology_NN
._.
Other_JJ
non-current_JJ
borrowings_GER
51.1_CD
51.9_CD
0.6_CD
en_IN
approximately_RB
8.3_CD
million_CD
and_CC
ck-up_JJ
period_NN
on_PIN
conversion_NN
of_PIN
the_DT
Total_JJ
non-current_JJ
borrowings_GER
114.7_CD
102.3_CD
0.6_CD
n_NN
conversion_NN
._.
The_DT
notes_NN
were_VBD [BEMA]
Total_JJ
borrowings_GER
118.1_CD
115.6_CD
1.4_CD
11.3_CD
Company_NN
Company_NN
Bank_NN
borrowings_GER
As_IN
at_PIN
As_IN
at_PIN
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
At_PIN
31_CD
December_NN
2005_CD
bank_NN
borrowings_GER
include_VPRT
two_CD
amounts_NN
due_JJ
to_PIN
the_DT
Basellandschaftliche_NN
Kantonalbank_NN
m_NN
m_NN [BEMA]
of_PIN
0.9_CD
million_CD
CHF_NN
2_CD
million_CD
and_CC
0.7_CD
million_CD
CHF_NN
1.5_CD
million_CD
2004_CD
:_:
0.9_CD
million_CD
CHF_NN
2_CD
million_CD
and_CC
24.1_CD
11.3_CD
0.7_CD
million_CD
CHF_NN
1.5_CD
million_CD
._.
Both_DT
loans_NN
can_POMD
be_VB [PASS]
terminated_VBN
with_PIN
six_CD
weeks_NN
notice_NN
by_PIN
either_DT
party_NN
and_PHC
bear_NN
7.5_CD
interest_NN
at_PIN
6.5_CD
%_NN
and_CC
6.0_CD
%_NN
respectively_RB
._.
Both_DT
loans_NN
are_VPRT [PASS]
secured_VBN
on_PIN
the_DT
assets_NN
of_PIN
Jago_NN
and_CC
the_DT
0.7_CD
million_CD
31.6_CD
11.3_CD
CHF_NN
1.5_CD
million_CD
loan_NN
is_VPRT [BYPA]
guaranteed_VBN [PUBV]
by_PIN
SkyePharma_NN
PLC._NN
._.
ollars_NN
,_,
which_WDT [SERE]
earns_VPRT
an_DT
effective_JJ
The_DT
Group_NN
had_VBD
a_DT
loan_NN
as_IN
at_PIN
31_CD
December_NN
2005_CD
with_PIN
GE_NN
Capital_NN
Corp_NN
of_PIN
1.4_CD
million_CD
$_$
2.4_CD
million_CD
5_CD
at_PIN
expiry_NN
,_,
the_DT
7.5_CD
million_CD
deposit_NN
2004_CD
:_:
1.9_CD
million_CD
$_$
3.7_CD
million_CD
._.
The_DT
loan_NN
is_VPRT [BYPA]
secured_VBN
by_PIN
certain_JJ
assets_NN
of_PIN
SkyePharma_NN
Inc_NN
,_,
SkyePharma_NN
US_FPP1
Inc_NN
eturned_VBD
in_PIN
sterling_GER
._.
The_DT
loan_NN
bears_VPRT
interest_NN
at_PIN
8.0_CD
%_NN
and_CC
is_VPRT [BEMA]
repayable_PRED
by_PIN
instalments_NOMZ
until_IN
September_NN
2007_CD
._.
Convertible_JJ
bonds_NN
Company_NN
Company_NN
Convertible_JJ
bonds_NN
are_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
Note_NN
24_CD
:_:
Convertible_JJ
bonds_NN
._.
As_IN
at_PIN
As_IN
at_PIN
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_NN
m_NN
Property_NN
mortgage_NN
0.6_CD
0.6_CD
At_PIN
31_CD
December_NN
2005_CD
,_,
the_DT
Group_NN
had_VBD
a_DT
property_NN
mortgage_NN
facility_NOMZ
with_PIN
the_DT
Basellandschaftliche_NN
Kantonalbank_NN
89.7_CD
77.3_CD
of_PIN
6.9_CD
million_CD
CHF_NN
15.5_CD
million_CD
2004_CD
:_:
7.4_CD
million_CD
CHF_NN
16.1_CD
million_CD
._.
The_DT
mortgage_NN
is_VPRT [BEMA]
in_PIN
two_CD
tranches_NN
,_,
both_DT
0.1_CD
0.1_CD
secured_VBN
by_PIN
the_DT
assets_NN
of_PIN
Jago_NN
._.
The_DT
first_JJ
tranche_NN
of_PIN
2.7_CD
million_CD
CHF_NN
6.2_CD
million_CD
bears_NN
interest_NN
at_PIN
2.75_CD
%_NN
and_CC
1.1_CD
2.5_CD
is_VPRT [BEMA]
repayable_PRED
by_PIN
instalments_NOMZ
over_IN
20_CD
years_NN
semi-annually_RB
._.
The_DT
second_JJ
tranche_NN
of_PIN
4.1_CD
million_CD
CHF_NN
9.3_CD
million_CD
91.5_CD
80.5_CD
bears_NN
interest_NN
at_PIN
2.75_CD
%_NN
and_CC
is_VPRT [BEMA]
repayable_PRED
by_PIN
instalments_NOMZ
over_IN
50_CD
years_NN
semi-annually_RB
._.
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
87_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
88_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
Paul_NN
Capital_NN
funding_VBG [WZPRES]
liabilities_NOMZ
The_DT
Group_NN
entered_VBD
into_PIN
two_CD
transactions_NOMZ
with_PIN
Paul_NN
Capital_NN
Royalty_NN
Acquisition_NOMZ
Fund_NN
Paul_NN
Capital_NN
in_PIN
2000_CD
and_CC
2002_CD
._.
Under_IN
these_DEMO
transactions_NOMZ
Paul_NN
Capital_NN
provided_VBD
a_DT
total_NN
of_PIN
$_$
60_CD
million_CD
in_PIN
return_NN
for_PIN
the_DT
sale_NN
of_PIN
a_DT
portion_NOMZ
of_PIN
the_DT
potential_JJ
future_NN
royalty_NN
and_PHC
revenue_NN
streams_NN
on_PIN
a_DT
selection_NOMZ
of_PIN
the_DT
Groups_NN
products_NN
._.
Whilst_OSUB
the_DT
contractual_JJ
arrangement_NOMZ
with_PIN
Paul_NN
Capital_NN
is_VPRT [BEMA]
a_DT
royalty_NN
agreement_NOMZ
under_IN
which_WDT
royalties_NN
are_VPRT [BEMA]
payable_PRED
on_PIN
revenues_NN
earned_VBN
and_CC
payments_NOMZ
received_VBD
,_,
the_DT
proceeds_NN
received_VBD
from_PIN
Paul_NN
Capital_NN
meet_VPRT
the_DT
definition_NOMZ
of_PIN
a_DT
financial_JJ
liability_NOMZ
under_IN
IAS_NN
39_CD
,_,
and_ANDC
are_VPRT [PASS]
treated_VBN
as_IN
a_DT
financial_JJ
liability_NOMZ
._.
Royalties_NN
paid_VBD
to_PIN
Paul_NN
Capital_NN
are_VPRT [PASS]
treated_VBN
as_IN
repayment_NOMZ
of_PIN
the_DT
liability_NOMZ
and_PHC
interest_NN
is_VPRT [PASS]
charged_VBN
on_PIN
the_DT
liability_NOMZ
using_VBG [WZPRES]
the_DT
effective_JJ
interest_NN
rate_NN
at_PIN
inception_NOMZ
of_PIN
each_QUAN
agreement_NOMZ
._.
The_DT
estimated_JJ
future_JJ
payments_NOMZ
to_PIN
Paul_NN
Capital_NN
are_VPRT [PASS]
discounted_VBN
using_VBG
each_QUAN
contracts_NN
original_JJ
effective_JJ
interest_NN
and_CC
any_QUAN
adjustment_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
income_NN
or_CC
expense_NN
in_PIN
the_DT
income_NN
statement_NOMZ
Finance_NN
lease_NN
liabilities_NOMZ
Obligations_NOMZ
under_IN
hire_NN
purchase_NN
and_PHC
finance_NN
leases_NN
are_VPRT [PASS]
secured_VBN
upon_PIN
the_DT
assets_NN
to_PIN
which_WDT [PIRE]
they_TPP3
relate_VPRT
and_CC
as_RB
at_PIN
31_CD
December_NN
2005_CD
Nil_NN
2004_CD
:_:
0.1_CD
million_CD
SKR_NN
0.9_CD
million_CD
is_VPRT [BYPA]
guaranteed_VBN [PUBV]
by_PIN
SkyePharma_NN
PLC._NN
._.
Maturity_NOMZ
analysis_NN
of_PIN
non-current_JJ
borrowings_GER
As_IN
at_PIN
31_CD
December_NN
2005_CD
1_CD
to_PIN
2_CD
Years_NN
2_CD
to_PIN
5_CD
Years_NN
Over_IN
5_CD
Years_NN
Total_JJ
m_NN
m_FW
m_FW
m_FW [BEMA]
Convertible_JJ
bonds_NN
63.6_CD
63.6_CD
Bank_NN
borrowings_GER
0.6_CD
0.6_CD
Property_NN
mortgage_NN
0.3_CD
0.8_CD
5.5_CD
6.6_CD
Paul_NN
Capital_NN
funding_VBG [WZPRES]
liabilities_NOMZ
4.9_CD
22.1_CD
16.9_CD
43.9_CD
Non-current_JJ
borrowings_GER
5.8_CD
22.9_CD
86.0_CD
114.7_CD
As_IN
at_PIN
31_CD
December_NN
2004_CD
1_CD
to_PIN
2_CD
Years_NN
2_CD
to_PIN
5_CD
Years_NN
Over_IN
5_CD
Years_NN
Total_JJ
m_NN
m_FW
m_FW
m_FW [BEMA]
Convertible_JJ
bonds_NN
50.4_CD
50.4_CD
Property_NN
mortgage_NN
0.3_CD
0.8_CD
6.0_CD
7.1_CD
Paul_NN
Capital_NN
funding_VBG [WZPRES]
liabilities_NOMZ
10.6_CD
21.5_CD
12.6_CD
44.7_CD
Finance_NN
lease_NN
liabilities_NOMZ
0.1_CD
0.1_CD
Non-current_JJ
borrowings_GER
11.0_CD
22.3_CD
69.0_CD
102.3_CD
Currency_NN
analysis_NN
of_PIN
borrowings_GER
As_IN
at_PIN
31_CD
December_NN
2005_CD
Sterling_GER
$_$
US_FPP1
Swiss_JJ
francs_NN
Total_JJ
m_NN
m_FW
m_FW
m_FW [BEMA]
Convertible_JJ
bonds_NN
63.6_CD
63.6_CD
Bank_NN
borrowings_GER
0.6_CD
0.6_CD
Property_NN
mortgage_NN
6.6_CD
6.6_CD
Paul_NN
Capital_NN
funding_VBG [WZPRES]
liabilities_NOMZ
43.9_CD
43.9_CD
Total_JJ
borrowings_GER
63.6_CD
44.5_CD
6.6_CD
114.7_CD
88_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
89_CD
As_IN
at_PIN
31_CD
December_NN
2004_CD
Sterling_GER
$_$
US_FPP1
Swiss_JJ
francs_NN
Total_JJ
tion_NOMZ
Fund_NN
Paul_NN
Capital_NN
in_PIN
2000_CD
m_FW
m_FW
m_FW
m_FW [BEMA]
million_CD
in_PIN
return_NN
for_PIN
the_DT
sale_NN
of_PIN
a_DT
Convertible_JJ
bonds_NN
50.4_CD
50.4_CD
of_PIN
the_DT
Groups_NN
products_NN
._.
Property_NN
mortgage_NN
7.1_CD
7.1_CD
Paul_NN
Capital_NN
funding_VBG [WZPRES]
liabilities_NOMZ
44.7_CD
44.7_CD
ent_NN
under_IN
which_WDT
royalties_NN
are_VPRT [BEMA]
payable_JJ
Finance_NN
lease_NN
liabilities_NOMZ
0.1_CD
0.1_CD
Paul_NN
Capital_NN
meet_VPRT
the_DT
definition_NOMZ
of_PIN
a_DT
Total_JJ
borrowings_GER
50.4_CD
44.7_CD
7.2_CD
102.3_CD
lties_NN
paid_VBN [WZPAST]
to_PIN
Paul_NN
Capital_NN
are_VPRT [PASS]
treated_VBN
he_TPP3
effective_JJ
interest_NN
rate_NN
at_PIN
inception_NOMZ
Interest_NN
rate_NN
analysis_NN
scounted_VBD
using_VBG
each_QUAN
contracts_NN
As_IN
at_PIN
31_CD
December_NN
2005_CD
expense_NN
in_PIN
the_DT
income_NN
statement_NOMZ
Sterling_GER
$_$
US_FPP1
Swiss_JJ
francs_NN
%_NN
%_NN
%_NN
Convertible_JJ
bonds_NN
8.9_CD
._.
9.5_CD
13.3_CD
assets_NN
to_PIN
which_WDT [PIRE]
they_TPP3
relate_VPRT
and_CC
Bank_NN
borrowings_GER
8.0_CD
anteed_NN
by_PIN
SkyePharma_NN
PLC._NN
._.
Property_NN
mortgage_NN
2.8_CD
Paul_NN
Capital_NN
Funding_GER
liabilities_NOMZ
24.0_CD
30.0_CD
As_IN
at_PIN
31_CD
December_NN
2005_CD
As_IN
at_PIN
31_CD
December_NN
2004_CD
Over_IN
5_CD
Years_NN
Total_JJ
Sterling_GER
$_$
US_FPP1
Swiss_JJ
francs_NN
m_VPRT [BEMA]
m_JJ
%_NN
%_NN
%_NN
63.6_CD
63.6_CD
Convertible_JJ
bonds_NN
8.9_CD
._.
9.5_CD
13.3_CD
0.6_CD
Property_NN
mortgage_NN
2.8_CD
5.5_CD
6.6_CD
Paul_NN
Capital_NN
Funding_GER
liabilities_NOMZ
24.0_CD
30.0_CD
16.9_CD
43.9_CD
Finance_NN
lease_NN
liabilities_NOMZ
6.5_CD
86.0_CD
114.7_CD
Fair_NN
values_NN
As_IN
at_PIN
31_CD
December_NN
2004_CD
At_PIN
31_CD
December_NN
2005_CD
,_,
the_DT
carrying_VBG
amount_NN
of_PIN
non-current_JJ
liabilities_NOMZ
,_,
compared_VBN [PASTP]
with_PIN
the_DT
fair_JJ
value_NN
was_VBD
as_IN
follows_VPRT
:_:
Over_IN
5_CD
Years_NN
Total_JJ
m_NN
m_NN
Carrying_VBG [WZPRES]
Amount_NN
Fair_NN
Value_NN
50.4_CD
50.4_CD
m_NN
m_NN [BEMA]
6.0_CD
7.1_CD
Convertible_JJ
bonds_NN
63.6_CD
83.5_CD
12.6_CD
44.7_CD
Bank_NN
borrowings_GER
0.6_CD
0.6_CD
0.1_CD
Property_NN
mortgage_NN
6.6_CD
6.6_CD
69.0_CD
102.3_CD
Paul_NN
Capital_NN
funding_VBG [WZPRES]
liabilities_NOMZ
43.9_CD
43.9_CD
114.7_CD
134.6_CD
As_IN
at_PIN
31_CD
December_NN
2005_CD
At_PIN
31_CD
December_NN
2004_CD
,_,
the_DT
carrying_VBG
amount_NN
of_PIN
non-current_JJ
liabilities_NOMZ
,_,
compared_VBN [PASTP]
with_PIN
the_DT
fair_JJ
value_NN
was_VBD
as_IN
follows_VPRT
:_:
Swiss_JJ
francs_NN
Total_JJ
m_NN
m_NN
Carrying_VBG [WZPRES]
Amount_NN
Fair_NN
Value_NN
63.6_CD
m_NN
m_NN [BEMA]
0.6_CD
Convertible_JJ
bonds_NN
50.4_CD
85.9_CD
6.6_CD
6.6_CD
Property_NN
mortgage_NN
7.1_CD
7.1_CD
43.9_CD
Paul_NN
Capital_NN
funding_VBG [WZPRES]
liabilities_NOMZ
44.7_CD
44.7_CD
6.6_CD
114.7_CD
Finance_NN
lease_NN
liabilities_NOMZ
0.1_CD
0.1_CD
102.3_CD
137.8_CD
Undrawn_JJ
facility_NOMZ
At_PIN
31_CD
December_NN
2005_CD
the_DT
Group_NN
had_VBD
an_DT
overdraft_NN
facility_NOMZ
of_PIN
1.3_CD
million_CD
CHF_NN
3_CD
million_CD
2004_CD
:_:
1.4_CD
million_CD
,_,
CHF_NN
3_CD
million_CD
with_PIN
the_DT
Basellandschaftliche_NN
Kantonalbank_NN
secured_VBN [WZPAST]
on_PIN
the_DT
assets_NN
of_PIN
Jago_NN
._.
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
89_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
90_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
24_CD
Convertible_JJ
bonds_NN
In_PIN
June_NN
2005_CD
the_DT
Group_NN
issued_VBD
20_CD
million_CD
8_CD
%_NN
convertible_JJ
bonds_NN
,_,
with_PIN
a_DT
first_RB
put_VBN
after_IN
five_CD
years_NN
by_PIN
the_DT
holder_NN
of_PIN
the_DT
bonds_NN
,_,
and_ANDC
a_DT
final_JJ
maturity_NOMZ
of_PIN
June_NN
2025_CD
._.
The_DT
bonds_NN
are_VPRT [BEMA]
convertible_PRED
at_PIN
the_DT
option_NOMZ
of_PIN
the_DT
holder_NN
into_PIN
SkyePharma_NN
Ordinary_NN
Shares_NN
at_PIN
an_DT
initial_JJ
conversion_NN
price_NN
of_PIN
77_CD
pence_NN
at_PIN
any_QUAN
time_NN
prior_RB
to_PIN
maturity_NOMZ
._.
The_DT
bond_NN
contains_VPRT
a_DT
price_NN
reset_VB
feature_NN
such_OSUB
that_NULL
if_COND
on_PIN
3_CD
June_NN
2006_CD
the_DT
Companys_NN
average_JJ
share_NN
price_NN
for_PIN
the_DT
preceding_VBG
10_CD
days_NN
reset_VB
price_NN
is_VPRT [BEMA]
less_PRED
than_PIN
the_DT
conversion_NN
price_NN
,_,
then_RB
the_DT
conversion_NN
price_NN
shall_PRMD
be_VB [PASS]
adjusted_VBN
to_PIN
the_DT
reset_NN
price_NN
subject_JJ
to_PIN
a_DT
maximum_NN
reduction_NOMZ
of_PIN
25_CD
%_NN
in_PIN
the_DT
conversion_NN
price_NN
._.
Unless_COND
previously_TIME
redeemed_VBN
or_CC
converted_VBN
,_,
the_DT
bonds_NN
will_PRMD
be_VB [BYPA]
redeemed_VBN
by_PIN
the_DT
Group_NN
at_PIN
their_TPP3
principal_JJ
amount_NN
in_PIN
June_NN
2025_CD
._.
The_DT
convertible_JJ
bonds_NN
existing_VBG [WZPRES]
at_PIN
31_CD
December_NN
2005_CD
,_,
due_RB
in_PIN
May_POMD
2024_CD
,_,
were_VBD [BYPA]
not_XX0
affected_VBN
by_PIN
this_DEMO
transaction_NOMZ
._.
On_PIN
19_CD
June_NN
2005_CD
9.8_CD
million_CD
of_PIN
convertible_JJ
bonds_NN
due_JJ
June_NN
2005_CD
were_VBD [PASS]
redeemed_VBN
in_PIN
full_JJ
by_PIN
the_DT
Company_NN
at_PIN
their_TPP3
principal_JJ
amount_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
these_DEMO
transactions_NOMZ
the_DT
Group_NN
has_VPRT
69.6_CD
million_CD
convertible_JJ
bonds_NN
due_JJ
May_POMD
2024_CD
at_PIN
a_DT
conversion_NN
price_NN
of_PIN
95_CD
pence_NN
,_,
and_ANDC
20_CD
million_CD
convertible_JJ
bonds_NN
due_JJ
June_NN
2025_CD
at_PIN
a_DT
conversion_NN
price_NN
of_PIN
77_CD
pence_NN
._.
25_CD
Derivative_JJ
financial_JJ
instruments_NOMZ
As_IN
at_PIN
As_IN
at_PIN
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
Group_NN
and_PHC
Company_NN
m_FW
m_FW
Interest_NN
rate_NN
swap_NN
0.2_CD
Total_JJ
derivative_JJ
financial_JJ
instrument_NOMZ
liabilities_NOMZ
0.2_CD
The_DT
Groups_NN
policy_NN
is_VPRT
to_TO
hedge_VB
interest_NN
rate_NN
exposures_NN
through_PIN
the_DT
use_NN
of_PIN
interest_NN
rate_NN
swaps_NN
and_PHC
currency_NN
exposures_NN
through_PIN
the_DT
use_NN
of_PIN
currency_NN
options_NOMZ
,_,
accrual_NN
forward_RB
options_NOMZ
and_CC
forward_JJ
currency_NN
contracts_NN
._.
None_INPR
of_PIN
these_DEMO
derivative_JJ
financial_JJ
instruments_NOMZ
qualify_VPRT
to_TO
be_VB [PASS]
treated_VBN
as_IN
hedges_NN
and_CC
accordingly_RB
gains_NN
and_PHC
losses_NN
are_VPRT [PASS]
recorded_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
._.
26_CD
Provisions_NN
Pension_NN
Restructuring_GER
Total_NN
Group_NN
m_FW
m_FW
m_FW [BEMA]
At_PIN
1_CD
January_NN
2005_CD
1.7_CD
0.3_CD
2.0_CD
Actuarial_JJ
gains_NN
losses_NN
0.3_CD
0.3_CD
Charge_NN
for_PIN
the_DT
year_NN
0.1_CD
0.1_CD
Utilised_NN
0.3_CD
0.3_CD
At_PIN
31_CD
December_NN
2005_CD
1.9_CD
1.9_CD
As_IN
at_PIN
As_IN
at_PIN
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
Current_JJ
restructuring_GER
0.3_CD
Non-Current_NN
pension_NN
1.9_CD
1.7_CD
1.9_CD
2.0_CD
Pension_NN
provision_NN
The_DT
pension_NN
provision_NN
relates_VPRT
to_PIN
the_DT
retirement_NOMZ
commitments_NOMZ
under_IN
its_PIT
defined_VBN
benefit_NN
schemes_NN
in_PIN
respect_NN
of_PIN
its_PIT
employees_NN
in_PIN
Switzerland_NN
and_PHC
France_NN
._.
Restructuring_GER
provision_NN
The_DT
restructuring_GER
provision_NN
relates_VPRT
to_PIN
the_DT
reorganisation_NOMZ
of_PIN
research_NN
and_PHC
development_NOMZ
operations_NOMZ
and_CC
other_JJ
business_NOMZ
functions_NOMZ
involving_VBG [WZPRES]
reductions_NOMZ
in_PIN
staff_NN
at_PIN
most_EMPH
sites_NN
._.
90_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
91_CD
27_CD
Retirement_NOMZ
benefit_NN
obligations_NOMZ
first_RB
put_VBN
after_IN
five_CD
years_NN
by_PIN
the_DT
holder_NN
le_FW
at_PIN
the_DT
option_NOMZ
of_PIN
the_DT
holder_NN
into_PIN
Defined_JJ
contribution_NOMZ
plans_VPRT
any_QUAN
time_NN
prior_RB
to_PIN
maturity_NOMZ
._.
The_DT
bond_NN
The_DT
Group_NN
operates_VPRT
various_JJ
defined_VBN
contribution_NOMZ
plans_NN
for_PIN
its_PIT
employees_NN
in_PIN
the_DT
UK_NN
and_PHC
US_FPP1
._.
The_DT
Groups_NN
average_JJ
share_NN
price_NN
for_PIN
the_DT
preceding_VBG
contributions_NOMZ
to_PIN
these_DEMO
plans_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
in_PIN
the_DT
period_NN
to_PIN
which_WDT [PIRE]
they_TPP3
relate_VPRT
,_,
n_JJ
price_NN
shall_PRMD
be_VB [PASS]
adjusted_VBN
to_PIN
the_DT
reset_NN
and_CC
the_DT
assets_NN
are_VPRT [PASS]
held_VBN [PRIV]
in_PIN
separate_JJ
trustee_NN
administered_VBN
funds_NN
._.
The_DT
income_NN
statement_NOMZ
charge_NN
related_JJ
ss_NN
previously_TIME
redeemed_VBN
or_CC
converted_VBN
,_,
to_TO
defined_VBN
contributions_NOMZ
plan_VPRT
is_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
Note_NN
7_CD
:_:
Staff_NN
costs_NN
._.
Defined_VBN
benefit_NN
plan_NN
The_DT
Group_NN
operates_VPRT
unfunded_JJ
defined_VBN
benefit_NN
schemes_NN
in_PIN
respect_NN
of_PIN
its_PIT
employees_NN
in_PIN
Switzerland_NN
and_PHC
France_NN
._.
deemed_VBN [PRIV] [PASTP]
in_PIN
full_JJ
by_PIN
the_DT
Company_NN
The_DT
liabilities_NOMZ
of_PIN
the_DT
defined_VBN
benefit_NN
schemes_NN
operated_VBN [WZPAST]
by_PIN
the_DT
Group_NN
are_VPRT [PASS]
presented_VBN
below_PLACE
:_:
As_IN
at_PIN
As_IN
at_PIN
bonds_NN
due_JJ
May_POMD
2024_CD
at_PIN
a_DT
conversion_NN
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
onversion_NN
price_NN
of_PIN
77_CD
pence_NN
._.
m_FW
m_FW
Balance_NN
sheet_NN
obligations_NOMZ
for_PIN
:_:
Defined_VBN
benefit_NN
pension_NN
benefits_NN
1.9_CD
1.7_CD
As_IN
at_PIN
As_IN
at_PIN
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW [BEMA]
The_DT
amounts_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
balance_NN
sheet_NN
are_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
as_IN
follows_VPRT
:_:
As_IN
at_PIN
As_IN
at_PIN
0.2_CD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
0.2_CD
m_NN
m_NN [BEMA]
Present_JJ
value_NN
of_PIN
funded_JJ
obligations_NOMZ
6.4_CD
6.3_CD
interest_NN
rate_NN
swaps_NN
and_PHC
currency_NN
Fair_NN
value_NN
of_PIN
plan_NN
assets_NN
5.3_CD
5.3_CD
nd_NN
forward_RB
currency_NN
contracts_NN
._.
None_INPR
1.1_CD
1.0_CD
nd_NN
accordingly_RB
gains_VPRT
and_CC
losses_NN
are_VPRT [BEMA]
Present_JJ
value_NN
of_PIN
unfunded_JJ
obligations_NOMZ
0.8_CD
0.7_CD
Liability_NOMZ
in_PIN
the_DT
balance_NN
sheet_NN
1.9_CD
1.7_CD
The_DT
amounts_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
income_NN
statement_NOMZ
are_VPRT
as_IN
follows_VPRT
:_:
Restructuring_GER
Total_NN
Year_NN
ended_VBD
Year_NN
ended_VBD
m_FW
m_FW [BEMA]
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_NN
m_NN [BEMA]
0.3_CD
2.0_CD
0.3_CD
Current_JJ
service_NN
cost_NN
0.3_CD
0.2_CD
0.1_CD
Interest_NN
cost_NN
0.3_CD
0.3_CD
0.3_CD
0.3_CD
Expected_VBN [PRIV]
losses_NN
on_PIN
assets_NN
0.2_CD
0.2_CD
1.9_CD
Total_JJ
included_VBN
in_PIN
staff_NN
cost_NN
0.4_CD
0.3_CD
As_IN
at_PIN
As_IN
at_PIN
The_DT
actuarial_JJ
return_NN
on_PIN
plans_NN
assets_NN
was_VBD [BEMA]
0.2_CD
million_CD
2004_CD
:_:
0.2_CD
million_CD
._.
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
0.3_CD
The_DT
movement_NOMZ
in_PIN
the_DT
defined_VBN
benefit_NN
obligation_NOMZ
over_IN
the_DT
year_NN
is_VPRT
as_IN
follows_VPRT
:_:
1.9_CD
1.7_CD
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
1.9_CD
2.0_CD
m_NN
m_NN
Beginning_GER
of_PIN
the_DT
year_NN
7.0_CD
6.7_CD
Exchange_NN
adjustment_NOMZ
0.1_CD
0.1_CD
efined_VBN
benefit_NN
schemes_NN
in_PIN
respect_NN
Current_JJ
service_NN
cost_NN
0.3_CD
0.2_CD
Contributions_NOMZ
0.3_CD
0.3_CD
Interest_NN
on_PIN
pension_NN
scheme_NN
liabilities_NOMZ
0.3_CD
0.3_CD
Expected_VBN [PRIV]
losses_NN
on_PIN
assets_NN
0.2_CD
0.2_CD
development_NOMZ
operations_NOMZ
and_CC
other_JJ
Actuarial_JJ
losses_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
equity_NOMZ
0.2_CD
0.4_CD
End_NN
of_PIN
the_DT
year_NN
7.2_CD
7.0_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
91_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
92_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
The_DT
movement_NOMZ
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
plan_NN
assets_NN
over_IN
the_DT
year_NN
is_VPRT
as_IN
follows_VPRT
:_:
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW
Beginning_GER
of_PIN
the_DT
year_NN
5.3_CD
4.7_CD
Exchange_NN
adjustment_NOMZ
0.1_CD
0.3_CD
Current_JJ
service_NN
cost_NN
0.3_CD
0.2_CD
Interest_NN
on_PIN
pension_NN
scheme_NN
liabilities_NOMZ
0.3_CD
0.3_CD
Benefits_NN
paid_VBD
0.7_CD
0.5_CD
Actuarial_JJ
gains_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
equity_NOMZ
0.2_CD
0.3_CD
End_NN
of_PIN
the_DT
year_NN
5.3_CD
5.3_CD
At_PIN
31_CD
December_NN
2005_CD
and_CC
2004_CD
actuarial_JJ
valuations_NOMZ
were_VBD [BYPA]
performed_VBN
by_PIN
professionally_RB
qualified_VBN
actuaries_NN
on_PIN
the_DT
present_JJ
value_NN
of_PIN
the_DT
accrued_VBN
liabilities_NOMZ
calculated_VBN [PRIV]
under_IN
the_DT
projected_VBN
unit_NN
method_NN
._.
The_DT
principal_JJ
assumptions_NOMZ
made_VBN [WZPAST]
by_PIN
the_DT
actuaries_NN
were_VBD
:_:
2005_CD
2004_CD
%_NN
per_PIN
annum_NN
%_NN
per_PIN
annum_NN
Inflation_NOMZ
rate_NN
1.9_CD
2.0_CD
Rate_NN
of_PIN
increase_NN
in_PIN
salaries_NN
2.3_CD
2.5_CD
Discount_NN
rate_NN
3.7_CD
4.0_CD
Expected_VBN [PRIV]
return_NN
on_PIN
plan_NN
assets_NN
2.0_CD
2.4_CD
Assumptions_NOMZ
regarding_VBG [WZPRES]
future_JJ
mortality_NOMZ
experience_NN
are_VPRT [PASS]
set_VBN
based_VBN
on_PIN
advice_NN
in_PIN
accordance_NN
with_PIN
published_VBN
statistics_NN
and_PHC
experience_NN
in_PIN
Switzerland_NN
and_PHC
France_NN
._.
2005_CD
2004_CD
years_NN
years_NN
Male_NN
17.3_CD
17.3_CD
Female_NN
20.8_CD
20.8_CD
2005_CD
2004_CD
m_NN
m_NN [BEMA]
Actuarial_JJ
gains_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
equity_NOMZ
0.3_CD
Cumulative_JJ
actuarial_JJ
gains_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
equity_NOMZ
0.3_CD
Plan_NN
assets_NN
are_VPRT [PASS]
comprised_VBN
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
m_NN
m_NN
Equity_NOMZ
4.7_CD
4.3_CD
Other_JJ
0.6_CD
1.0_CD
5.3_CD
5.3_CD
Expected_VBN [PRIV]
contributions_NOMZ
to_TO
post_VB
employment_NOMZ
benefit_NN
plans_NN
for_PIN
the_DT
year_NN
ending_VBG [WZPRES]
31_CD
December_NN
2006_CD
are_VPRT [BEMA]
0.6_CD
million_CD
._.
28_CD
Share_NN
capital_NN
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
Group_NN
and_PHC
Company_NN
Number_NN
of_PIN
shares_NN
Number_NN
of_PIN
shares_NN
m_FW
m_FW
Authorised_NN
Ordinary_NN
Shares_NN
of_PIN
10p_CD
each_QUAN
1,102,000_CD
1,102,000_CD
110.2_CD
110.2_CD
92_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
93_CD
ws_NN
:_:
Ordinary_NN
Shares_NN
of_PIN
Nominal_JJ
value_NN
Deferred_VBN
B_NN
Shares_NN
Nominal_NN
value_NN
Total_JJ
nominal_JJ
Year_NN
ended_VBD
Year_NN
ended_VBD
10p_CD
each_QUAN
Number_NN
m_NN [BEMA]
of_PIN
10p_CD
each_QUAN
Number_NN
m_NN
value_NN
m_NN [BEMA]
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
At_PIN
1_CD
January_NN
2004_CD
618,669,940_CD
61.9_CD
12,000,000_CD
1.2_CD
63.1_CD
m_NN
m_NN
Exercise_NN
of_PIN
share_NN
options_NOMZ
478,803_CD
5.3_CD
4.7_CD
Issue_NN
of_PIN
shares_NN
to_PIN
Research_NN
0.1_CD
0.3_CD
Development_NOMZ
Foundation_NOMZ
3,250,000_CD
0.3_CD
0.3_CD
0.3_CD
0.2_CD
At_PIN
1_CD
January_NN
2005_CD
622,398,743_CD
62.2_CD
12,000,000_CD
1.2_CD
63.4_CD
0.3_CD
0.3_CD
Rights_NN
issue_NN
125,627,357_CD
12.6_CD
12.6_CD
0.7_CD
0.5_CD
Acquisition_NOMZ
of_PIN
shares_NN
in_PIN
Astralis_NN
5,482,238_CD
0.6_CD
0.6_CD
0.2_CD
0.3_CD
Exercise_NN
of_PIN
share_NN
options_NOMZ
255,808_CD
5.3_CD
5.3_CD
At_PIN
31_CD
December_NN
2005_CD
753,764,146_CD
75.4_CD
12,000,000_CD
1.2_CD
76.6_CD
rofessionally_RB
qualified_VBN
actuaries_NN
The_DT
Group_NN
raised_VBD
34.8_CD
million_CD
net_NN
of_PIN
expenses_NN
by_PIN
means_NN
of_PIN
a_DT
rights_NN
issue_NN
of_PIN
125,627,357_CD
new_JJ
ordinary_JJ
shares_NN
._.
The_DT
principal_JJ
The_DT
Group_NN
also_RB
issued_VBD
5,482,238_CD
Ordinary_NN
Shares_NN
to_PIN
two_CD
former_JJ
Astralis_NN
Directors_NN
to_TO
acquire_VB
11,160,000_CD
2005_CD
2004_CD
%_NN
per_PIN
annum_NN
%_NN
per_PIN
annum_NN
common_JJ
shares_NN
in_PIN
Astralis_NN
._.
1.9_CD
2.0_CD
2.3_CD
2.5_CD
Deferred_VBN
B_NN
shares_NN
3.7_CD
4.0_CD
In_PIN
July_NN
2000_CD
,_,
12_CD
million_CD
deferred_VBN
A_DT
and_CC
12_CD
million_CD
deferred_VBN
B_NN
shares_NN
were_VBD [PASS]
issued_VBN
to_PIN
Dr_NN
Gonella_NN
,_,
the_DT
vendor_NN
of_PIN
2.0_CD
2.4_CD
Jago_NN
,_,
under_IN
a_DT
settlement_NOMZ
agreement_NOMZ
that_TSUB
established_VBD [PRIV]
the_DT
full_JJ
and_PHC
final_JJ
settlement_NOMZ
of_PIN
the_DT
deferred_JJ
consideration_NOMZ
payable_JJ
on_PIN
the_DT
acquisition_NOMZ
of_PIN
Jago_NN
._.
The_DT
holders_NN
of_PIN
deferred_VBN
A_DT
and_CC
B_NN
shares_NN
have_VPRT
no_SYNE
rights_NN
to_TO
participate_VB
in_PIN
the_DT
profits_NN
of_PIN
the_DT
Company_NN
,_,
no_SYNE
voting_NN
rights_NN
and_CC
on_PIN
a_DT
winding_VBG
up_RP
or_CC
other_JJ
return_NN
of_PIN
capital_NN
only_DWNT
receive_VB
the_DT
ce_NN
in_PIN
accordance_NN
with_PIN
published_VBN
nominal_JJ
value_NN
of_PIN
their_TPP3
shares_NN
if_COND
the_DT
holders_NN
of_PIN
Ordinary_NN
Shares_NN
in_PIN
the_DT
capital_NN
of_PIN
the_DT
Company_NN
have_VPRT [PEAS]
received_VBN
2005_CD
2004_CD
the_DT
sum_NN
of_PIN
1_CD
million_CD
per_PIN
Ordinary_NN
Share_NN
._.
Under_IN
the_DT
terms_NN
of_PIN
the_DT
settlement_NOMZ
agreement_NOMZ
,_,
following_VBG [PRESP]
the_DT
US_FPP1
years_NN
years_NN
launch_NN
and_CC
first_JJ
commercial_JJ
sale_NN
of_PIN
Paxil_NN
CR_NN
by_PIN
GlaxoSmithKline_NN
in_PIN
2002_CD
,_,
the_DT
12_CD
million_CD
deferred_VBN
A_DT
shares_NN
17.3_CD
17.3_CD
were_VBD [SPAU] [PASS]
automatically_RB
converted_VBN
into_PIN
12_CD
million_CD
Ordinary_NN
Shares_NN
._.
20.8_CD
20.8_CD
The_DT
12_CD
million_CD
deferred_VBN
B_NN
shares_NN
automatically_RB
convert_VPRT
to_PIN
12_CD
million_CD
Ordinary_NN
Shares_NN
on_PIN
the_DT
Companys_NN
2005_CD
2004_CD
receipt_NN
of_PIN
a_DT
royalty_NN
statement_NOMZ
under_IN
the_DT
current_JJ
license_NN
agreement_NOMZ
stating_VBG [PUBV] [THATD] [WZPRES]
that_DEMP
reported_VBD [PUBV]
sales_NN
of_PIN
Paxil_NN
CR_NN
m_FW
m_FW
have_VPRT [PEAS]
exceeded_VBN
$_$
1,000_CD
million_CD
during_PIN
any_QUAN
calendar_NN
period_NN
prior_RB
to_PIN
1_CD
January_NN
2006_CD
or_CC
exceeded_VBD
$_$
337_CD
million_CD
0.3_CD
between_PIN
1_CD
January_NN
2006_CD
and_CC
3_CD
May_POMD
2006_CD
._.
The_DT
conditions_NOMZ
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
met_VBN
and_CC
the_DT
deferred_VBN
B_NN
shares_NN
0.3_CD
will_PRMD
be_VB [PASS]
transferred_VBN
to_PIN
the_DT
Company_NN
Secretary_NN
for_PIN
no_SYNE
consideration_NOMZ
for_PIN
him_TPP3
to_TO
hold_VB [PRIV]
as_IN
custodian_NN
._.
2005_CD
2004_CD
Warrants_NN
m_FW
m_FW [BEMA]
The_DT
Company_NN
has_VPRT
the_DT
following_JJ
warrants_NN
outstanding_JJ
:_:
4.7_CD
4.3_CD
0.6_CD
1.0_CD
a_DT
D_NN
and_PHC
E_NN
warrants_NN
5.3_CD
5.3_CD
The_DT
D_NN
and_PHC
E_NN
warrants_NN
were_VBD [PASS]
issued_VBN
in_PIN
March_NN
2002_CD
as_IN
part_NN
of_PIN
the_DT
consideration_NOMZ
for_PIN
the_DT
agreement_NOMZ
with_PIN
Paul_NN
Capital_NN
to_TO
fund_VB
new_JJ
product_NN
development_NOMZ
._.
The_DT
D_NN
and_PHC
E_NN
warrants_NN
entitle_VPRT
the_DT
holders_NN
to_TO
subscribe_VB
g_NN
31_CD
December_NN
2006_CD
are_VPRT [BEMA]
0.6_CD
million_CD
._.
for_PIN
a_DT
total_NN
of_PIN
5_CD
million_CD
Ordinary_NN
Shares_NN
at_PIN
any_QUAN
time_NN
during_PIN
the_DT
period_NN
to_PIN
31_CD
December_NN
2008_CD
at_PIN
an_DT
exercise_NN
price_NN
of_PIN
73.75_CD
pence_NN
per_PIN
Ordinary_NN
Share_NN
._.
A_DT
value_NN
of_PIN
0.3_CD
million_CD
,_,
deemed_VBD [PRIV]
to_TO
be_VB [BEMA]
the_DT
fair_JJ
value_NN
of_PIN
the_DT
D_NN
and_PHC
E_NN
warrants_NN
,_,
has_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
in_PIN
Other_JJ
Reserves_NN
._.
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_NN
m_NN
b_NN
F_NN
warrants_NN
The_DT
F_NN
warrants_NN
were_VBD [PASS]
issued_VBN
in_PIN
December_NN
2003_CD
as_IN
part_NN
of_PIN
the_DT
2.7_CD
million_CD
$_$
5_CD
million_CD
loan_NN
with_PIN
GE_NN
Capital_NN
110.2_CD
110.2_CD
Corp._NN
._.
The_DT
F_NN
warrants_NN
entitle_VPRT
the_DT
holders_NN
to_TO
subscribe_VB
for_PIN
a_DT
total_NN
of_PIN
300,000_CD
Ordinary_NN
Shares_NN
at_PIN
any_QUAN
time_NN
until_IN
the_DT
repayment_NOMZ
date_NN
of_PIN
the_DT
loan_NN
at_PIN
an_DT
exercise_NN
price_NN
of_PIN
1.20_CD
per_PIN
Ordinary_NN
Share_NN
._.
A_DT
value_NN
of_PIN
39,000_CD
,_,
deemed_VBD [PRIV]
to_TO
be_VB [BEMA]
the_DT
fair_JJ
value_NN
of_PIN
the_DT
F_NN
warrants_NN
,_,
has_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
in_PIN
Other_JJ
Reserves_NN
._.
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
93_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
94_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
c_NN
Other_JJ
warrants_NN
Warrants_NN
were_VBD [PASS]
issued_VBN
in_PIN
December_NN
1999_CD
as_IN
part_NN
of_PIN
the_DT
acquisition_NOMZ
of_PIN
DepoTech_NN
and_CC
entitle_VB
the_DT
holders_NN
to_TO
subscribe_VB
for_PIN
371,353_CD
Ordinary_NN
Shares_NN
at_PIN
any_QUAN
time_NN
during_PIN
the_DT
period_NN
beginning_VBG [WZPRES]
31_CD
December_NN
1999_CD
and_CC
ending_VBG
on_PIN
25_CD
February_NN
2005_CD
at_PIN
an_DT
exercise_NN
price_NN
of_PIN
$_$
1.142_CD
59.5_CD
pence_NN
per_PIN
Ordinary_NN
Share_NN
._.
All_QUAN
of_PIN
these_DEMO
warrants_NN
lapsed_VBD
unexercised_JJ
on_PIN
25_CD
February_NN
2005_CD
._.
Potential_JJ
Issues_NN
of_PIN
ordinary_JJ
shares_NN
a_DT
Employee_NN
share_NN
schemes_NN
The_DT
Group_NN
encourages_VPRT
employee_NN
participation_NOMZ
in_PIN
its_PIT
shares_NN
through_PIN
ownership_NN
and_CC
continues_VPRT
to_TO
operate_VB
various_JJ
incentive_NN
schemes_NN
whereby_OSUB
Directors_NN
and_PHC
employees_NN
are_VPRT [BEMA]
to_PIN
able_JJ
to_TO
acquire_VB
shares_NN
,_,
and_ANDC
potential_JJ
shares_NN
,_,
in_PIN
the_DT
Company_NN
._.
Further_JJ
details_NN
are_VPRT [PASS]
provided_VBN
in_PIN
Note_NN
29_CD
:_:
Share_NN
based_VBN
payments_NOMZ
._.
b_NN
Deferred_JJ
consideration_NOMZ
on_PIN
acquisition_NOMZ
of_PIN
Krypton_NN
The_NN
deferred_JJ
consideration_NOMZ
on_PIN
the_DT
acquisition_NOMZ
of_PIN
Krypton_NN
provides_VPRT
that_DEMO
a_DT
maximum_NN
of_PIN
37.5_CD
million_CD
Ordinary_NN
Shares_NN
would_PRMD
be_VB [PASS]
issued_VBN
contingent_NN
on_PIN
a_DT
change_NN
in_PIN
control_NN
of_PIN
the_DT
Company_NN
at_PIN
a_DT
share_NN
price_NN
of_PIN
not_XX0
less_JJ
than_PIN
80_CD
pence_NN
compounded_VBN [WZPAST]
at_PIN
an_DT
annual_JJ
rate_NN
of_PIN
10_CD
%_NN
2.08_CD
as_RB
at_PIN
31_CD
December_NN
2005_CD
,_,
or_CC
satisfaction_NOMZ
of_PIN
various_JJ
conditions_NOMZ
and_PHC
hurdles_NN
which_WDT [WHSUB]
lapsed_VBD
on_PIN
31_CD
December_NN
2003_CD
._.
No_SYNE
provision_NN
for_PIN
deferred_JJ
consideration_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
as_IN
at_PIN
31_CD
December_NN
2005_CD
._.
c_NN
Paul_NN
Capital_NN
Royalty_NN
Acquisition_NOMZ
Fund_NN
In_PIN
March_NN
2002_CD
the_DT
Group_NN
announced_VBD [PUBV]
a_DT
second_JJ
transaction_NOMZ
with_PIN
Paul_NN
Capital_NN
Royalty_NN
Acquisition_NOMZ
Fund_NN
under_IN
which_WDT
SkyePharma_NN
would_PRMD
issue_VB
Ordinary_NN
Shares_NN
up_IN
to_PIN
a_DT
value_NN
of_PIN
$_$
7.5_CD
million_CD
if_COND
royalties_NN
and_PHC
milestones_NN
received_VBN [WZPAST]
by_PIN
SkyePharma_NN
in_PIN
respect_NN
of_PIN
those_DEMO
products_NN
included_VBD
in_PIN
the_DT
transaction_NOMZ
were_VBD [BEMA]
not_XX0
in_PIN
excess_NN
of_PIN
minimum_JJ
annual_JJ
payments_NOMZ
required_VBN [SUAV]
to_TO
be_VB [PASS]
made_VBN
to_PIN
Paul_NN
Capital_NN
._.
During_PIN
2005_CD
the_DT
royalties_NN
received_VBN [WZPAST]
by_PIN
SkyePharma_NN
were_VBD [BEMA]
substantially_RB
in_PIN
excess_NN
of_PIN
the_DT
minimum_JJ
payments_NOMZ
required_VBN [SUAV]
to_TO
be_VB [PASS]
made_VBN
to_PIN
Paul_NN
Capital_NN
,_,
consequently_CONJ
the_DT
Company_NN
has_VPRT [PEAS]
not_XX0
recognized_VBN [PRIV]
a_DT
provision_NN
._.
29_CD
Share_NN
based_VBN
payments_NOMZ
The_DT
Group_NN
operates_VPRT
various_JJ
share_NN
based_VBN
compensation_NOMZ
plans_NN
as_IN
follows_VPRT
:_:
Option_NOMZ
schemes_NN
Options_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
UK_NN
and_CC
European_JJ
employees_NN
are_VPRT [BEMA]
only_DWNT
exercisable_PRED
between_PIN
the_DT
third_JJ
and_CC
tenth_NN
anniversary_NN
of_PIN
the_DT
date_NN
of_PIN
grant_NN
,_,
and_ANDC
are_VPRT [BEMA]
subject_PRED
to_PIN
the_DT
Companys_NN
Code_NN
of_PIN
Business_NOMZ
Conduct_NN
and_PHC
Ethics_NN
for_PIN
dealing_VBG
in_PIN
Shares_NN
,_,
and_ANDC
the_DT
Model_NN
Code_NN
._.
Options_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
US_FPP1
employees_NN
prior_RB
to_PIN
2001_CD
vest_NN
at_PIN
25_CD
%_NN
per_PIN
annum_NN
from_PIN
the_DT
date_NN
of_PIN
grant_NN
and_CC
there_EX
were_VBD
no_SYNE
performance_NN
criteria_NN
._.
UK_NN
and_CC
European_JJ
options_NOMZ
granted_VBN [SUAV] [WZPAST]
prior_RB
to_PIN
2001_CD
may_POMD [SPAU]
only_DWNT
be_VB [PASS]
exercised_VBN
if_COND
the_DT
growth_NN
in_PIN
the_DT
Companys_NN
share_NN
price_NN
over_IN
a_DT
consecutive_JJ
three-year_JJ
period_NN
exceeds_VPRT
the_DT
growth_NN
over_IN
the_DT
same_JJ
period_NN
in_PIN
the_DT
FTSE_NN
All_QUAN
Share_NN
Index_NN
._.
This_DEMO
criteria_NN
was_VBD [PASS]
satisfied_VBN
for_PIN
the_DT
first_JJ
time_NN
in_PIN
March_NN
2000_CD
._.
Employees_NN
with_PIN
options_NOMZ
that_TSUB
are_VPRT [BEMA]
within_PIN
their_TPP3
exercise_NN
period_NN
are_VPRT [BEMA]
now_TIME
able_PRED
to_TO
exercise_VB
those_DEMO
options_NOMZ
within_PIN
any_QUAN
one-year_JJ
period_NN
from_PIN
the_DT
date_NN
the_DT
performance_NN
condition_NOMZ
is_VPRT [PASS]
satisfied_VBN
._.
Super_NN
Options_NOMZ
are_VPRT [BEMA]
exercisable_PRED
after_IN
five_CD
years_NN
and_CC
are_VPRT [BEMA]
subject_PRED
to_PIN
higher_JJ
performance_NN
conditions_NOMZ
in_PIN
accordance_NN
with_PIN
those_DEMP
recommended_VBN [SUAV]
by_PIN
the_DT
Association_NOMZ
of_PIN
British_NN
Insurers_NN
._.
Following_VBG
changes_NN
to_PIN
the_DT
option_NOMZ
plans_VPRT
approved_VBN
at_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
in_PIN
June_NN
2001_CD
,_,
options_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
Directors_NN
and_CC
senior_JJ
employees_NN
since_OSUB
that_DEMO
date_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
performance_NN
conditions_NOMZ
linked_VBN [WZPAST]
to_PIN
the_DT
total_JJ
shareholder_NN
return_NN
of_PIN
a_DT
comparator_NN
group_NN
of_PIN
companies_NN
,_,
and_ANDC
are_VPRT [BEMA]
not_XX0
subject_PRED
to_TO
retesting_VBG
._.
Options_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
other_JJ
US_FPP1
employees_NN
continue_VPRT
to_PIN
vest_NN
at_PIN
25_CD
%_NN
per_PIN
annum_NN
with_PIN
no_SYNE
performance_NN
criteria_NN
,_,
and_ANDC
other_JJ
European_JJ
employees_NN
who_WP [WHSUB]
are_VPRT
not_XX0
Directors_NN
or_CC
senior_JJ
employees_NN
can_POMD
exercise_VB
their_TPP3
options_NOMZ
after_IN
three_CD
years_NN
and_CC
are_VPRT [BEMA]
not_XX0
subject_PRED
to_PIN
performance_NN
conditions_NOMZ
._.
The_DT
Groups_NN
option_NOMZ
plans_NN
are_VPRT [PASS]
detailed_VBN
further_RB
in_PIN
the_DT
Remuneration_NOMZ
Report_NN
._.
It_PIT
is_VPRT [BEMA]
the_DT
intention_NOMZ
of_PIN
the_DT
Group_NN
that_TOBJ
no_SYNE
further_JJ
options_NOMZ
grants_NN
will_PRMD
be_VB [PASS]
made_VBN
under_IN
any_QUAN
of_PIN
the_DT
option_NOMZ
plans_NN
._.
94_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
95_CD
The_DT
following_JJ
table_NN
summarises_VPRT
the_DT
activity_NOMZ
in_PIN
share_NN
options_NOMZ
for_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2005_CD
:_:
oTech_NN
and_CC
entitle_VB
the_DT
holders_NN
to_PIN
Share_NN
options_NOMZ
Option_NOMZ
price_NN
nning_JJ
31_CD
December_NN
1999_CD
and_CC
ending_VBG
At_PIN
1_CD
January_NN
2004_CD
52,345,218_CD
44.8_CD
p_NN
93.0_CD
p_NN
ary_JJ
Share_NN
._.
All_QUAN
of_PIN
these_DEMO
warrants_NN
Exercised_VBN
478,803_CD
44.8_CD
p_NN
66.5_CD
p_NN
Cancelled_VBN
or_CC
expired_VBN
3,883,170_CD
46.5_CD
p_NN
91.3_CD
p_NN
At_PIN
31_CD
December_NN
2004_CD
47,983,245_CD
44.8_CD
p_NN
93.0_CD
p_NN
Exercised_VBN
255,808_CD
46.5_CD
p_NN
55.6_CD
p_NN
Forfeited_NN
9,654,453_CD
46.5_CD
p_NN
92.0_CD
p_NN
Cancelled_VBN
or_CC
expired_VBN
2,171,974_CD
46.5_CD
p_NN
92.0_CD
p_NN
rship_NN
and_CC
continues_VPRT
to_TO
operate_VB
Rights_NN
issue_NN
adjustment_NOMZ
see_VPRT [PRIV]
below_PLACE
1,596,534_CD
1.8_CD
p_NN
3.7_CD
p_NN
o_NN
acquire_VB
shares_NN
,_,
and_ANDC
potential_JJ
At_PIN
31_CD
December_NN
2005_CD
37,497,544_CD
43.0_CD
p_NN
89.3_CD
p_NN
sed_VBD
payments_NOMZ
._.
Exercisable_JJ
22,180,175_CD
43.0_CD
p_NN
89.3_CD
p_NN
maximum_NN
of_PIN
37.5_CD
million_CD
Ordinary_NN
The_DT
weighted_JJ
average_JJ
exercise_NN
price_NN
as_IN
at_PIN
31_CD
December_NN
2005_CD
was_VBD [BEMA]
58.6_CD
pence_NN
._.
y_RB
at_PIN
a_DT
share_NN
price_NN
of_PIN
not_XX0
less_JJ
than_PIN
r_NN
2005_CD
,_,
or_CC
satisfaction_NOMZ
of_PIN
various_JJ
The_DT
market_NN
value_NN
of_PIN
Ordinary_NN
Shares_NN
as_IN
at_PIN
31_CD
December_NN
2005_CD
was_VBD [BEMA]
49.75_CD
pence_NN
._.
The_DT
market_NN
value_NN
of_PIN
Ordinary_NN
for_PIN
deferred_JJ
consideration_NOMZ
has_VPRT [PEAS]
been_VBN
Shares_NN
during_PIN
2005_CD
ranged_VBD
from_PIN
the_DT
lowest_JJ
closing_GER
mid-price_NN
of_PIN
34.25_CD
pence_NN
to_PIN
the_DT
highest_JJ
closing_GER
mid-price_NN
of_PIN
66.75_CD
pence_NN
per_PIN
share_NN
._.
No_SYNE
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
during_PIN
the_DT
current_JJ
year_NN
._.
At_PIN
31_CD
December_NN
2005_CD
the_DT
following_VBG
Ordinary_NN
Shares_NN
were_VBD
under_IN
option_NOMZ
to_PIN
employees_NN
or_CC
former_JJ
employees_NN
of_PIN
tal_JJ
Royalty_NN
Acquisition_NOMZ
Fund_NN
under_IN
the_DT
Group_NN
:_:
lion_NN
if_COND
royalties_NN
and_PHC
milestones_NN
Option_NOMZ
price_NN
for_PIN
each_QUAN
Number_NN
of_PIN
options_NOMZ
over_IN
saction_NOMZ
were_VBD [BEMA]
not_XX0
in_PIN
excess_NN
of_PIN
Normal_JJ
expiry_NN
date_NN
Ordinary_NN
Share_NN
of_PIN
10p_CD
Ordinary_NN
Shares_NN
of_PIN
10p_CD
2005_CD
the_DT
royalties_NN
received_VBN [WZPAST]
by_PIN
29_CD
April_NN
2006_CD
72.0_CD
p_NN
930,937_CD
ired_VBD
to_TO
be_VB [PASS]
made_VBN
to_PIN
Paul_NN
Capital_NN
,_,
7_CD
April_NN
2007_CD
63.8_CD
p_NN
529,100_CD
28_CD
January_NN
2008_CD
49.0_CD
p_NN
129,254_CD
31_CD
March_NN
2008_CD
89.3_CD
p_NN
829,615_CD
5_CD
October_NN
2008_CD
43.0_CD
p_NN
570,128_CD
19_CD
April_NN
2009_CD
66.7_CD
p_NN
2,272,318_CD
25_CD
May_POMD
2009_CD
54.4_CD
p_NN
5,076,891_CD
7_CD
September_NN
2009_CD
54.6_CD
p_NN
199,044_CD
ween_VPRT
the_DT
third_JJ
and_CC
tenth_NN
anniversary_NN
6_CD
June_NN
2010_CD
87.6_CD
p_NN
442,185_CD
Conduct_NN
and_PHC
Ethics_NN
for_PIN
dealing_VBG
in_PIN
3_CD
November_NN
2010_CD
78.4_CD
p_NN
1,411,387_CD
001_CD
vest_NN
at_PIN
25_CD
%_NN
per_PIN
annum_NN
from_PIN
the_DT
12_CD
June_NN
2011_CD
77.4_CD
p_NN
4,066,007_CD
options_NOMZ
granted_VBN [SUAV] [WZPAST]
prior_RB
to_PIN
2001_CD
may_POMD
31_CD
October_NN
2011_CD
53.4_CD
p_NN
913,309_CD
cutive_JJ
three-year_JJ
period_NN
exceeds_VPRT
the_DT
12_CD
April_NN
2012_CD
69.4_CD
p_NN
4,847,662_CD
s_PRP
satisfied_VBD
for_PIN
the_DT
first_JJ
time_NN
in_PIN
March_NN
24_CD
May_POMD
2012_CD
75.4_CD
p_NN
447,637_CD
w_NN
able_JJ
to_TO
exercise_VB
those_DEMO
options_NOMZ
25_CD
September_NN
2012_CD
49.6_CD
p_NN
1,114,377_CD
tisfied_VBN
._.
Super_NN
Options_NOMZ
are_VPRT [BEMA]
exercisable_PRED
7_CD
April_NN
2013_CD
44.6_CD
p_NN
13,570,809_CD
dance_NN
with_PIN
those_DEMP
recommended_VBN [SUAV]
by_PIN
26_CD
September_NN
2013_CD
59.5_CD
p_NN
146,884_CD
37,497,544_CD
eeting_NN
in_PIN
June_NN
2001_CD
,_,
options_NOMZ
granted_VBD [SUAV]
ance_NN
conditions_NOMZ
linked_VBN [WZPAST]
to_PIN
the_DT
total_JJ
Following_VBG
completion_NOMZ
of_PIN
the_DT
Companys_NN
Rights_NN
Issue_NN
announced_VBD [PUBV]
on_PIN
28_CD
September_NN
2005_CD
the_DT
number_NN
and_CC
ect_VB
to_TO
retesting_VBG
._.
Options_NOMZ
granted_VBN [SUAV]
to_TO
exercise_VB
price_NN
applicable_JJ
to_PIN
options_NOMZ
were_VBD [PASS]
adjusted_VBN
to_TO
take_VB
account_NN
of_PIN
the_DT
dilution_NOMZ
in_PIN
the_DT
value_NN
of_PIN
options_NOMZ
caused_VBD
ance_NN
criteria_NN
,_,
and_ANDC
other_JJ
European_JJ
by_PIN
the_DT
Rights_NN
Issue_NN
._.
The_DT
number_NN
of_PIN
options_NOMZ
was_VBD [BYPA]
increased_VBN
by_PIN
4_CD
%_NN
and_CC
the_DT
exercise_NN
price_NN
was_VBD [BYPA]
reduced_VBN
by_PIN
4_CD
%_NN
._.
options_NOMZ
after_IN
three_CD
years_NN
and_CC
are_VPRT
not_XX0
further_RB
in_PIN
the_DT
Remuneration_NOMZ
Report_NN
._.
As_IN
stated_VBN [PUBV]
above_PLACE
,_,
no_SYNE
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
to_PIN
employees_NN
in_PIN
2004_CD
or_CC
2005_CD
._.
For_PIN
those_DEMO
options_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
prior_JJ
e_SYM
under_IN
any_QUAN
of_PIN
the_DT
option_NOMZ
plans_NN
._.
years_NN
which_WDT [WHSUB]
impact_VPRT
the_DT
income_NN
statement_NOMZ
,_,
fair_JJ
values_NN
were_VBD [PASS]
determined_VBN [SUAV] [PRIV]
using_VBG
an_DT
option_NOMZ
pricing_GER
model_NN
based_VBN
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
95_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
96_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
on_PIN
Black-Scholes_NN
but_CC
adjusted_VBN
to_TO
model_VB
the_DT
particular_JJ
features_NN
of_PIN
the_DT
options_NOMZ
._.
The_DT
fair_JJ
value_NN
of_PIN
these_DEMO
options_NOMZ
is_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
values_NN
previously_TIME
disclosed_VBN [PUBV]
for_PIN
SEC_NN
filing_NN
purposes_NN
._.
The_DT
Rights_NN
Issue_NN
had_VBD
no_SYNE
effect_NN
on_PIN
the_DT
fair_JJ
value_NN
of_PIN
options_NOMZ
._.
The_DT
total_JJ
expense_NN
relating_VBG [WZPRES]
to_TO
share_VB
based_VBN
payments_NOMZ
,_,
which_WDT [SERE]
are_VPRT [BEMA]
all_QUAN
equity_NOMZ
settled_VBD
transactions_NOMZ
,_,
is_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
Note_NN
7_CD
:_:
Staff_NN
costs_NN
._.
Deferred_JJ
Share_NN
Bonus_NN
Plan_NN
DSB_NN
Under_IN
the_DT
rules_NN
of_PIN
this_DEMO
plan_NN
,_,
Directors_NN
and_CC
senior_JJ
employees_NN
receive_VPRT
conditional_JJ
rights_NN
to_TO
acquire_VB
Ordinary_NN
Shares_NN
in_PIN
the_DT
Company_NN
,_,
at_PIN
the_DT
prevailing_VBG
market_NN
rates_NN
at_PIN
the_DT
time_NN
of_PIN
grant_NN
._.
Eligible_JJ
employees_NN
are_VPRT [PASS]
awarded_VBN
rights_NN
to_TO
acquire_VB
a_DT
maximum_JJ
number_NN
of_PIN
shares_NN
at_PIN
the_DT
beginning_GER
of_PIN
a_DT
three_CD
year_NN
period_NN
,_,
a_DT
proportion_NOMZ
of_PIN
which_WDT [PIRE]
they_TPP3
will_PRMD
be_VB [PASS]
entitled_VBN
to_TO
receive_VB
at_PIN
the_DT
end_NN
of_PIN
that_DEMO
period_NN
depending_VBG [WZPRES]
on_PIN
the_DT
extent_NN
to_PIN
which_WDT [PIRE]
the_DT
performance_NN
conditions_NOMZ
set_VBN [WZPAST]
by_PIN
the_DT
Remuneration_NOMZ
Committee_NN
at_PIN
the_DT
time_NN
the_DT
allocation_NOMZ
is_VPRT [PASS]
made_VBN
are_VPRT [PASS]
satisfied_VBN
._.
If_COND
the_DT
performance_NN
conditions_NOMZ
are_VPRT [PASS]
not_XX0
satisfied_VBN
the_DT
share_NN
award_NN
will_PRMD
lapse_NN
._.
Awards_NN
are_VPRT [SPAU] [PASS]
either_RB
linked_VBN
to_PIN
the_DT
deferral_NN
of_PIN
annual_JJ
bonus_NN
DSB_NN
Matching_GER
Share_NN
Awards_NN
or_CC
stand_VB
alone_JJ
share_NN
awards_NN
LTIP_NN
Awards_NN
._.
Further_JJ
information_NOMZ
on_PIN
awards_NN
and_PHC
performance_NN
conditions_NOMZ
are_VPRT [PASS]
detailed_VBN
in_PIN
the_DT
Remuneration_NOMZ
Report_NN
._.
DSB_NN
Matching_VBG [WZPRES]
LTIP_NN
Awards_NN
Share_NN
Awards_NN
Outstanding_JJ
At_PIN
1_CD
January_NN
2005_CD
3,679,499_CD
2,046,093_CD
Granted_VBN [SUAV]
3,979,684_CD
640,103_CD
Rights_NN
Issue_NN
Adjustment_NOMZ
301,830_CD
90,299_CD
Forfeited_NN
Cancelled_NN
or_CC
expired_VBD
518,084_CD
88,801_CD
Released_VBN
434,395_CD
At_PIN
31_CD
December_NN
2005_CD
7,442,929_CD
2,253,299_CD
Following_VBG
completion_NOMZ
of_PIN
the_DT
Companys_NN
Rights_NN
Issue_NN
announced_VBD [PUBV]
on_PIN
28_CD
September_NN
2005_CD
the_DT
number_NN
of_PIN
shares_NN
comprising_VBG [WZPRES]
the_DT
LTIP_NN
Awards_NN
and_PHC
DSB_NN
Matching_VBG [WZPRES]
Share_NN
Awards_NN
was_VBD [PASS]
adjusted_VBN
to_TO
take_VB
account_NN
of_PIN
the_DT
dilution_NOMZ
in_PIN
the_DT
value_NN
of_PIN
conditional_JJ
shares_NN
caused_VBN [WZPAST]
by_PIN
the_DT
Rights_NN
Issue_NN
._.
The_DT
number_NN
of_PIN
shares_NN
under_IN
award_NN
was_VBD [BYPA]
increased_VBN
by_PIN
4_CD
%_NN
._.
For_PIN
the_DT
purposes_NN
of_PIN
IFRS_NN
2_CD
the_DT
fair_JJ
values_NN
of_PIN
LTIP_NN
Awards_NN
and_PHC
DSB_NN
Matching_GER
Shares_NN
Awards_NN
have_VPRT [PEAS]
been_VBN [PASS]
determined_VBN [SUAV] [PRIV]
using_VBG
a_DT
Monte_NN
Carlo_NN
Simulation_NOMZ
model_NN
._.
The_DT
Monte_NN
Carlo_NN
Simulation_NOMZ
model_NN
takes_VPRT
into_PIN
account_NN
the_DT
comparative_JJ
total_JJ
shareholder_NN
return_NN
performance_NN
element_NOMZ
attaching_VBG [WZPRES]
to_PIN
these_DEMO
share_NN
awards_NN
._.
The_DT
following_JJ
table_NN
sets_VPRT
out_PIN
the_DT
assumptions_NOMZ
used_VBN [WZPAST]
in_PIN
determining_VBG [SUAV] [PRIV]
the_DT
fair_JJ
value_NN
of_PIN
these_DEMO
share_NN
awards_NN
:_:
DSB_NN
Matching_VBG [WZPRES]
LTIP_NN
Awards_NN
Share_NN
Awards_NN
Model_NN
Monte_NN
Carlo_NN
Simulation_NOMZ
Rationale_NN
This_DEMO
model_NN
takes_VPRT
into_PIN
account_NN
the_DT
market_NN
based_VBN
performance_NN
conditions_NOMZ
comparative_JJ
TSR_NN
attaching_VBG [WZPRES]
to_PIN
the_DT
LTIP_NN
Awards_NN
and_PHC
DSB_NN
Matching_VBG [WZPRES]
Share_NN
Awards_NN
._.
Date_NN
of_PIN
Grant_NN
3_CD
June_NN
2005_CD
9_CD
June_NN
2005_CD
2_CD
February_NN
2005_CD
Share_NN
Price_NN
on_PIN
Grant_NN
0.54_CD
0.53_CD
0.64_CD
Exercise_NN
Price_NN
nil_NN
nil_NN
nil_NN
Expected_NN
Dividend_NN
Yield_NN
n_VBD
a_DT
n_NN
a_DT
n_NN
a_DT
Expected_NN
Volatility_NOMZ
47.23_CD
%_NN
47.18_CD
%_NN
48.96_CD
%_NN
Risk_NN
Free_NN
Interest_NN
Rate_NN
4.22_CD
%_NN
4.73_CD
%_NN
4.57_CD
%_NN
Expected_NN
Life_NN
3_CD
years_NN
3_CD
years_NN
3_CD
years_NN
Fair_NN
Value_NN
0.40_CD
0.40_CD
0.57_CD
96_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
97_CD
ions_NN
._.
The_DT
fair_JJ
value_NN
of_PIN
these_DEMO
options_NOMZ
The_DT
excepted_JJ
volatility_NOMZ
is_VPRT [PASS]
calculated_VBN [PRIV]
as_IN
the_DT
historic_JJ
volatility_NOMZ
of_PIN
the_DT
Company_NN
share_NN
return_NN
over_IN
the_DT
three_CD
years_NN
prior_RB
to_PIN
each_QUAN
grant_NN
date_NN
._.
In_PIN
determining_VBG [SUAV] [PRIV]
the_DT
charge_NN
to_PIN
the_DT
income_NN
statement_NOMZ
,_,
the_DT
Company_NN
has_VPRT [PEAS]
assumed_VBN [PRIV]
that_THVC
the_DT
number_NN
of_PIN
share_NN
settled_VBN
transactions_NOMZ
,_,
is_VPRT [PASS]
disclosed_VBN [PUBV]
awards_NN
that_TSUB
will_PRMD
ultimately_RB
vest_NN
is_VPRT [BYPA]
reduced_VBN
by_PIN
5_CD
%_NN
per_PIN
annum_NN
._.
The_DT
Rights_NN
Issue_NN
had_VBD
no_SYNE
effect_NN
on_PIN
the_DT
fair_JJ
value_NN
of_PIN
LTIP_NN
Awards_NN
and_PHC
DSB_NN
Matching_VBG [WZPRES]
Share_NN
Awards_NN
._.
ditional_JJ
rights_NN
to_TO
acquire_VB
Ordinary_NN
The_DT
total_JJ
expense_NN
relating_VBG [WZPRES]
to_TO
share_VB
based_VBN
payments_NOMZ
,_,
which_WDT [SERE]
are_VPRT [BEMA]
all_QUAN
equity_NOMZ
settled_VBD
transactions_NOMZ
,_,
is_VPRT [PASS]
disclosed_VBN [PUBV]
t._IN
Eligible_JJ
employees_NN
are_VPRT [PASS]
awarded_VBN
in_PIN
Note_NN
7_CD
:_:
Staff_NN
costs_NN
._.
e_LS
year_NN
period_NN
,_,
a_DT
proportion_NOMZ
of_PIN
which_WDT [PIRE]
extent_NN
to_PIN
which_WDT [PIRE]
the_DT
performance_NN
International_NN
Share_NN
Purchase_NN
Plan_NN
ISPP_NN
is_VPRT [PASS]
made_VBN
are_VPRT [PASS]
satisfied_VBN
._.
If_COND
the_DT
All_QUAN
employees_NN
are_VPRT [BEMA]
eligible_PRED
to_TO
participate_VB
in_PIN
the_DT
ISPP_NN
whereby_OSUB
employees_NN
buy_VPRT
shares_NN
in_PIN
the_DT
Company_NN
._.
rds_NN
are_VPRT [SPAU] [PASS]
either_RB
linked_VBN
to_PIN
the_DT
deferral_JJ
These_DEMO
shares_NN
are_VPRT [PASS]
called_VBN
Partnership_NN
Shares_NN
and_CC
are_VPRT [PASS]
held_VBN [PRIV]
in_PIN
trust_NN
on_PIN
behalf_NN
of_PIN
the_DT
employee_NN
._.
For_PIN
every_QUAN
rds_NN
LTIP_NN
Awards_NN
._.
Further_JJ
Partnership_NN
Share_NN
bought_VBD
by_PIN
the_DT
employee_NN
the_DT
Company_NN
will_PRMD
give_VB
the_DT
employee_NN
one_CD
share_NN
free_JJ
of_PIN
charge_NN
muneration_NOMZ
Report_NN
._.
The_DT
employees_NN
have_VPRT
to_TO
take_VB
their_TPP3
shares_NN
out_PIN
of_PIN
the_DT
plan_NN
on_PIN
leaving_VBG
the_DT
Company_NN
and_CC
will_PRMD
not_XX0
be_VB [PASS]
entitled_VBN
to_PIN
the_DT
Matching_GER
Shares_NN
if_COND
they_TPP3
leave_VPRT
within_PIN
three_CD
years_NN
of_PIN
buying_VBG
the_DT
Partnership_NN
Shares_NN
._.
DSB_NN
Matching_VBG [WZPRES]
In_CONJ
addition_NULL
,_,
the_DT
Company_NN
can_POMD
also_RB
award_NN
employees_NN
rights_NN
to_TO
acquire_VB
up_RP
to_PIN
a_DT
maximum_NN
of_PIN
3,000_CD
of_PIN
shares_NN
LTIP_NN
Awards_NN
Share_NN
Awards_NN
Free_NN
Shares_NN
._.
There_EX
are_VPRT
no_SYNE
vesting_GER
conditions_NOMZ
attaching_VBG [WZPRES]
to_PIN
the_DT
Free_NN
Shares_NN
other_JJ
than_PIN
being_VBG [BEMA]
continuously_RB
3,679,499_CD
2,046,093_CD
employed_VBN
by_PIN
a_DT
Group_NN
company_NN
on_PIN
the_DT
third_JJ
anniversary_NN
of_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
3,979,684_CD
640,103_CD
301,830_CD
90,299_CD
Matching_GER
Shares_NN
Free_NN
Shares_NN
Outstanding_JJ
At_PIN
1_CD
January_NN
2005_CD
348,831_CD
30,411_CD
518,084_CD
88,801_CD
Granted_VBN [SUAV]
211,460_CD
434,395_CD
Rights_NN
Issue_NN
Adjustment_NOMZ
n_VBD
a_DT
2,723_CD
7,442,929_CD
2,253,299_CD
Forfeited_NN
Cancelled_NN
or_CC
expired_VBD
41,109_CD
7,855_CD
ptember_NN
2005_CD
the_DT
number_NN
of_PIN
shares_NN
Released_VBN
88,347_CD
ed_VBD
to_TO
take_VB
account_NN
of_PIN
the_DT
dilution_NOMZ
in_PIN
At_PIN
31_CD
December_NN
2005_CD
430,835_CD
25,279_CD
f_SYM
shares_NN
under_IN
award_NN
Following_VBG [WZPRES]
the_DT
completion_NOMZ
of_PIN
the_DT
Companys_NN
Rights_NN
Issue_NN
announced_VBD [PUBV]
on_PIN
28_CD
September_NN
2005_CD
the_DT
number_NN
of_PIN
shares_NN
applicable_JJ
to_PIN
Free_NN
Shares_NN
was_VBD [PASS]
adjusted_VBN
to_TO
take_VB
account_NN
of_PIN
the_DT
dilution_NOMZ
in_PIN
the_DT
value_NN
of_PIN
conditional_JJ
shares_NN
ing_VBG [WZPRES]
Shares_NN
Awards_NN
have_VPRT [PEAS]
been_VBN [BYPA]
caused_VBN
by_PIN
the_DT
Rights_NN
Issue_NN
._.
ulation_NOMZ
model_NN
takes_VPRT
into_PIN
account_NN
to_PIN
these_DEMO
share_NN
awards_NN
._.
For_PIN
the_DT
purposes_NN
of_PIN
IFRS_NN
2_CD
the_DT
fair_JJ
value_NN
of_PIN
these_DEMO
Matching_GER
Shares_NN
and_PHC
Free_NN
Shares_NN
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
as_IN
the_DT
value_NN
of_PIN
these_DEMO
share_NN
awards_NN
:_:
market_NN
value_NN
of_PIN
the_DT
shares_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
In_PIN
determining_VBG [SUAV] [PRIV]
the_DT
charge_NN
to_PIN
the_DT
income_NN
statement_NOMZ
,_,
the_DT
Company_NN
has_VPRT [PEAS]
assumed_VBN [PRIV]
that_THVC
the_DT
number_NN
of_PIN
share_NN
awards_NN
that_TSUB
will_PRMD
ultimately_RB
vest_NN
is_VPRT [BYPA]
reduced_VBN
by_PIN
10_CD
%_NN
per_PIN
annum_NN
._.
DSB_NN
Matching_VBG [WZPRES]
LTIP_NN
Awards_NN
Share_NN
Awards_NN
The_NN
Rights_NN
Issue_NN
had_VBD
no_SYNE
effect_NN
on_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
Free_NN
Shares_NN
._.
Monte_NN
Carlo_NN
Simulation_NOMZ
model_NN
takes_VPRT
into_PIN
account_NN
the_DT
market_NN
based_VBN
ce_NN
conditions_NOMZ
comparative_JJ
TSR_NN
attaching_VBG [WZPRES]
to_PIN
The_DT
total_JJ
expense_NN
relating_VBG [WZPRES]
to_TO
share_VB
based_VBN
payments_NOMZ
,_,
which_WDT [SERE]
are_VPRT [BEMA]
all_QUAN
equity_NOMZ
settled_VBD
transactions_NOMZ
,_,
is_VPRT [PASS]
disclosed_VBN [PUBV]
P_NN
Awards_NN
and_PHC
DSB_NN
Matching_VBG [WZPRES]
Share_NN
Awards_NN
._.
9_CD
June_NN
2005_CD
2_CD
February_NN
2005_CD
0.53_CD
0.64_CD
nil_NN
nil_NN
n_VBD
a_DT
n_NN
a_DT
47.18_CD
%_NN
48.96_CD
%_NN
4.73_CD
%_NN
4.57_CD
%_NN
3_CD
years_NN
3_CD
years_NN
0.40_CD
0.57_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
97_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
98_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
30_CD
Reserves_NN
Share_NN
premium_NN
Translation_NOMZ
reserve_NN
Fair_NN
value_NN
reserve_NN
Retained_VBN
losses_NN
Group_NN
m_FW
m_FW
m_FW
m_FW [BEMA]
At_PIN
1_CD
January_NN
2004_CD
319.3_CD
1.6_CD
364.3_CD
On_PIN
issue_NN
of_PIN
shares_NN
to_PIN
Research_NN
Development_NOMZ
Foundation_NOMZ
1.5_CD
Exercise_NN
of_PIN
share_NN
options_NOMZ
0.2_CD
Exchange_NN
adjustments_NOMZ
2.5_CD
Revaluation_NOMZ
deficit_NN
transfer_NN
0.5_CD
Loss_NN
for_PIN
the_DT
year_NN
18.6_CD
Share_NN
based_VBN
payments_NOMZ
charge_VPRT
4.1_CD
Pension_NN
actuarial_JJ
losses_NN
0.1_CD
At_PIN
31_CD
December_NN
2004_CD
321.0_CD
0.9_CD
0.5_CD
378.9_CD
Rights_NN
issue_NN
25.1_CD
Expenses_NN
of_PIN
rights_NN
issue_NN
2.9_CD
Acquisition_NOMZ
of_PIN
shares_NN
in_PIN
Astralis_NN
2.3_CD
Exercise_NN
of_PIN
share_NN
options_NOMZ
0.1_CD
Exchange_NN
adjustments_NOMZ
0.3_CD
Impairments_NOMZ
0.5_CD
Revaluation_NOMZ
surplus_NN
transfer_NN
0.2_CD
Loss_NN
for_PIN
the_DT
year_NN
50.9_CD
Share_NN
based_VBN
payments_NOMZ
charge_VPRT
2.4_CD
Purchase_NN
of_PIN
own_JJ
shares_NN
0.4_CD
Repayment_NOMZ
of_PIN
convertible_JJ
bonds_NN
due_JJ
June_NN
2005_CD
0.7_CD
At_PIN
31_CD
December_NN
2005_CD
345.6_CD
1.2_CD
0.2_CD
427.1_CD
Share_NN
premium_NN
Fair_NN
value_NN
reserve_NN
Retained_VBN
losses_NN
Company_NN
m_NN
m_FW
m_FW [BEMA]
At_PIN
1_CD
January_NN
2004_CD
319.3_CD
18.4_CD
On_PIN
issue_NN
of_PIN
shares_NN
to_PIN
Research_NN
Development_NOMZ
Foundation_NOMZ
1.5_CD
Exercise_NN
of_PIN
share_NN
options_NOMZ
0.2_CD
Revaluation_NOMZ
deficit_NN
transfer_NN
0.5_CD
Loss_NN
for_PIN
the_DT
year_NN
32.0_CD
Share_NN
based_VBN
payments_NOMZ
charge_VPRT
1.1_CD
At_PIN
31_CD
December_NN
2004_CD
321.0_CD
0.5_CD
49.3_CD
Rights_NN
issue_NN
25.1_CD
Expenses_NN
of_PIN
rights_NN
issue_NN
2.9_CD
Acquisition_NOMZ
of_PIN
shares_NN
in_PIN
Astralis_NN
2.3_CD
Exercise_NN
of_PIN
share_NN
options_NOMZ
0.1_CD
Impairments_NOMZ
0.5_CD
Revaluation_NOMZ
surplus_NN
transfer_NN
0.2_CD
Loss_NN
for_PIN
the_DT
year_NN
98.3_CD
Share_NN
based_VBN
payments_NOMZ
charge_VPRT
1.3_CD
Purchase_NN
of_PIN
own_JJ
shares_NN
0.4_CD
Repayment_NOMZ
of_PIN
convertible_JJ
bonds_NN
due_JJ
June_NN
2005_CD
0.7_CD
At_PIN
31_CD
December_NN
2005_CD
345.6_CD
0.2_CD
146.0_CD
As_IN
permitted_VBN
by_PIN
Section_NOMZ
230_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
the_DT
Income_NN
Statement_NOMZ
of_PIN
the_DT
Company_NN
is_VPRT [PASS]
not_XX0
presented_VBN
._.
The_DT
loss_NN
of_PIN
the_DT
Company_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
was_VBD [BEMA]
98.3_CD
million_CD
2004_CD
:_:
32.0_CD
million_CD
._.
98_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
99_CD
31_CD
Other_JJ
reserves_NN
Fair_NN
value_NN
reserve_NN
Retained_VBN
losses_NN
Equity_NOMZ
of_PIN
m_NN
m_NN
Merger_NN
reserve_NN
Warrants_NN
reserve_NN
convertible_JJ
bonds_NN
Total_JJ
other_JJ
reserves_NN
Group_NN
m_FW
m_FW
m_FW
m_FW [BEMA]
364.3_CD
At_PIN
1_CD
January_NN
2004_CD
9.0_CD
0.4_CD
0.7_CD
10.1_CD
Exchange_NN
and_PHC
issue_NN
of_PIN
convertible_JJ
bonds_NN
due_JJ
May_POMD
2024_CD
22.3_CD
22.3_CD
At_PIN
31_CD
December_NN
2004_CD
9.0_CD
0.4_CD
23.0_CD
32.4_CD
Issue_NN
of_PIN
convertible_JJ
bonds_NN
due_JJ
June_NN
2025_CD
6.1_CD
6.1_CD
0.5_CD
Repayment_NOMZ
of_PIN
convertible_JJ
bonds_NN
due_JJ
June_NN
2005_CD
0.7_CD
0.7_CD
18.6_CD
At_PIN
31_CD
December_NN
2005_CD
9.0_CD
0.4_CD
28.4_CD
37.8_CD
4.1_CD
0.1_CD
The_DT
merger_NN
reserve_NN
relates_VPRT
to_PIN
the_DT
acquisition_NOMZ
of_PIN
Krypton_NN
Limited_NN
during_PIN
1996_CD
._.
The_DT
warrant_NN
reserve_NN
relates_VPRT
to_PIN
0.5_CD
378.9_CD
the_DT
D_NN
,_,
E_NN
and_PHC
F_NN
warrants_NN
described_VBN [WZPAST]
in_PIN
note_NN
28_CD
:_:
Share_NN
capital_NN
._.
The_DT
equity_NOMZ
element_NOMZ
of_PIN
the_DT
convertible_JJ
bonds_NN
reserve_NN
relates_VPRT
to_PIN
the_DT
convertible_JJ
bonds_NN
due_JJ
May_POMD
2024_CD
and_CC
June_NN
2025_CD
._.
Equity_NOMZ
of_PIN
Merger_NN
reserve_NN
Warrants_NN
reserve_NN
convertible_JJ
bonds_NN
Total_JJ
other_JJ
reserves_NN
Company_NN
m_NN
m_FW
m_FW
m_FW [BEMA]
0.5_CD
At_PIN
1_CD
January_NN
2004_CD
and_CC
31_CD
December_NN
2004_CD
9.0_CD
0.4_CD
0.7_CD
10.1_CD
0.2_CD
Repayment_NOMZ
of_PIN
convertible_JJ
bonds_NN
due_JJ
June_NN
2005_CD
0.7_CD
0.7_CD
50.9_CD
At_PIN
31_CD
December_NN
2005_CD
9.0_CD
0.4_CD
9.4_CD
2.4_CD
0.4_CD
32_CD
Commitments_NOMZ
Group_NN
Group_NN
Company_NN
Company_NN
0.7_CD
As_IN
at_PIN
As_IN
at_PIN
As_IN
at_PIN
As_IN
at_PIN
0.2_CD
427.1_CD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
31_CD
December_NN
2005_CD
31_CD
December_NN
2004_CD
m_FW
m_FW
m_FW
m_FW
Fair_NN
value_NN
reserve_NN
Retained_VBN
losses_NN
Commitments_NOMZ
under_IN
operating_VBG
leases_NN
m_FW
m_FW
Operating_GER
leases_NN
on_PIN
land_NN
and_PHC
buildings_GER
:_:
18.4_CD
In_PIN
one_CD
year_NN
or_CC
less_JJ
2.3_CD
2.5_CD
0.6_CD
In_PIN
two_CD
to_PIN
five_CD
years_NN
10.4_CD
10.7_CD
In_PIN
five_CD
years_NN
or_CC
more_EMPH
14.6_CD
15.6_CD
0.3_CD
0.5_CD
27.3_CD
28.8_CD
0.3_CD
0.6_CD
32.0_CD
1.1_CD
Other_JJ
operating_GER
leases_NN
:_:
0.5_CD
49.3_CD
In_PIN
one_CD
year_NN
or_CC
less_JJ
0.1_CD
0.1_CD
In_CONJ
addition_NULL
the_DT
Group_NN
has_VPRT [PEAS]
committed_VBN
to_TO
undertake_VB
certain_JJ
clinical_JJ
trials_NN
on_PIN
behalf_NN
of_PIN
its_PIT
partners_NN
under_IN
development_NOMZ
and_PHC
licensing_GER
agreements_NOMZ
._.
0.5_CD
0.2_CD
The_DT
Group_NN
is_VPRT [PASS]
committed_VBN
to_TO
make_VB
certain_JJ
payments_NOMZ
to_PIN
third_JJ
parties_NN
contingent_JJ
upon_PIN
future_JJ
events_NN
such_JJ
98.3_CD
as_IN
the_DT
approval_NN
and_PHC
launch_NN
of_PIN
products_NN
._.
1.3_CD
0.4_CD
0.7_CD
0.2_CD
146.0_CD
ement_NOMZ
of_PIN
the_DT
Company_NN
er_NN
2005_CD
was_VBD [BEMA]
98.3_CD
million_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
99_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
100_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
33_CD
Contingencies_NN
At_PIN
31_CD
December_NN
2005_CD
the_DT
Company_NN
had_VBD [PEAS]
provided_VBN
guarantees_NN
on_PIN
various_JJ
bank_NN
borrowings_GER
of_PIN
its_PIT
subsidiaries_NN
as_IN
set_VBN
out_PIN
in_PIN
Note_NN
23_CD
:_:
Borrowings_GER
._.
In_PIN
common_JJ
with_PIN
most_EMPH
business_NOMZ
enterprises_NN
,_,
Group_NN
companies_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
a_DT
number_NN
of_PIN
claims_NN
from_PIN
third_JJ
parties_NN
,_,
the_DT
outcome_NN
of_PIN
which_WDT [PIRE]
can_POMD
not_XX0
at_PIN
present_JJ
be_VB [PASS]
determined_VBN [SUAV] [PRIV]
but_CC
which_WDT
are_VPRT [PASS]
not_XX0
considered_VBN [PRIV]
to_TO
be_VB
material_NN
in_PIN
the_DT
context_NN
of_PIN
these_DEMO
financial_JJ
statements_NOMZ
._.
Provisions_NN
have_VPRT [PEAS]
been_VBN [PASS]
made_VBN
in_PIN
these_DEMO
financial_JJ
statements_NOMZ
for_PIN
any_QUAN
liabilities_NOMZ
which_WDT [WHSUB]
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
materialise_VB
from_PIN
such_JJ
claims_NN
._.
34_CD
Related_VBN
Parties_NN
Group_NN
Directors_NN
transactions_NOMZ
At_PIN
the_DT
end_NN
of_PIN
December_NN
1998_CD
,_,
Ian_NN
Gowrie-Smith_NN
through_PIN
a_DT
family-owned_JJ
trust_NN
acquired_VBD
a_DT
51_CD
%_NN
interest_NN
in_PIN
10_CD
East_NN
63rd_NN
Street_NN
Inc._NN
the_DT
company_NN
which_WDT [WHSUB]
owns_VPRT
10_CD
East_NN
63rd_NN
Street_NN
,_,
a_DT
property_NN
in_PIN
New_NN
York_NN
._.
In_PIN
December_NN
2002_CD
Mr._NN
Gowrie-Smith_NN
acquired_VBD
a_DT
further_JJ
49_CD
%_NN
interest_NN
._.
SkyePharma_NN
PLC_NN
has_VPRT [PEAS]
been_VBN [BEMA]
in_PIN
occupation_NOMZ
of_PIN
approximately_RB
half_DT
of_PIN
that_DEMO
property_NN
since_OSUB
January_NN
1997_CD
,_,
subject_JJ
to_PIN
tenancy_NN
agreements_NOMZ
based_VBN [WZPAST]
upon_PIN
independent_JJ
valuation_NOMZ
._.
In_PIN
August_NN
2003_CD
the_DT
Company_NN
took_VBD
occupation_NOMZ
of_PIN
the_DT
entire_JJ
building_GER
under_IN
an_DT
eight-year_JJ
tenancy_NN
agreement_NOMZ
,_,
at_PIN
which_WDT [PIRE]
time_NN
the_DT
annual_JJ
rent_NN
was_VBD [PASS]
increased_VBN
from_PIN
$_$
420,000_CD
per_PIN
annum_NN
to_TO
$_$
720,000_CD
per_PIN
annum_NN
until_IN
August_NN
2008_CD
,_,
and_ANDC
$_$
942,500_CD
per_PIN
annum_NN
from_PIN
August_NN
2008_CD
to_PIN
August_NN
2011_CD
._.
A_DT
portion_NOMZ
of_PIN
these_DEMO
premises_NN
is_VPRT [BEMA]
currently_RB
sub-let_PRED
by_PIN
the_DT
Group_NN
._.
Company_NN
The_DT
Company_NN
has_VPRT [PEAS]
issued_VBN
share_NN
options_NOMZ
to_PIN
employees_NN
of_PIN
subsidiary_NN
undertakings_GER
and_CC
in_PIN
accordance_NN
with_PIN
IFRS_NN
2_CD
has_VPRT [PEAS]
made_VBN
a_DT
charge_NN
of_PIN
1.3_CD
million_CD
2004_CD
:_:
1.1_CD
million_CD
._.
The_DT
Company_NN
has_VPRT [PEAS]
charged_VBN
1.6_CD
m_NN [BEMA]
2004_CD
:_:
1.9_CD
m_NN [BEMA]
to_PIN
subsidiary_NN
undertakings_GER
and_CC
the_DT
Company_NN
was_VBD [PASS]
charged_VBN
0.5_CD
m_NN [BEMA]
2004_CD
:_:
0.3_CD
m_NN [BEMA]
by_PIN
subsidiary_NN
undertakings_GER
for_PIN
corporate_JJ
services_NN
provided_VBN
._.
The_DT
Company_NN
has_VPRT
intercompany_NN
loans_NN
and_PHC
accounts_NN
with_PIN
its_PIT
subsidiary_NN
undertakings_GER
and_PHC
details_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
notes_NN
17_CD
:_:
Shares_NN
in_PIN
and_CC
loans_NN
to_PIN
Group_NN
undertakings_GER
,_,
19_CD
:_:
Trade_NN
and_CC
other_JJ
receivables_NN
and_CC
22_CD
:_:
Trade_NN
and_CC
other_JJ
payables_NN
._.
Interest_NN
is_VPRT [PASS]
charged_VBN
on_PIN
inter_NN
company_NN
loans_NN
and_PHC
accounts_NN
at_PIN
0.5_CD
%_NN
above_PLACE
one_CD
month_NN
LIBOR_NN
or_CC
1.0_CD
%_NN
above_PLACE
three_CD
month_NN
LIBOR_NN
and_CC
totalled_VBD
7.5_CD
m_NN [BEMA]
for_PIN
the_DT
year_NN
2004_CD
:_:
9.1_CD
m._FW
The_DT
Groups_NN
key_JJ
management_NOMZ
comprises_VPRT
only_DWNT
Directors_NN
and_PHC
Director_NN
remuneration_NOMZ
for_PIN
the_DT
year_NN
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
audited_JJ
part_NN
of_PIN
the_DT
Remuneration_NOMZ
Report_NN
._.
There_EX
are_VPRT
no_SYNE
material_NN
balances_NN
held_VBN [PRIV] [WZPAST]
with_PIN
associates_NN
at_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
or_CC
2004_CD
._.
100_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
101_CD
35_CD
Principal_NN
subsidiaries_NN
ank_VPRT
borrowings_GER
of_PIN
its_PIT
subsidiaries_NN
Subsidiary_NN
undertakings_GER
%_NN
held_VBN [PRIV] [WZPAST]
of_PIN
Country_NN
of_PIN
nominal_JJ
value_NN
t_NN
to_PIN
a_DT
number_NN
of_PIN
claims_NN
from_PIN
third_JJ
Company_NN
incorporation_NOMZ
and_PHC
voting_NN
rights_NN
Principal_NN
activities_NOMZ
are_VPRT [PASS]
not_XX0
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
material_JJ
SkyePharma_NN
Canada_NN
Inc._NN
._.
Canada_NN
100_CD
%_NN
Research_NN
and_PHC
development_NOMZ
n_NN
these_DEMO
financial_JJ
statements_NOMZ
for_PIN
SkyePharma_NN
Production_NOMZ
SAS_NN
France_NN
100_CD
%_NN
Manufacturing_GER
of_PIN
pharmaceuticals_NN
SkyePharma_NN
Jersey_NN
Limited_NN
Jersey_NN
100_CD
%_NN
Issue_NN
of_PIN
bonds_NN
Krypton_NN
Limited_NN
Gibraltar_NN
100_CD
%_NN
Exploitation_NOMZ
of_PIN
intellectual_JJ
property_NN
SkyePharma_NN
AB_NN
Sweden_NN
100_CD
%_NN
Research_NN
and_PHC
development_NOMZ
Jago_NN
Holding_GER
AG_NN
Switzerland_NN
100_CD
%_NN
Holding_VBG [PRIV] [WZPRES]
company_NN
Jagotec_NN
AG_NN
Switzerland_NN
100_CD
%_NN
Exploitation_NOMZ
of_PIN
intellectual_JJ
property_NN
trust_NN
acquired_VBD
a_DT
51_CD
%_NN
interest_NN
in_PIN
SkyePharma_NN
AG_NN
Switzerland_NN
100_CD
%_NN
Research_NN
and_PHC
development_NOMZ
perty_NN
in_PIN
New_NN
York_NN
._.
In_PIN
December_NN
2002_CD
SkyePharma_NN
Holding_GER
AG_NN
Switzerland_NN
100_CD
%_NN
Holding_VBG [PRIV] [WZPRES]
company_NN
een_NN
in_PIN
occupation_NOMZ
of_PIN
approximately_RB
SkyePharma_NN
Holding_GER
Inc._NN
._.
US_FPP1
100_CD
%_NN
Holding_VBG [PRIV] [THATD] [WZPRES]
company_NN
ased_VBD
upon_PIN
independent_JJ
valuation_NOMZ
._.
US_FPP1
100_CD
%_NN
Development_NOMZ
of_PIN
pharmaceuticals_NN
an_DT
eight-year_JJ
tenancy_NN
agreement_NOMZ
,_,
SkyePharma_NN
US_FPP1
Inc._NN
._.
US_FPP1
100_CD
%_NN
Development_NOMZ
of_PIN
pharmaceuticals_NN
and_PHC
licensing_GER
o_VPRT
$_$
720,000_CD
per_PIN
annum_NN
until_IN
August_NN
Directly_RB
held_VBN [PRIV]
by_PIN
the_DT
Company_NN
._.
on_PIN
of_PIN
these_DEMO
premises_NN
is_VPRT
currently_RB
Associates_NN
%_NN
held_VBN [PRIV] [WZPAST]
of_PIN
Country_NN
of_PIN
nominal_JJ
value_NN
Company_NN
incorporation_NOMZ
and_PHC
voting_NN
rights_NN
Principal_NN
activities_NOMZ
takings_GER
and_CC
in_PIN
accordance_NN
with_PIN
Astralis_NN
Limited_NN
US_FPP1
40_CD
%_NN
Research_NN
and_PHC
development_NOMZ
36_CD
Subsequent_JJ
event_NN
gs_NN
and_CC
the_DT
Company_NN
was_VBD [PASS]
charged_VBN
In_PIN
May_POMD
2006_CD
SkyePharma_NN
announced_VBD [PUBV]
that_THVC
it_PIT
had_VBD [PEAS]
entered_VBN
into_PIN
an_DT
agreement_NOMZ
with_PIN
Kos_NN
Pharmaceuticals_NN
Inc_NN
rovided_VBD
._.
Kos_NN
will_PRMD
have_VB
exclusive_JJ
rights_NN
to_PIN
market_NN
Flutiform_NN
in_PIN
the_DT
US_FPP1
and_CC
a_DT
right_NN
of_PIN
first_JJ
negotiation_NOMZ
in_PIN
Canada_NN
._.
SkyePharma_NN
could_POMD
receive_VB
up_IN
to_TO
$_$
165_CD
million_CD
in_PIN
milestone_NN
payments_NOMZ
on_PIN
achievement_NOMZ
ndertakings_GER
and_PHC
details_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
of_PIN
all_QUAN
regulatory_JJ
and_CC
revenue_NN
targets_NN
of_PIN
which_WDT [PIRE]
$_$
25_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
paid_VBN
up_RP
front_JJ
together_RB
with_PIN
royalties_NN
her_TPP3
receivables_NN
and_CC
22_CD
:_:
Trade_NN
and_CC
starting_VBG
in_PIN
the_DT
mid_JJ
teens_NN
on_PIN
sales_NN
by_PIN
Kos_NN
._.
at_PIN
0.5_CD
%_NN
above_PLACE
one_CD
month_NN
LIBOR_NN
9.1_CD
m._NN
muneration_NOMZ
for_PIN
the_DT
year_NN
is_VPRT [PASS]
shown_VBN [PRIV]
December_NN
2005_CD
or_CC
2004_CD
._.
SkyePharma_NN
Annual_JJ
Report_NN
20051018155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
102_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
37_CD
Transition_NOMZ
from_PIN
accounting_VBG
practices_NN
generally_RB
accepted_VBN [PRIV]
in_PIN
the_DT
UK_NN
to_PIN
International_NN
Financial_NN
Reporting_GER
Standards_NN
The_NN
Group_NN
reported_VBD [PUBV]
under_IN
UK_NN
GAAP_NN
in_PIN
its_PIT
financial_JJ
statements_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
._.
The_DT
Group_NN
is_VPRT [PASS]
required_VBN [SUAV]
under_IN
the_DT
Listing_GER
Rules_NN
to_TO
report_VB [PUBV]
under_IN
IFRS_NN
for_PIN
the_DT
year_NN
ending_VBG [WZPRES]
31_CD
December_NN
2005_CD
and_CC
present_JJ
comparatives_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
._.
Consequently_CONJ
,_,
the_DT
Groups_NN
date_NN
of_PIN
transition_NOMZ
to_PIN
IFRS_NN
is_VPRT [BEMA]
1_CD
January_NN
2004_CD
._.
Set_VBN [PASTP]
out_PIN
below_PLACE
are_VPRT
reconciliations_NOMZ
of_PIN
total_JJ
equity_NOMZ
and_PHC
reserves_NN
and_PHC
income_NN
from_PIN
UK_NN
GAAP_NN
to_PIN
IFRS_NN
._.
Total_JJ
equity_NOMZ
and_PHC
reserves_NN
31_CD
December_NN
2004_CD
1_CD
January_NN
2004_CD
Notes_NN
m_FW
m_FW [BEMA]
Total_JJ
equity_NOMZ
and_PHC
reserves_NN
as_IN
reported_VBN [PUBV]
under_IN
UK_NN
GAAP_NN
63.6_CD
84.9_CD
Adjustments_NOMZ
to_TO
conform_VB
to_PIN
IFRS_NN
Revenue_NN
recognition_NOMZ
a_DT
6.7_CD
19.6_CD
Sale_NN
of_PIN
royalty_NN
interests_NN
to_PIN
Paul_NN
Capital_NN
b_NN
39.0_CD
36.1_CD
Goodwill_NN
amortisation_NOMZ
d_SYM
4.1_CD
Convertible_JJ
bonds_NN
e_LS
16.4_CD
1.5_CD
Fixed_VBN
assets_NN
investments_NOMZ
f_LS
0.5_CD
Other_JJ
financial_JJ
instruments_NOMZ
g_VPRT
0.2_CD
0.4_CD
Pensions_NN
h_VPRT
1.2_CD
1.3_CD
Total_JJ
equity_NOMZ
and_PHC
reserves_NN
under_IN
IFRS_NN
36.5_CD
29.8_CD
Loss_NN
for_PIN
the_DT
year_NN
Year_NN
ended_VBD
31_CD
December_NN
2004_CD
Notes_NN
m_NN
Loss_NN
for_PIN
the_DT
year_NN
as_IN
reported_VBN [PUBV]
under_IN
UK_NN
GAAP_NN
24.3_CD
Adjustments_NOMZ
to_TO
conform_VB
to_PIN
IFRS_NN
Revenue_NN
recognition_NOMZ
a_DT
13.1_CD
Sale_NN
of_PIN
royalty_NN
interests_NN
to_PIN
Paul_NN
Capital_NN
b_NN
1.7_CD
Share_NN
based_VBN
payments_NOMZ
c_NN
2.8_CD
Goodwill_NN
amortisation_NOMZ
d_SYM
4.1_CD
Convertible_JJ
bonds_NN
e_LS
6.5_CD
Other_JJ
financial_JJ
instruments_NOMZ
g_VPRT
0.5_CD
Loss_NN
for_PIN
the_DT
year_NN
under_IN
IFRS_NN
18.6_CD
Cash_NN
flow_NN
statement_NOMZ
The_DT
transition_NOMZ
from_PIN
UK_NN
GAAP_NN
to_PIN
IFRS_NN
does_VPRT
not_XX0
change_VB
any_QUAN
of_PIN
the_DT
cash_NN
flows_VPRT
of_PIN
the_DT
Group_NN
._.
The_DT
IFRS_NN
cash_NN
flow_NN
statement_NOMZ
is_VPRT [BEMA]
similar_PRED
to_PIN
UK_NN
GAAP_NN
,_,
but_CC
presents_VPRT
various_JJ
cash_NN
flows_NN
in_PIN
different_JJ
categories_NN
and_CC
in_PIN
a_DT
different_JJ
order_NN
from_PIN
the_DT
UK_NN
GAAP_NN
cash_NN
flow_NN
statement_NOMZ
._.
All_QUAN
of_PIN
the_DT
IFRS_NN
accounting_GER
adjustments_NOMZ
net_JJ
out_PIN
within_PIN
cash_NN
generated_VBD
from_PIN
operations_NOMZ
,_,
except_PIN
for_PIN
the_DT
inclusion_NN
of_PIN
the_DT
repayment_NOMZ
of_PIN
the_DT
Paul_NN
Capital_NN
funding_VBG [WZPRES]
liabilities_NOMZ
._.
102_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
103_CD
The_DT
IFRS_NN
adjustments_NOMZ
set_VBD
out_PIN
in_PIN
the_DT
reconciliations_NOMZ
are_VPRT [PASS]
explained_VBN [PUBV]
below_PLACE
:_:
ar_NN
ended_VBD
31_CD
December_NN
2004_CD
._.
a_DT
Revenue_NN
recognition_NOMZ
e_SYM
year_NN
ending_VBG [WZPRES]
31_CD
December_NN
2005_CD
Under_IN
UK_NN
GAAP_NN
SkyePharma_NN
has_VPRT [SPAU] [PEAS]
generally_RB
recognized_VBN [PRIV]
up_RP
front_JJ
payments_NOMZ
immediately_TIME
in_PIN
full_JJ
where_RB
there_EX
uently_RB
,_,
the_DT
Groups_NN
date_NN
of_PIN
transition_NOMZ
are_VPRT [BEMA]
no_SYNE
material_NN
future_NN
obligations_NOMZ
and_CC
the_DT
payments_NOMZ
are_VPRT [BEMA]
non-refundable_PRED
,_,
on_PIN
the_DT
basis_NN
that_TOBJ
the_DT
up_RP
front_JJ
payment_NOMZ
relates_VPRT
to_PIN
past_JJ
services_NN
._.
Under_IN
IFRS_NN
up_IN
front_JJ
payments_NOMZ
will_PRMD [SPAU]
generally_RB
be_VB [PASS]
deferred_VBN
and_PHC
amortised_VBN
on_PIN
a_DT
systematic_JJ
basis_NN
over_IN
the_DT
period_NN
of_PIN
product_NN
development_NOMZ
to_PIN
filing_NN
._.
However_CONJ
,_,
the_DT
accounting_GER
for_PIN
each_QUAN
from_PIN
UK_NN
GAAP_NN
to_PIN
IFRS_NN
._.
agreement_NOMZ
will_PRMD
continue_VB
to_TO
be_VB [PASS]
determined_VBN [SUAV] [PRIV]
on_PIN
an_DT
individual_JJ
basis_NN
._.
The_DT
IFRS_NN
restatement_NOMZ
increases_VPRT
revenue_NN
in_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2004_CD
by_PIN
13.1_CD
million_CD
so_IN
reducing_VBG
31_CD
December_NN
2004_CD
1_CD
January_NN
2004_CD
operating_GER
and_CC
retained_VBD
loss_NN
by_PIN
13.1_CD
million_CD
._.
This_DEMP
relates_VPRT
to_TO
up_RB
front_JJ
payments_NOMZ
that_TSUB
have_VPRT [PEAS]
been_VBN
previously_TIME
m_FW
m_FW [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
UK_NN
GAAP_NN
financial_JJ
statements_NOMZ
in_PIN
earlier_TIME
years_NN
but_CC
which_WDT
under_IN
IFRS_NN
would_PRMD
not_XX0
have_VB [PEAS]
been_VBN [BEMA]
63.6_CD
84.9_CD
recognized_VBN [PRIV]
in_PIN
full_JJ
,_,
but_CC
deferred_VBN
across_PLACE
the_DT
period_NN
of_PIN
development_NOMZ
to_PIN
filing_NN
._.
The_DT
restatement_NOMZ
increases_VPRT
deferred_JJ
income_NN
at_PIN
31_CD
December_NN
2004_CD
by_PIN
6.7_CD
million_CD
2003_CD
:_:
19.6_CD
million_CD
._.
6.7_CD
19.6_CD
39.0_CD
36.1_CD
b_NN
Sale_NN
of_PIN
royalty_NN
interests_NN
to_PIN
Paul_NN
Capital_NN
4.1_CD
The_NN
Group_NN
entered_VBD
into_PIN
two_CD
transactions_NOMZ
with_PIN
Paul_NN
Capital_NN
Royalty_NN
Acquisition_NOMZ
Fund_NN
Paul_NN
Capital_NN
in_PIN
2000_CD
and_CC
16.4_CD
1.5_CD
2002_CD
._.
Under_IN
these_DEMO
transactions_NOMZ
Paul_NN
Capital_NN
provided_VBD
a_DT
total_NN
of_PIN
$_$
60_CD
million_CD
in_PIN
return_NN
for_PIN
the_DT
sale_NN
of_PIN
a_DT
portion_NOMZ
0.5_CD
of_PIN
the_DT
potential_JJ
future_NN
royalty_NN
and_PHC
revenue_NN
streams_NN
on_PIN
a_DT
selection_NOMZ
of_PIN
the_DT
Groups_NN
products_NN
._.
Under_IN
UK_NN
GAAP_NN
the_DT
0.2_CD
0.4_CD
proceeds_NN
received_VBN [WZPAST]
from_PIN
Paul_NN
Capital_NN
are_VPRT [PASS]
treated_VBN
as_IN
a_DT
sale_NN
and_CC
recorded_VBN
as_IN
operating_GER
income_NN
and_CC
the_DT
royalties_NN
1.2_CD
1.3_CD
are_VPRT [PASS]
expensed_VBN
when_RB
incurred_VBN
._.
36.5_CD
29.8_CD
Under_IN
IFRS_NN
the_DT
proceeds_NN
received_VBD
from_PIN
Paul_NN
Capital_NN
meet_VPRT
the_DT
definition_NOMZ
of_PIN
a_DT
financial_JJ
liability_NOMZ
under_IN
IAS_NN
39_CD
,_,
and_ANDC
are_VPRT [PASS]
treated_VBN
as_IN
such_JJ
._.
No_SYNE
operating_GER
income_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
,_,
royalties_NN
paid_VBD
to_PIN
Paul_NN
Capital_NN
are_VPRT [PASS]
treated_VBN
as_IN
Year_NN
ended_VBD
31_CD
December_NN
2004_CD
repayment_NOMZ
of_PIN
the_DT
liability_NOMZ
and_ANDC
in_CONJ
addition_NULL
interest_NN
is_VPRT [BEMA]
imputed_PRED
on_PIN
the_DT
liability_NOMZ
using_VBG [WZPRES]
the_DT
effective_JJ
rate_NN
as_IN
at_PIN
Notes_NN
m_NN
inception_NOMZ
of_PIN
the_DT
agreement_NOMZ
._.
The_DT
contractual_JJ
arrangement_NOMZ
with_PIN
Paul_NN
Capital_NN
is_VPRT [BEMA]
unaffected_PRED
by_PIN
this_DEMO
change_NN
in_PIN
24.3_CD
accounting_GER
and_CC
the_DT
arrangement_NOMZ
remains_VPRT
a_DT
royalty_NN
agreement_NOMZ
under_IN
which_WDT
royalties_NN
are_VPRT [BEMA]
payable_PRED
on_PIN
revenues_NN
earned_VBN
and_CC
payments_NOMZ
received_VBD
._.
The_DT
liability_NOMZ
has_VPRT
no_SYNE
face_NN
amount_NN
but_CC
represents_VPRT
the_DT
net_JJ
present_JJ
value_NN
of_PIN
a_DT
13.1_CD
royalties_NN
we_FPP1
expect_VPRT [PRIV]
to_TO
pay_VB
Paul_NN
Capital_NN
over_IN
the_DT
term_NN
of_PIN
the_DT
agreement_NOMZ
,_,
discounted_VBN [PASTP]
at_PIN
the_DT
effective_JJ
rate_NN
at_PIN
b_NN
1.7_CD
inception_NOMZ
of_PIN
the_DT
agreement_NOMZ
._.
c_NN
2.8_CD
d_SYM
4.1_CD
The_DT
IFRS_NN
restatement_NOMZ
increases_VPRT
the_DT
loss_NN
in_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2004_CD
by_PIN
1.7_CD
million_CD
and_CC
decreases_VPRT
e_SYM
6.5_CD
net_JJ
assets_NN
at_PIN
31_CD
December_NN
2004_CD
by_PIN
39.0_CD
million_CD
2003_CD
:_:
36.1_CD
million_CD
._.
g_RB
0.5_CD
18.6_CD
c_NN
Share_NN
based_VBN
payments_NOMZ
IFRS_VPRT
2_CD
requires_VPRT [SUAV]
that_THVC
for_PIN
share_NN
option_NOMZ
awards_NN
to_PIN
employees_NN
,_,
the_DT
fair_JJ
value_NN
of_PIN
the_DT
employee_NN
services_NN
received_VBD
should_NEMD
be_VB [BYPA]
measured_VBN
by_PIN
reference_NN
to_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
share_NN
option_NOMZ
at_PIN
the_DT
grant_NN
date_NN
._.
This_DEMP
differs_VPRT
ws_NN
of_PIN
the_DT
Group_NN
._.
The_DT
IFRS_NN
cash_NN
flow_NN
significantly_RB
from_PIN
the_DT
treatment_NOMZ
under_IN
UK_NN
GAAP_NN
where_RB
the_DT
charge_NN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
was_VBD [PASS]
based_VBN
rent_NN
categories_NN
and_CC
in_PIN
a_DT
different_JJ
on_PIN
the_DT
difference_NN
between_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
shares_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
and_CC
the_DT
exercise_NN
price_NN
._.
Since_OSUB
adjustments_NOMZ
net_JJ
out_PIN
within_PIN
cash_NN
SkyePharma_NN
has_VPRT [SPAU] [PEAS]
historically_RB
granted_VBN [SUAV]
employee_NN
options_NOMZ
where_RB
the_DT
share_NN
price_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
equals_VPRT
he_TPP3
Paul_NN
Capital_NN
funding_VBG [WZPRES]
liabilities_NOMZ
._.
the_DT
exercise_NN
price_NN
,_,
there_EX
has_VPRT [PEAS]
been_VBN
no_SYNE
charge_NN
recorded_VBN
under_IN
UK_NN
GAAP_NN
._.
SkyePharma_NN
has_VPRT [PEAS]
adopted_VBN
full_JJ
retrospective_NN
application_NOMZ
of_PIN
IFRS_NN
2_CD
._.
The_DT
IFRS_NN
restatement_NOMZ
results_NN
in_PIN
an_DT
additional_JJ
charge_NN
to_PIN
the_DT
income_NN
statement_NOMZ
in_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2004_CD
of_PIN
2.8_CD
million_CD
,_,
increasing_VBG [PRESP]
both_DT
operating_GER
and_CC
retained_VBD
loss_NN
._.
The_DT
restatement_NOMZ
has_VPRT
no_SYNE
impact_NN
on_PIN
net_JJ
assets_NN
._.
d_LS
Goodwill_NN
amortisation_NOMZ
Under_IN
UK_NN
GAAP_NN
goodwill_NN
has_VPRT [PEAS]
been_VBN [PASS]
amortised_VBN
over_IN
its_PIT
estimated_VBN [PRIV]
expected_VBN [PRIV]
useful_JJ
life_NN
which_WDT [WHOBJ]
the_DT
Directors_NN
determined_VBD [SUAV] [PRIV]
as_IN
20_CD
years_NN
._.
Under_IN
IFRS_NN
,_,
goodwill_NN
is_VPRT [PASS]
considered_VBN [PRIV]
to_TO
have_VB
an_DT
indefinite_JJ
life_NN
and_CC
so_RB
is_VPRT [PASS]
not_XX0
amortised_VBN
,_,
but_CC
is_VPRT [BEMA]
subject_PRED
to_PIN
annual_JJ
impairment_NOMZ
testing_GER
._.
Therefore_CONJ
the_DT
annual_JJ
goodwill_NN
charge_NN
made_VBN
under_IN
UK_NN
GAAP_NN
will_PRMD
SkyePharma_NN
Annual_JJ
Report_NN
20051038155_CD
LR_NN
Back_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:41_CD
Page_NN
104_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
not_XX0
be_VB [PASS]
recorded_VBN
under_IN
IFRS_NN
from_PIN
1_CD
January_NN
2004_CD
,_,
the_DT
IFRS_NN
transition_NOMZ
date_NN
._.
The_DT
IFRS_NN
restatement_NOMZ
results_NN
in_PIN
a_DT
reduction_NOMZ
in_PIN
the_DT
amortisation_NOMZ
charge_NN
in_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2004_CD
of_PIN
4.1_CD
million_CD
thereby_RB
reducing_VBG
both_DT
operating_GER
and_CC
retained_VBD
loss_NN
._.
e_LS
Convertible_JJ
bonds_NN
Under_IN
UK_NN
GAAP_NN
the_DT
total_JJ
net_JJ
proceeds_NN
of_PIN
the_DT
convertible_JJ
bond_NN
issues_NN
in_PIN
2000_CD
due_JJ
in_PIN
2005_CD
and_CC
2004_CD
due_JJ
in_PIN
2024_CD
were_VBD [PASS]
recorded_VBN
as_IN
debt_NN
._.
Under_IN
IFRS_NN
the_DT
conversion_NN
feature_NN
of_PIN
each_QUAN
of_PIN
the_DT
bonds_NN
must_NEMD
be_VB [PASS]
split_VBN
from_PIN
the_DT
debt_NN
and_CC
classified_VBN
as_IN
equity_NOMZ
._.
The_DT
net_JJ
impact_NN
of_PIN
the_DT
changes_NN
to_PIN
IFRS_NN
and_ANDC
in_CONJ
particular_NULL
the_DT
split_NN
of_PIN
the_DT
equity_NOMZ
component_NN
of_PIN
each_QUAN
bond_NN
has_VPRT [PEAS]
led_VBN
,_,
at_PIN
31_CD
December_NN
2004_CD
,_,
to_PIN
a_DT
reduction_NOMZ
in_PIN
the_DT
carrying_VBG
value_NN
of_PIN
convertible_JJ
debt_NN
of_PIN
16.4_CD
million_CD
2003_CD
:_:
1.5_CD
million_CD
and_CC
a_DT
corresponding_JJ
increase_NN
in_PIN
equity_NOMZ
._.
While_OSUB
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
convertible_JJ
debt_NN
in_PIN
the_DT
balance_NN
sheet_NN
is_VPRT [PASS]
reduced_VBN
,_,
the_DT
amount_NN
of_PIN
debt_NN
repayable_NN
at_PIN
maturity_NOMZ
is_VPRT [BEMA]
unchanged_PRED
and_ANDC
consequently_CONJ
under_IN
IFRS_NN
the_DT
Group_NN
records_NN
higher_JJ
interest_NN
charges_NN
in_PIN
each_QUAN
year_NN
to_PIN
maturity_NOMZ
or_CC
conversion_NN
._.
In_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2004_CD
,_,
the_DT
impact_NN
of_PIN
these_DEMO
factors_NN
led_VBD
to_PIN
an_DT
additional_JJ
interest_NN
charge_NN
of_PIN
0.3_CD
million_CD
._.
The_DT
terms_NN
of_PIN
the_DT
debt_NN
are_VPRT [BEMA]
unaffected_PRED
and_CC
the_DT
physical_JJ
cash_NN
payments_NOMZ
due_JJ
remain_VPRT
the_DT
same_JJ
:_:
as_IN
such_JJ
the_DT
cost_NN
of_PIN
the_DT
debt_NN
in_PIN
cash_NN
terms_NN
is_VPRT [BEMA]
unaffected_PRED
._.
During_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2004_CD
the_DT
Group_NN
exchanged_VBD
49.6_CD
million_CD
of_PIN
the_DT
convertible_JJ
bonds_NN
due_JJ
2005_CD
for_PIN
bonds_NN
due_JJ
2024_CD
in_PIN
the_DT
same_JJ
amount_NN
,_,
leaving_VBG [PRESP]
9.8_CD
million_CD
2005_CD
bonds_NN
outstanding_JJ
._.
Under_IN
UK_NN
GAAP_NN
no_SYNE
gain_NN
or_CC
loss_NN
arose_VBD
on_PIN
the_DT
exchange_NN
._.
However_CONJ
un-amortised_JJ
issue_NN
costs_NN
of_PIN
0.3_CD
million_CD
were_VBD [PASS]
written_VBN [PUBV]
off_PIN
under_IN
UK_NN
GAAP_NN
as_IN
exceptional_JJ
interest_NN
charge_NN
._.
Under_IN
IFRS_NN
the_DT
refinancing_GER
of_PIN
the_DT
49.6_CD
million_CD
convertible_NN
is_VPRT [PASS]
treated_VBN
as_IN
an_DT
extinguishment_NOMZ
of_PIN
the_DT
original_JJ
debt_NN
and_CC
the_DT
issue_NN
of_PIN
new_JJ
debt_NN
recorded_VBN [WZPAST]
at_PIN
fair_JJ
value_NN
since_OSUB
the_DT
discounted_JJ
present_JJ
value_NN
of_PIN
the_DT
cash_NN
flows_VPRT
of_PIN
the_DT
two_CD
instruments_NOMZ
differ_VPRT
by_PIN
more_EMPH
than_PIN
10_CD
%_NN
2005_CD
Bond_NN
replaced_VBN [WZPAST]
by_PIN
a_DT
2024_CD
Bond_NN
._.
The_DT
extinguishment_NOMZ
and_PHC
debt_NN
issue_NN
costs_NN
lead_VPRT
to_PIN
the_DT
additional_JJ
charge_NN
of_PIN
6.2_CD
million_CD
recorded_VBN
in_PIN
the_DT
IFRS_NN
income_NN
statement_NOMZ
in_PIN
2004_CD
._.
In_PIN
total_JJ
the_DT
IFRS_NN
adjustments_NOMZ
on_PIN
the_DT
convertible_JJ
bonds_NN
result_VPRT
in_PIN
an_DT
additional_JJ
interest_NN
charge_NN
in_PIN
the_DT
2004_CD
income_NN
statement_NOMZ
of_PIN
6.5_CD
million_CD
and_CC
an_DT
increase_NN
in_PIN
net_JJ
assets_NN
at_PIN
31_CD
December_NN
2004_CD
by_PIN
16.4_CD
million_CD
._.
Of_PIN
the_DT
6.5_CD
m_NN [BEMA]
additional_JJ
interest_NN
charge_NN
,_,
0.3_CD
m_NN
relates_VPRT
to_PIN
the_DT
IFRS_NN
accounting_GER
for_PIN
convertible_JJ
bonds_NN
in_PIN
general_JJ
and_CC
6.2_CD
million_CD
is_VPRT [BEMA]
an_DT
additional_JJ
charge_NN
caused_VBN [WZPAST]
by_PIN
the_DT
2004_CD
refinancing_GER
of_PIN
SkyePharmas_NN
convertible_JJ
bond_NN
due_JJ
2005_CD
._.
f_LS
Fixed_VBN
assets_NN
investments_NOMZ
Under_IN
UK_NN
GAAP_NN
fixed_JJ
asset_NN
investments_NOMZ
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
._.
Under_IN
IFRS_NN
most_EMPH
of_PIN
SkyePharmas_NN
investments_NOMZ
are_VPRT [PASS]
classified_VBN
as_IN
Available-for-sale_JJ
financial_JJ
assets_NN
and_CC
as_IN
such_JJ
stated_VBN [PUBV]
at_PIN
fair_JJ
value_NN
with_PIN
any_QUAN
unrealised_JJ
gains_NN
or_CC
losses_NN
recorded_VBN [WZPAST]
in_PIN
equity_NOMZ
._.
The_DT
IFRS_NN
restatement_NOMZ
reduces_VPRT
net_JJ
assets_NN
at_PIN
31_CD
December_NN
2004_CD
by_PIN
0.5_CD
million_CD
2003_CD
:_:
Nil_NN
and_CC
does_VPRT
not_XX0
effect_VB
the_DT
income_NN
statement_NOMZ
._.
g_NN
Other_JJ
financial_JJ
instruments_NOMZ
Under_IN
UK_NN
GAAP_NN
,_,
periodic_JJ
gains_NN
and_PHC
losses_NN
on_PIN
interest_NN
and_CC
foreign_JJ
currency_NN
derivatives_NN
designated_VBN
as_IN
hedges_NN
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
until_IN
the_DT
operational_JJ
transactions_NOMZ
to_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [PASS]
linked_VBN
occur_VPRT
._.
No_SYNE
derivatives_NN
have_VPRT [PEAS]
qualified_VBN
as_IN
hedges_NN
under_IN
IFRS_NN
and_ANDC
therefore_CONJ
in_PIN
accordance_NN
with_PIN
IAS_NN
39_CD
such_JJ
instruments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
at_PIN
fair_JJ
value_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
with_PIN
gains_NN
and_PHC
losses_NN
being_VBG [WZPRES] [PASS]
recorded_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
._.
104_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Covers_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:44_CD
Page_NN
2_CD
Contents_NN
01_CD
Our_FPP1
Mission_NN
SkyePharma_NN
is_VPRT
adopting_VBG
full_JJ
retrospective_JJ
application_NOMZ
of_PIN
IAS_NN
32_CD
and_CC
IAS_NN
39_CD
and_CC
has_VPRT [SPAU] [PEAS]
therefore_CONJ
restated_VBN
02_CD
Corporate_JJ
Highlights_NN
its_PIT
opening_GER
balance_NN
and_CC
2004_CD
result_NN
accordingly_RB
._.
This_DEMO
restatement_NOMZ
has_VPRT [PEAS]
led_VBN
to_PIN
an_DT
additional_JJ
charge_NN
in_PIN
the_DT
year_NN
03_CD
Financial_NN
Highlights_NN
to_PIN
31_CD
December_NN
2004_CD
of_PIN
0.5_CD
million_CD
,_,
increasing_VBG [PRESP]
both_DT
operating_GER
and_CC
retained_VBD
loss_NN
._.
As_IN
at_PIN
31_CD
December_NN
2004_CD
04_CD
Chairmans_NN
Statement_NOMZ
the_DT
IFRS_NN
restatement_NOMZ
reduces_VPRT
net_JJ
assets_NN
by_PIN
0.2_CD
million_CD
2003_CD
:_:
0.4_CD
million_CD
increase_NN
._.
06_CD
Our_FPP1
Strategy_NN
07_CD
Review_NN
of_PIN
Operations_NOMZ
h_VPRT
Pensions_NN
12_CD
Product_NN
Pipeline_NN
The_NN
IFRS_NN
adjustment_NOMZ
on_PIN
pensions_NN
relates_VPRT
to_PIN
the_DT
Companys_NN
pension_NN
schemes_NN
in_PIN
Switzerland_NN
and_PHC
France_NN
._.
14_CD
Products_NN
on_PIN
the_DT
Market_NN
In_PIN
accordance_NN
with_PIN
IFRS_NN
1_CD
,_,
the_DT
Group_NN
has_VPRT [SPAU] [PEAS]
fully_AMP
recognized_VBN [PRIV]
all_QUAN
actuarial_JJ
gains_NN
and_PHC
losses_NN
on_PIN
its_PIT
pension_NN
15_CD
Upcoming_GER
Products_NN
schemes_NN
in_PIN
Switzerland_NN
and_PHC
France_NN
at_PIN
1_CD
January_NN
2004_CD
,_,
its_PIT
transition_NOMZ
date_NN
._.
Ongoing_JJ
actuarial_JJ
gains_NN
and_CC
16_CD
Flutiform_NN
losses_NN
will_PRMD
be_VB [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
Statement_NOMZ
of_PIN
Recognised_NN
Income_NN
and_PHC
Expenditure_NN
._.
17_CD
The_DT
Shares_NN
20_CD
Corporate_JJ
Social_NN
Responsibility_NOMZ
i_FPP1
Other_JJ
22_CD
Financial_NN
Review_NN
Under_IN
IFRS_NN
the_DT
Group_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
capitalize_VB
research_NN
and_PHC
development_NOMZ
costs_NN
when_RB
the_DT
criteria_NN
laid_VBN [WZPAST]
out_PIN
in_PIN
26_CD
Directors_NN
and_PHC
Officers_NN
IAS_NN
38_CD
are_VPRT [PASS]
met_VBN
._.
The_DT
Group_NN
has_VPRT [PEAS]
reviewed_VBN
its_PIT
historical_JJ
research_NN
and_PHC
development_NOMZ
projects_NN
and_CC
determined_VBD [SUAV] [PRIV]
that_THVC
28_CD
Report_NN
of_PIN
the_DT
Directors_NN
no_SYNE
expenditure_NN
incurred_VBN [WZPAST]
to_PIN
date_NN
meets_VPRT
the_DT
criteria_NN
for_PIN
capitalization_NOMZ
in_PIN
IAS_NN
38_CD
._.
However_CONJ
the_DT
Group_NN
will_PRMD
continue_VB
30_CD
Corporate_JJ
Governance_NN
to_TO
review_VB
its_PIT
development_NOMZ
expenditure_NN
against_PIN
the_DT
relevant_JJ
criteria_NN
and_CC
will_PRMD
capitalize_VB
such_JJ
expenditure_NN
when_RB
36_CD
Statement_NOMZ
of_PIN
Directors_NN
'_POS
Responsibility_NOMZ
it_PIT
is_VPRT [BEMA]
appropriate_PRED
._.
in_PIN
Relation_NOMZ
to_PIN
the_DT
Accounts_NN
37_CD
Remuneration_NOMZ
Report_NN
Company_NN
53_CD
Independent_NN
Auditors_NN
Report_NN
to_PIN
the_DT
Members_NN
of_PIN
SkyePharma_NN
PLC_NN
Total_NN
equity_NOMZ
and_PHC
reserves_NN
31_CD
December_NN
2004_CD
1_CD
January_NN
2004_CD
55_CD
Consolidated_NN
Income_NN
Statement_NOMZ
m_NN
m_NN [BEMA]
56_CD
Consolidated_NN
Balance_NN
Sheet_NN
Total_NN
equity_NOMZ
and_PHC
reserves_NN
as_IN
reported_VBN [PUBV]
under_IN
UK_NN
GAAP_NN
349.6_CD
373.1_CD
57_CD
Company_NN
Balance_NN
Sheet_NN
Adjustments_NOMZ
to_TO
conform_VB
to_PIN
IFRS_NN
58_CD
Consolidated_NN
Statement_NOMZ
of_PIN
Recognised_NN
Share_NN
based_VBN
payments_NOMZ
1.1_CD
Income_NN
and_PHC
Expense_NN
Convertible_NN
bonds_NN
3.1_CD
1.5_CD
58_CD
Company_NN
Statement_NOMZ
of_PIN
Recognised_NN
Income_NN
Fixed_NN
assets_NN
investments_NOMZ
0.5_CD
and_CC
Expense_NN
Other_JJ
financial_JJ
instruments_NOMZ
0.2_CD
0.4_CD
59_CD
Consolidated_NN
Cash_NN
Flow_NN
Statement_NOMZ
Total_NN
equity_NOMZ
and_PHC
reserves_NN
under_IN
IFRS_NN
344.7_CD
375.0_CD
61_CD
Company_NN
Cash_NN
Flow_NN
Statement_NOMZ
63_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
Loss_NN
for_PIN
the_DT
year_NN
Year_NN
ended_VBD
31_CD
December_NN
2004_CD
m_NN
Loss_NN
for_PIN
the_DT
year_NN
as_IN
reported_VBN [PUBV]
under_IN
UK_NN
GAAP_NN
26.9_CD
Adjustments_NOMZ
to_TO
conform_VB
to_PIN
IFRS_NN
Share_NN
based_VBN
payments_NOMZ
1.1_CD
Convertible_JJ
bonds_NN
3.8_CD
Other_JJ
financial_JJ
instruments_NOMZ
0.2_CD
Loss_NN
for_PIN
the_DT
year_NN
under_IN
IFRS_NN
32.0_CD
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
8155_CD
LR_NN
Covers_NN
22_CD
05_CD
._.
qxp_NN
28_CD
5_CD
06_CD
22:44_CD
Page_NN
1_CD
Registered_NN
Head_NN
Office_NN
105_CD
Piccadilly_NN
London_NN
W1J_NN
7NJ_NN
Telephone_NN
:_:
02074911777_CD
Fax_NN
:_:
02074913338_CD
Registered_NN
No_NN
:_:
107582_CD
Company_NN
Secretary_NN
:_:
Douglas_NN
Parkhill_NN
Auditors_NN
LLP_NN
Chartered_NN
Accountants_NN
1_CD
Embankment_NOMZ
Place_NN
London_NN
WC2N_NN
6RH_NN
Solicitors_NN
UK_NN
Stringer_NN
Saul_NN
17_CD
Hanover_NN
Square_NN
London_NN
W1S_NN
1HU_NN
US_FPP1
Sullivan_NN
&_CC
Cromwell_NN
1_CD
New_NN
Fetter_NN
Lane_NN
London_NN
EC4A_NN
1AN_NN
Corporate_NN
Broker_NN
and_PHC
Financial_NN
Adviser_NN
Credit_NN
Suisse_NN
First_NN
Boston_NN
20_CD
Columbus_NN
Courtyard_NN
London_NN
E14_NN
4DA_NN
Bankers_NN
National_NN
Westminster_NN
Bank_NN
plc_NN
Bishopsgate_NN
Business_NOMZ
Centre_NN
PO_NN
Box_NN
34_CD
15_CD
Bishopsgate_NN
London_NN
EC2P_NN
2AP_NN
Registrars_NN
Capita_NN
Registrars_NN
The_DT
Registry_NN
34_CD
Beckenham_NN
Road_NN
Beckenham_NN
Kent_NN
BR3_NN
4TU_NN
Depositary_NN
The_NN
Bank_NN
of_PIN
New_NN
York_NN
101_CD
Barclay_NN
Street_NN
New_NN
York_NN
NY_NN
10286_CD
USA_NN
Annual_JJ
Report_NN
2005_CD
Making_VBG
Good_JJ
Drugs_NN
Better_RB
SkyePharma_NN
Annual_JJ
Report_NN
2005_CD
